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A b s t r a c t  
Eating behaviour is an important aspect of social behaviour, and illnesses like 
eating disorders thus have a profound impact on quality of life. Family and twin 
studies provide compelling evidence for the heritability of eating disorders; it is 
estimated that roughly half of the phenotypic variance is accounted for by 
genetic factors. The presumed genetic architecture of eating disorders 
constitutes multiple genetic variants, each with a small effect size. This thesis 
aimed to replicate findings from the most extensive genetic studies of eating 
disorders done thus far, in a sample of 700 anorexia nervosa cases and 700 
controls from the United Kingdom, the Netherlands, and Austria. The results are 
non-significant, which is in line with genetic studies of other psychiatric 
disorders, as well as complex traits such as human intelligence, height, and body 
mass index. Power to detect genetic risk variants with small effect sizes could be 
increased by larger samples sizes, and by focussing on disease related 
quantitative traits rather than diagnoses. Candidate quantitative traits for eating 
disorders include drive for thinness, bulimia, and body dissatisfaction as 
measured by the Eating Disorders Inventory (EDI) questionnaire. Chapter 3 of 
this thesis presents the distribution of these traits in a general population sample 
from the United Kingdom (n = 3,624 females), and Chapter 4 presents the results 
of genome-wide association gene (GWAG) analyses of these traits. No gene p 
values passed a multiple gene testing correction, but among the top genes were 
several previously implicated in the aetiology of eating disorders. Larger sample 
sizes would be needed to verify these results. The results of this thesis 
underscore the phenotypic and aetiologic complexity of eating disorders, but 
demonstrate that a general population approach using quantitative trait 
measurements combined with genome-wide hypothesis-free gene analyses can 
be fruitful.  
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C h a p t e r  1  I n t r o d u c t i o n  
The everyday act of eating lies at the core of human behaviour. Without food we 
cannot survive. But food represents much more than basic survival; it is deeply 
embedded in our cultures as a symbol of comfort and security, of health, 
nationality, hospitality, social status, and even religion. Illnesses affecting eating 
behaviour thus have a profound impact on quality of life. The first part of this 
chapter will discuss the normal regulation of eating behaviour, including hunger 
and satiety mechanisms, hedonic regulation, and social and cognitive aspects of 
normal eating behaviour. For disordered eating behaviour three clinical 
categories currently exist: anorexia nervosa (AN), bulimia nervosa (BN), and 
eating disorder not otherwise specified (EDNOS). The second part of this chapter 
will discuss the prevalence and incidence of these eating disorders, their clinical 
presentation, comorbidity, and risk factors. The third and final part of this 
chapter will outline the status quo of genetic research on eating disorders. Since 
genetic studies of eating disorders have typically been non-significant or non-
replicated, parallels will be drawn with the genetic architecture of other complex 
traits, including other psychiatric disorders, human intelligence, height, and body 
mass index. Understanding the nature of eating behaviour, and specifically the 
biological processes underlying (aberrant) eating behaviour, will add to the 
evidence-base needed for intervention in disordered eating behaviour.   
Energy intake and expenditure are carefully matched through the process of 
energy homeostasis. The gastro-intestinal system and related organs convey the 
energy status of the body to the brain via hormonal, neural, and metabolic 
signals upon which energy intake and expenditure are modulated. Leptin is one 
1. Introduction 
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of the key proteins involved in energy homeostasis, it is produced by adipose 
tissue and secreted in direct proportion to body fat mass (Gautron and Elmquist, 
2011). Leptin deficiency causes morbid obesity, diabetes, and general 
neuroendocrine anomalies (Gautron and Elmquist, 2011). Leptin has an 
important role in one of the earliest systems implicated in energy homeostasis, 
namely the glucostatic regulation; the glucostatic regulation assumed that 
changes in plasma glucose regulated food intake (Mayer and Thomas, 1967). 
Leptin – discovered only in 1994 – affects glucose metabolism through altering 
insulin sensitivity and hepatic glucose production in an antidiabetic mode 
(Gautron and Elmquist, 2011).  
 
The most profound and best characterized effect of leptin on the brain is on two 
neuron populations in the arcuate nucleus of the hypothalamus; pro-
opiomelanocortin (POMC) neurons, and neuropeptide-Y (NPY) and agouti-related 
peptide (AgRP) neurons. Leptin stimulates the anorexigenic POMC neurons and 
inhibits the orexigenic NPY/AgRP neurons (Cowley et al., 2001). The expression 
of POMC neurons is regulated by several endogenous molecules, including 
corticotropin-releasing hormone (CRH), insulin, glucocorticoids (GC), serotonin, 
and leptin (Shimizu et al., 2007,Heisler et al., 2006). Ghrelin, a well known 
metabolic protein important in meal initiation, stimulates NPY/AgRP neurons 
(Briggs and Andrews, 2011). Both neuron populations interact with 
melanocortin-4-receptor (MC4R) expressing neurons; also key regulators of 
energy metabolism. MC4R knock-out mice have a metabolic syndrome-like 
phenotype, and many of the effects of leptin are MC4R dependent (Gautron and 
Elmquist, 2011). The effects of leptin are however much more wide spread; 
leptin modulates various aspects of eating behaviour including meal size (Kahler 
et al., 1998), taste (Shigemura et al., 2004), smell (Julliard et al., 2007), and food 
reward (Hommel et al., 2006). For example low levels (or absence) of leptin 
(which normally indicates a state of deprivation) enables mice to find buried food 
ten times faster than when their leptin levels have been normalized (Getchell et 
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al., 2006). Meal size for example, which is influenced by gastrointestinal satiation 
signals including gut peptides like cholecystokinin (CCK) and glucagon-like 
protein-1 (GLP1) (Zhang et al., 2010), is surveyed by leptin; leptin is able to alter 
the brain’s sensitivity for satiation signals, it overrules short-term homeostasis in 
order to serve long-term energy homeostasis (Gautron and Elmquist, 2011). 
Figure 1 gives an overview of the aforementioned homeostatic regulators of 












Figure 1: Homeostatic regulators of eating behaviour (Gil-Campos et al., 2006) 
The figure shows a selection of the most important homeostatic regulators of eating 
behaviour (the figure was obtained from reference (Gil-Campos et al., 2006)). 
Another key protein implicated in the regulation of energy homeostasis is the 
brain derived neurotrophic factor (BDNF). BDNF is a member of the neurotrophin 
family of growth factors known to stimulate the development and differentiation 
of new neurons (Alderson et al., 1990,Knusel and Hefti, 1991), as well as 
promoting long-term potentiation (LTP) (Korte et al., 1996,Patterson et al., 
1996); a process of neuronal connection which is key to learning and memory. 
BDNF is a receptor-ligand with high affinity for the tropomyosin-related kinase B 
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(TrkB) receptor (Klein et al., 1991,Noble et al., 2011). Lapchak and Hefti noted in 
1992 that central administration of BDNF in rats prevented weight gain (Lapchak 
and Hefti, 1992). Since then many studies have reported effects of BDNF on food 
intake, body weight, glucose metabolism, physical activity, and metabolic rate 
(reviewed by (Noble et al., 2011) and by (Rios, 2011)).  
 
In 2007, FTO, another protein important in the regulation of food intake and 
body weight was discovered (Frayling et al., 2007). This discovery is one of the 
most prominent successes of non-hypothesis driven genetic research (thus far); 
Frayling and colleagues found that the protein FTO was associated with type 2 
diabetes, and particularly with body mass index (Frayling et al., 2007). Although 
this protein had first been discovered in 1999 by Peters et al (Peters et al., 1999), 
it was not implicated in the regulation of eating behaviour or body weight until 
2007 (Frayling et al., 2007). Funnily enough, in 1999, Peters and colleagues 
named the gene that they had discovered (through the ‘Fused toes (Ft)’ mouse 
mutation): Fatso (Fto), inspired by the large size of the new gene (Peters et al., 
1999), not knowing this gene would be associated with obesity eight years later. 
For obvious reasons the gene name has been changed given this new context, it 
is now refered to as FTO (or: fat mass and obesity associated). Since the FTO 
discovery, experimental work has focussed on elucidating the biological function 
of the gene in relation to body weight; experiments in mice have shown that FTO 
is abundantly expressed in the hypothalamus, and that expression levels are 
influenced by the nutritional state of the animal (Gerken et al., 2007). There is 
growing evidence that FTO is associated with increased food intake, and reduced 
satiety (Day and Loos, 2011).  
In times of scarcity survival depends on finding food. Especially during energy 
depletion food is attributed with reward and pleasure in brain systems to 
enforce searching. But even in times of plenty energy dense and nutritive food is 
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extremely rewarding, probably because energy storage is crucial in order to 
survive famines. In this situation homeostatic signalling must be overruled by the 
hedonic system. Nowadays prosperous societies have not suffered from famines 
in decades, but the brain reward system appears unchanged. Energy dense foods 
are readily available and apparently – given a high prevalence of obesity – 
homeostatic signalling is unable to prevent overeating. There are two main 
aspects of the hedonic regulation, for which nomenclature differs between 
authors, e.g., wanting vs liking; preparatory vs consummatory, appetitive vs 
consummatory etcetera, but the purpose of all the authors is to distinguish 
between the phase of wanting and getting the reward versus the phase of actual 
ingestion. I will refer to this as wanting and liking.  
 
In human eating behaviour these two concepts are very difficult to separate and 
they cause fierce debates (Havermans, 2011a,Finlayson and Dalton, 
2011,Havermans, 2011b), but animal research indicates that two distinct 
biological processes underlie these concepts. Wanting is driven by incentive 
expectancies; these are learned expectancies of a hedonic reward (e.g. tasty 
food, refreshing drinks, sexual partners, addictive drugs etcetera) (Berridge, 
2004). The extent of wanting changes equally with the value of the reward. A 
hedonic incentive is attention grabbing and will elicit goal-directed behaviour 
(Berridge, 2004), for example: sensing the odour of fresh bread passing a bakery 
can trigger a sudden urge for food. Dopaminergic projections from the brain’s 
ventral tegmental area (VTA) to the nucleus accumbens (NAc) are most 
important in this process (Berridge, 2004,Saper et al., 2002). The dopaminergic 
projections have an effect on wanting, but not on liking. Dopamine depleted 
mice still prefer sucrose solution over water but initiate licking less frequently 
(Cannon and Palmiter, 2003). In addition to this, hyperdopaminergic mice run 
faster in a runway test with sucrose rewards while they do not display a more 
positive affective reaction to sucrose (Pecina et al., 2003). Liking is the actual 
sensory pleasure of a reward (e.g. sweet taste) which is unconditioned (Berridge, 
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2004), and there is strong support for a role of opioids in the liking of food 
(Barbano and Cador, 2007,Kenny, 2011,Pecina and Smith, 2010). The opioid 
system regulates food intake by evaluation of the acute rewarding properties of 
palatable food. Opioid antagonists, such as naloxone or naltrexone, decrease the 
intake of highly palatable food (Barbano and Cador, 2006), whereas stimulation 
of opioid receptors enhances behavioural affective reaction and increases food 
intake (Pecina and Berridge, 2000). For a normal sense of reward both wanting 
and liking are necessary. If there is no liking then there is no need for wanting, 
and otherwise a feeling of desire (wanting) complements liking. Imbalanced 
liking and wanting processes have been suggested to be related to eating 
disorders and obesity (Finlayson et al., 2011,Berridge et al., 2010).  
It is well recognised that there is much more to eating behaviour than just 
balancing intake and expenditure. Cognitive, environmental, and social factors 
are, at the least, equally important in the regulation of eating behaviour. 
Homeostatic signals of a sated state can readily be overridden by learned cues, 
and equally, cues that signal danger can inhibit feeding even in the food-deprived 
(Petrovich, 2011). Homeostatic and non-homeostatic signals are so much 
intertwined that some even argue that a distinction between the two is no 
longer useful (Zheng and Berthoud, 2007). It has been hypothesized that for the 
regulation of energy balance it would be too risky to rely solely on changes in 
homeostatic parameters, rather, most regulation is thought to be anticipatory; to 
ensure what might be needed is provided for before it is needed, i.e. that the 
regulation of eating behaviour is aimed at preventing physiological imbalance 
(Woods and Ramsay, 2007,Benoit et al., 2010). Learning from past experience is 
of key importance in this, and interestingly the incentive value of certain foods 
depends on the circumstances; it is assigned cognitively, with higher incentive 
values assigned to foods when in a state of food deprivation (Benoit et al., 
2010,Zheng and Berthoud, 2007). This illustrates the complexity of decision 
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making in eating behaviour; internal homeostatic signals need to be evaluated in 
the context of past experience and current environment. Stress and social 
situations are important aspects of the environment. Perceived psychosocial 
stress has been linked to eating behaviour and body weight, and stress 
hormones are known to directly affect food intake (reviewed by (Spencer and 
Tilbrook, 2011)).  
 
Social norms affect the perception of an individuals own body weight, and are 
important determinants for changes in eating behaviour (reviewed by 
Hammond, 2010). Mueller et al show that the odds of an overweight girl trying 
to lose weight depend on whether her peers are also trying to lose weight 
(Mueller et al., 2010). Social networks actually relate to patterns of obesity; 
overweight adolescents tend to have overweight friends (Valente et al.,2009). 
The impact of friendship on eating was tested in a laboratory setting by Salvy and 
colleagues; they show that more food was consumed when individuals were 
paired with a friend than when they were paired with an unfamiliar peer, but 
interestingly – regardless of friendship – overweight youths consumed less food 
when paired up with a non-overweight peer (Salvy et al.,2009). This social 
influence on eating behaviour is also apparent when individuals are led to 
believe that food choices of others were either healthy or unhealthy, people 
tend to follow the example given to them (Burger et al., 2010). For the genetic 
studies of eating disorders it is most important to note that genes from a variety 
of processes (including homeostatic, hedonic, cognitive, and emotional) could 
harbour genetic risk variants for eating disorders (see Figure 2 for an overview of 



















Figure 2: Cognitive, reward, and homeostatic regulators (Zheng and Berthoud, 2007) 
A variety of processes are important in the regulation of eating behaviour. Apart from 
homeostatic regulators of energy balance reward, learning, memory, and decision 
making are important aspects of eating behaviour. This figure illustrates that a multitude 
of biological processes could harbour genetic risk variants for eating disorders. The 
figure was obtained from reference (Zheng and Berthoud, 2007).  
Broadly speaking, eating disorders (EDs) are characterised by distorted beliefs 
about weight, shape, and eating, and inappropriate behaviour to promote weight 
loss or to prevent weight gain. They are severe disorders associated with high 
levels of psychiatric comorbidity, and mortality; AN has the highest mortality rate 
of any psychiatric disorder (Jacobi et al., 2004b,Hoek, 2006,Swanson et al., 
2011,Crow et al., 2009). Furthermore, EDs are associated with an impaired 
quality of life (Swanson et al., 2011,Jenkins et al., 2011).  
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Three clinical ED categories are currently recognised in the Diagnostic and 
Statistical Manual of Mental Disorders fourth edition (DSM-IV): anorexia nervosa 
(AN), bulimia nervosa (BN), and eating disorder not otherwise specified (EDNOS). 
The difference between the categories lies a) in the weight; a diagnosis of AN 
requires a weight of less than 85% of that expected (or a body mass index (BMI) 
below 17.5), and b) in the frequency of inappropriate compensatory behaviours 
(such as self-induced vomiting and binging, i.e. eating an amount of food larger 
than most people would eat while experiencing a loss of control); which should 
occur at least twice a week for three months for BN, with all other ED cases 
categorised as EDNOS (note: the definitions of the categories are currently being 
reviewed and updated as part of the DSM-V development 
(http://www.dsm5.org; American Psychiatric Association), for which a series of 
reviews has been written in the International Journal of Eating Disorders 
specifically on the categorisation or subtyping of EDs (Peat et al., 2009,van 
Hoeken D et al., 2009,Wonderlich et al., 2009,Keel and Striegel-Moore, 
2009,Striegel-Moore et al., 2009,Becker et al., 2009,Wilson and Sysko, 2009)). In 
reality it is challenging to ‘fit’ a patient into these categories, most notably 
reflected by the disproportionate number of patients in the EDNOS category 
(Fairburn and Bohn, 2005), and because behaviour is not stable over time (Dalle, 
2011,Ackard et al., 2011). Especially the latter is complicating for aetiological 
research; when patients tend to migrate between categories it becomes very 
difficult to appoint specific risk factors to the categories, but merging the 
categories would potentially increase heterogeneity. Generally the weight 
criterion is considered a hallmark of AN (Bulik et al., 2007a), setting AN cases 
aside from other EDs. Chapter 2 of this thesis specifically studies the genetics of 
AN, whereas Chapter 3 and 4 study general ED traits, and for these reasons the 
next section will focus on general ED aspects, highlighting AN specifically where 
appropriate.      
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Prevalence studies of EDs are relatively recent; before the 1980s there was a 
general misconception about the frequency of mental disorders, a lack of reliable 
criteria and diagnostic instruments, and a focus on severe psychotic and neurotic 
disorders (Jacobi et al., 2004b). The diagnosis BN, as it is known now, was only 
defined in 1979 by Professor Gerald F.M. Russell from the Institute of Psychiatry 
in London (Russell, 1979). The general aim of prevalence and incidence (i.e. the 
rate at which new cases develop) studies is to aid health care management; for 
health care policy makers it is important to assess the cross-sectional size and 
scope of mental disorders, and the impairment, help-seeking behaviour, general 
correlates, and consequences associated with them. Even though these data are 
of significant value for aetiological research as they may hold important clues 
about the aetiology (Hoek and van Hoeken, 2003), the aims are however not 
always in line with the aims of aetiological research. E.g. with respect to 
aetiology lifetime prevalence of an individual is generally more important than 
cross-sectional prevalence in a population, and theoretically, there does not have 
to be any aetiological difference between a patient who receives treatment, and 
an individual with the disorder never detected by the health care system (Keski-
Rahkonen et al., 2007). Community studies show that most EDs are never 
treated, at least not specifically for their ED (Hoek and van Hoeken, 2003,Keski-
Rahkonen et al., 2007,Hudson et al., 2007,Swanson et al., 2011). Hoek and van 
Hoeken estimate that only one-third of AN cases receives specialised mental 
health care, and only 6% of BN cases (see Table 1) (Hoek and van Hoeken, 2003).  
 
[table unavailable in e-thesis] 
 
 
Table 1: Eating disorders at different levels of care (Hoek and van Hoeken, 2003) 
Hoek and van Hoeken estimate the one year period prevalence rates in the community 
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to be 370 for AN and 1,500 for BN per 100,000 young females (Hoek and van Hoeken, 
2003). They estimate that only one third of AN cases receives specialised mental health 
care, and only 6% of BN cases. Most ED cases remain undetected by the health care 
system.  
There are many factors that complicate the interpretation of prevalence and 
incidence studies, including different diagnostic definitions of disorders (Jacobi et 
al., 2004b), different definitions of prevalence and incidence (Hoek and van 
Hoeken, 2003), a learning curve in identification of EDs by primary care (van Son 
et al., 2006), sampling biases related to urban and rural areas; the prevalence of 
BN is associated with urban areas, and the same may hold true for EDNOS 
(Machado et al., 2007), community versus clinical samples (Hoek and van 
Hoeken, 2003), prevalence and incidence rates differing for different age groups, 
and for gender (Jacobi et al., 2004b,Currin et al., 2005,Hudson et al., 2007), and 
differences for birth cohorts, i.e. generation specific differences (Jacobi et al., 
2004b,van Son et al., 2006,Hudson et al., 2007). It is very difficult to assess 
whether there are true increases and decreases in incidence of a disorder, an 
interesting example of this occurred in the UK in the 1990s: Currin et al report an 
increase in incidence specifically of BN at primary care level, and they speculate 
that the media attention surrounding Princess Diana’s battle with BN may have 
temporarily decreased the shame associated with the illness, encouraging 
individuals to seek help for the first time (Currin et al., 2005). The apparent 
increase in incidence thus may have been caused by a shift in the level of health 
care utilisation, rather than a true increase of BN.   
 
Generally the lifetime prevalence of strictly defined EDs (by DSM-III and DSM-IV 
criteria) is 0.3% for AN, and 1% for BN, with higher prevalence rates for females 
than males (Hoek and van Hoeken, 2003,Jacobi et al., 2004b,Hudson et al., 
2007,Machado et al., 2007,Raevuori et al., 2009,Swanson et al., 2011). In 
Sweden, Finland, and Australia somewhat higher prevalence rates were found 
for AN in females, up to 2% (Bulik et al., 2006,Keski-Rahkonen et al., 2007,Isomaa 
et al., 2009,Wade et al., 2006). The peak age of onset of EDs is in adolescence: 
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roughly between 10 and 20 years of age (Hoek and van Hoeken, 2003,Currin et 
al., 2005,van Son et al., 2006,Hudson et al., 2007,Keski-Rahkonen et al., 
2007,Swanson et al., 2011), though it should be noted that study design can 
significantly bias age of onset estimates; several researchers note that 
retrospective age of onset is notoriously unreliable (Jacobi et al., 2004b,Swanson 
et al., 2011). Despite the fact that most prevalence studies have focussed on 
Western European and American populations EDs occur cross-culturally, 
particularly BN and binge eating occur frequently in non-white ethnic 
populations (reviewed by Hoek (Hoek, 2006))(Swanson et al., 2011).  
 
An important limitation of the prevalence and incidence studies is that they 
generally focus only on AN and BN, whereas most patients seen in clinical 
practice are EDNOS (Fairburn and Bohn, 2005). EDNOS includes patients that 
closely resemble AN or BN, but they fall short on one or more criteria by for 
example: having a BMI of 18 rather than below 17.5, or because they binge on 
amounts of food that are not ‘objectively’ large, or because they do not exhibit 
the inappropriate compensatory behaviour regularly enough during a period of 
three months, etcetera. Two specific EDNOS conditions have been described 
extensively in the literature and are being considered for DSM-V: binge eating 
disorder (recurring episodes of binge eating) (Wonderlich et al., 2009) and 
purging disorder (compensatory behaviour for weight and shape control by an 
individual of normal weight after eating small amounts of food) (Keel and 
Striegelmoore, 2009). From both a treatment and an aetiological perspective 
these ‘atypical’ ED cases are not necessarily different from the currently defined 
cases (Fairburn and Harrison, 2003). Even though most prevalence studies have 
only focussed on AN and BN, many studies have included sub-threshold or 
EDNOS cases, and they show that their prevalence is much higher than strictly 
defined AN and BN; up to 5% in the community (Hoek and van Hoeken, 
2003,Wade et al., 2006,Machado et al., 2007,Keski-Rahkonen et al., 
2007,Swanson et al., 2011). It is generally accepted that EDNOS cases are not 
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necessarily less severe EDs (Schmidt et al., 2008,Machado et al., 2007,Currin et 
al., 2005,Keski-Rahkonen et al., 2007,Swanson et al., 2011,Fairburn and Cooper, 
2011,Dalle, 2011); most notably illustrated by the high mental health services 
use of sub-threshold ED cases, and the higher number of sub-threshold AN cases 
with suicide plans and attempts versus strictly defined AN cases found by 
Swanson et al (Swanson et al., 2011). Community studies that have used 
dimensional measures of disordered eating behaviour have yielded even greater 
prevalence rates; up to 30% in adolescents in the community (Costarelli et al., 
2011,Jones et al., 2001,Treasure et al., 2010). Overall it can be concluded that 
there is much discussion about the definition of an ED, but it is clear that 
disordered eating is highly prevalent, especially among female adolescents.  
Inappropriate eating behaviour usually starts gradually and is often secretive, 
and can go unnoticed for long periods of time. Friends and teachers may be the 
first to notice abnormal behaviour and weight loss (Miller and Golden, 2010). 
Patients may present to primary care with non-specific medical complaints, such 
as menstrual irregularities, heightened sensitivity to cold, fatigue, constipation, 
dizziness, or abdominal pain, and their physical appearance may be gaunt and 
pale, with sunken eyes, and thin limbs (Fairburn and Harrison, 2003,Miller and 
Golden, 2010). Patients with AN will present particularly with signs of 
malnutrition and starvation; a (very) low weight, pubertal delay or poor growth, 
low heart rate and blood pressure, dry skin often with an excess of fine soft hair 
(i.e. lanugo), scalp hair may be thinning and brittle, and extremities may be cold 
and cyanotic (Fairburn and Harrison, 2003,Miller and Golden, 2010). There can 
be many haematological abnormalities including among others anaemia, 
hypoglycaemia, hypokalaemia, low levels of thyroid hormones, 
hypercholesterolaemia, and deficiencies in zinc, vitamin D, vitamin K, etcetera 
(Fairburn and Harrison, 2003,Miller and Golden, 2010). All of these 
characteristics tend to be secondary to the inappropriate eating behaviour and 
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weight loss, and are generally reversible with restoration of weight, with the 
exception of reduced bone density (Fairburn and Harrison, 2003). Osteoporosis is 
a common and serious consequence of AN, leaving patients with an increased 
lifetime risk of bone fractures (Mehler et al., 2011). In addition to severe 
restriction of food intake patients often present with increased physical activity, 
which contributes to their weight loss (reviewed by (Scheurink et al., 2010)). The 
core psychopathology of AN is often accompanied by symptoms of depression, 
anxiety, irritability, impaired concentration, loss of sexual appetite, and 
obsessionality, all of which typically improve with weight gain (Fairburn and 
Harrison, 2003).  
 
In patients with BN and EDNOS the physical symptoms are much more subtle; 
body weight is often in the normal range, though it can fluctuate significantly 
over time. BN and EDNOS (and sometimes AN) are typically characterised by 
repeated binges, in which a large amount of food is eaten, accompanied by a 
sense of lack of control. In most instances the binge is compensated for by self-
induced vomiting or misuse of laxatives (i.e. purging) (Fairburn and Harrison, 
2003). There can be signs of self-induced vomiting such as enlarged salivary 
glands, dental enamel erosion, Russell’s sign (a thickening of the skin on the back 
of the hand, caused by the scraping of the teeth when inducing vomiting 
(Daluiski et al., 1997), and electrolyte disturbances (Fairburn and Harrison, 
2003,Miller and Golden, 2010). Typically the behaviour is not regarded as 
problematic when it is ‘successful’; low weight is generally regarded as an 
achievement, whereas weight gain represents failure (Fairburn and Harrison, 
2003). Interestingly in health surveys AN patients tend to report themselves to 
be in excellent health (Bulik et al., 2006). However overall, binging and purging 
behaviour is associated with high levels of shame and distress, social withdrawal, 
and symptoms of depression and anxiety (Troop et al., 2008,Fairburn and 
Harrison, 2003).  
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As was mentioned earlier, in reality it is very challenging to ‘fit’ an individual into 
a diagnostic category, because there is substantial overlap between the 
symptoms and because migration between categories over time is very common 
(Fairburn and Harrison, 2003,Treasure et al., 2010,Dalle, 2011), nicely illustrated 
by Fairburn (see Figure 3, (Fairburn and Harrison, 2003)). Anderluh et al 
retrospectively assessed lifetime course of EDs in 97 patients, and found that 
40% had experienced at least one diagnostic cross-over (Anderluh et al., 2009). 
Keel and Brown conclude in their review that most AN had transitioned to BN or 
EDNOS at follow up 2.5 to 18 year later, and that many BN had transitioned to 
EDNOS (Keel and Brown, 2010). But they also note that AN patients were more 
likely to retain their AN diagnoses than to fully change into BN, and they 
speculate that these transitions could represent states of partial remission (Keel 
and Brown, 2010). A recent community survey of 2,516 adolescents confirms this 
instability of disordered eating behaviour; 82% of females with self-reported 
disordered eating at baseline had remained symptomatic five years later, but 









Figure 3: Cross-over between diagnostic categories of EDs (Fairburn and Harrison, 2003) 
Schematic illustration of the movement between the ED categories, larger arrows 
indicate the likelihood of direction (Fairburn and Harrison, 2003).  
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This ‘comorbidity’ within the ED category also holds true for psychiatric disorders 
in general; most ED patients fulfil at least one set of criteria for an another 
psychiatric disorder (Jacobi et al., 2004b,Hudson et al., 2007,Swanson et al., 
2011,Dalle, 2011,Treasure et al., 2010). In a nationally representative German 
community health survey it was found that more than 60% of individuals with an 
ED diagnosis had an additional psychiatric diagnosis (note: ED diagnosis was the 
12-month prevalence of ‘any eating disorder’ which included AN, BN, and 
atypical AN and BN, (Jacobi et al., 2004b)). Jacobi et al determined the most 
frequent combinations of diagnoses, and EDs were not among the five most 
frequent patterns of comorbidity, unlike depression, anxiety, and somatoform 
disorders (note: anxiety included obsessive compulsive disorder (OCD), and 
somatoform included somatisation disorders, hypochondriasis, and pain 
disorders, (Jacobi et al., 2004b)). This pattern was confirmed by more recent 
community health surveys; Hudson et al found that no single class of disorders 
stood out as showing frequent comorbidity with ED (Hudson et al., 2007), and 
Swanson et al found that AN was not associated with any particular disorder, 
apart from ‘oppositional defiant disorder’, and that in contrast, BN was 
significantly associated with nearly every other disorder (Swanson et al., 2011). 
In ED research this comorbidity between EDs and other disorders is studied 
intensively, because it could have significant implications for both treatment and 
aetiology (Altman and Shankman, 2009,Dellava et al., 2011,Treasure et al., 
2010,Dalle, 2011).  
It is perhaps not surprising, judging from the previously discussed problematical 
categorisation of EDs, and the instability of behaviour over time, that screening 
for EDs in the general population is challenging. It is generally accepted that a 
structured or semi-structured interview such as the Eating Disorder Examination 
(EDE) (Fairburn and Cooper, 1993) by a clinician or trained interviewer is the gold 
standard in diagnosing an ED, but self-report questionnaires are more cost- and 
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time-effective, especially when assessing a large number of individuals (Jacobi et 
al., 2004a,Tury et al., 2010). Historically, assessment methods have focussed on 
early detection of AN (Jacobi et al., 2004a); a complicated undertaking given the 
low prevalence of stricty defined AN. Many self-report assessment methods have 
been developed for EDs since (reviewed by (Tury et al., 2010)); some are general 
measures of disordered eating behaviour (such as the Eating Disorder Inventory 
(EDI) (Garner et al., 1983)), some are specifically designed as diagnostic 
instruments (such as the Eating Disorder Examination Questionnaire (EDE-Q) 
(Fairburn and Beglin, 1994) or the Eating Disorder Diagnostic Scale (EDDS) (Stice 
et al., 2000)), and some are aimed at screening the general population for 
individuals at risk (such as the Eating Attitudes Test (EAT) (Garner and Garfinkel, 
1979), and the SCOFF (Morgan et al., 2000)) (Tury et al., 2010). The EDI has been 
labelled as the most comprehensive self-report measure of eating disorders 
psychopathology, but has been critised for being too long as a screening 
instrument (Mond et al., 2004,Keski-Rahkonen et al., 2006), and for a lack of 
validity of the internal factor structure (Garcia-Grau et al., 2010). Because the EDI 
is the focus of two chapters of this thesis it will be more extensively discussed in 
the introduction of Chapter 3, page 107.  
 
Several possible risk factors have been identified for EDs, but few have proven to 
be specific, apart from pregnancy- and birth related complications (Cnattingius et 
al., 1999,Micali and Treasure, 2009). Generic risk factors associated with EDs 
include gender, negative self-evaluation, weight and shape concerns, dieting, 
perfectionism, selflessness, sexual abuse, a family history of EDs, genetics, and 
general psychiatric morbidity including depression and anxiety (Killen et al., 
1994,Fairburn and Harrison, 2003,Jacobi et al., 2004a,Bulik et al., 2006,Dalle, 
2011,Jacobi et al., 2011,Bachar et al., 2010). Many of these risk factors overlap 
with those for other psychiatric disorders, which is not surprising given the high 
level of comorbidity (also see paragraph 1.2.3 C r o s s - o v e r  a n d  c om o r b i d i t y ). 
From a prevention point of view the specificity of the risk factors is perhaps of 
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lesser importance, as Stice rightly points out: ‘It is arguably more important to 
identify youth at elevated risk for any eating disorder, because prevention 
programs should ideally target all eating disorders rather than just one type of 
eating disorder’ (Stice et al., 2011). Stice et al found in a eight-year prospective 
study of 496 adolescent girls that body dissatisfaction was the risk factor with the 
greatest predictive potency; participants with high body dissatisfaction had a 
four-fold increase in incidence for disorder onset compared to those with lower 
body dissatisfaction, and notably among those with high body dissatisfaction, 
dieting behaviour and symptoms of depression further increased the risk (Stice 
et al., 2011). Jacobi et al found similar interactions of risk factors; in their three-
year follow up study in a sample of 236 college-aged women critical comments 
about eating from teachers or siblings, and symptoms of depression predicted 
the onset of an ED best (Jacobi et al., 2011).  
Genetic risk factors have long been postulated to be important in the aetiology 
of EDs (Strober and Humphrey, 1987,Holland et al., 1988,Lilenfeld et al., 
1998,Strober et al., 2000,Bulik et al., 2000,Klump et al., 2001,Slof-Op 't Landt MC 
et al., 2005). However, given the complex clinical presentation of EDs (also see 
paragraph 1.2.2 C l i n i c a l  p r e s e n t a t i o n , page 32) it may be difficult to imagine 
how genetics could be relevant at all. We have however fewer difficulties 
accepting that ‘something runs in the family’, including (very complex) character 
traits. And we do not object when siblings – born and raised in the same family 
environment – differ substantially for these (very complex) character traits. 
Technically speaking, for something to be able to ‘run in the family’, genetics is 
likely to be involved, even for very complex traits.  
In the 1970s genetics was first considered in the aetiology of EDs, because an 
increased prevalence of EDs was reported in first degree relatives of sufferers 
1.3.  Genetics of eating disorders 
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(this history of was described in (Strober and Humphrey, 1987,Rutherford et al., 
1993,Gorwood et al., 1998) and (Gordon, 1998)). Correlation between relatives 
does not prove genetic influences per se, but the results of twin studies also 
support the notion of a heritable component in the aetiology of EDs (Bulik et al., 
2000,Klump et al., 2001,Slof-Op 't Landt MC et al., 2005). Twin studies are based 
on the difference in correlation of disease between monzygotic (MZ, i.e. 
identical) twins and dizygotic (DZ, i.e. fraternal) twins, who were born and raised 
together. The only assumed difference between MZ and DZ twins is their genetic 
resemblance; MZ twins are considered genetically identical, and DZ twins only 
share, on average, half of their genes. Genetically DZ twins and regular siblings 
are equally equal, but DZ twin pairs are a unique ‘control group’ for MZ twin 
pairs because they have also shared their prenatal environment, and are of equal 
age.  
 
The principle of twin studies is based on the following (note: this is a 
simplification aimed at explaining the principle rather than the details): 
Theoretically an entirely genetic trait would correlate 100% between MZ twins, 
and 50% between DZ twins. Any measurement error would lower the 
percentages, but the correlation between DZ twins would remain approximately 
half that of MZ twins. Accordingly, a completely environmental trait would 
correlate equally between MZ and DZ twins, because MZ and DZ twin pairs share 
their environment to an equal extent, at least, that is the assumption. There has 
however been much discussion about the assumptions on which twin study 
designs were based, and not only has the validity of the equal environment 
assumption been questioned (e.g. (Richardson and Norgate, 2005) and (Mitchell 
et al., 2007)), the presumed genetical identicality of MZ twins does not hold 
completely true either (reviewed by (Kato et al., 2005), (Machin, 2009), and 
(Zwijnenburg et al., 2010)) (note: in this context epigenetic differences are 
relevant too (Kato et al., 2005,Wong et al., 2010,Campbell et al., 2011)). While 
genetic discordance between MZ twins is an exciting new opportunity to study 
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the genetics of disease, it must be noted that the genetic discordance between 
MZ twins is only minor, and the true effect size of these differences has yet to be 
established. There is no question that MZ twins have a very much higher genetic 
resemblance than DZ twins, and even though the heritability estimates may have 
to be adjusted as they may slightly overestimate the role of genes, they are 
widely accepted (Manolio et al., 2009,Bulik et al., 2010). As Manolio et al point 
out; the exact heritability estimate is of lesser importance if genetic research 
leads to one new insight into the aetiology of complex disorders (Manolio et al., 
2009), the finding of FTO in obestity is a good example of this (Frayling et al., 
2007) (also see paragraph 1.1 N o rm a l  r e gu l a t i on  o f  e a t i n g  beha v io u r , 
page 20). 
 
Twin studies of EDs have reported estimated heritabilities of EDs of around 50% 
(Bulik et al., 2000,Wade et al., 2000,Slof-Op 't Landt MC et al., 2005,Klump et al., 
2001,Bulik et al., 2010), with a slightly lower estimate in a recent study using a 
marginal maximal likelihood approach (Mazzeo et al., 2009). The confidence 
intervals of these estimates are however generally very wide, e.g. in the 2010 
paper by Bulik et al the estimated heritability of strictly defined AN was 60%, 
however the 95% confidence intervals ranged from 0.00 to 0.81 (Bulik et al., 
2010). Given the problematic categorisation, the overlap in symptoms between 
categories, the instability of diagnoses over time, and the generally complex 
clinical presentation of EDs (see paragraph 1.2 Ea t i ng  d i so rd e r s , page 27) 
this is however not surprising; it is merely a reflection of the complexity of EDs. 
An important finding from family and twin studies is that EDs do not ‘breed true’; 
i.e. relatives of patients with AN could for example present with BN, or EDNOS 
(Strober and Humphrey, 1987,Bulik et al., 2007b,Bulik et al., 2010). In 1987 
Strober and Humphrey already suggested that the heritability of EDs may lie in 
their personality traits (Strober and Humphrey, 1987). Personality is a very 
important concept in EDs (recently reviewed by Lilenfeld (Lilenfeld, 2011)), and 
several twin studies have studied the heritability of (personality) traits, attitudes, 
- 40 - 
and temperament in EDs, and have demonstrated substantial heritability 
(reviewed by Thornton (Thornton et al., 2011)).  
The classical approach to the detection of genes for genetic disorders has been 
family-based linkage analysis followed by positional cloning. Genetic linkage is 
the tendency of genetic loci to be inherited together, and family-based linkage 
analysis aims to associate the inheritance of these loci with the disorder. This 
approach can be used to find the chromosomal position of disease genes using 
genetic markers, if a disease gene is close to a particular genetic marker they will 
tend to be inherited together in a family, or shared by affected relatives. This 
was very successful for single-gene disorders such as cystic fibrosis, and was 
consequently attempted for complex disorders such as AN and BN. The 
difficulties in linkage analysis of complex disorders are likely to relate to their 
genetic architecture (also see paragraph 1.3.4.3 Und e t e c t e d  h e r i t a b i l i t y  a n d  
g e n e t i c  a r c h i t e c t u r e , page 52). Large scale genome-wide association studies 
now show that complex disorders tend to be associated with common, low risk 
genetic variants (Cichon et al., 2009,Visscher et al., 2011,Day and Loos, 2011). 
Linkage analysis however is unable to detect these, because the effect size is too 
small to see in a practical number of pedigrees (Risch and Merikangas, 1996).  
 
Several studies have attempted to detect susceptibility loci for EDs using 
genome-wide linkage analysis, they have focussed primarily on affected relative 
pairs with EDs because multiply affected families with AN are very rare. Grice et 
al performed genome-wide linkage analysis of 192 families with at least one 
affected relative pair with AN and related EDs, including BN (Grice et al., 2002). 
Analysis resulted in modest evidence for linkage at marker D4S2367 on 
chromosome 4, and when they reduced the sample heterogeneity by only 
including families with at least two relatives with restricting AN (n=37) they 
1 .3 . 2 .  L i nka g e  s t u d i e s
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found suggestive evidence for an AN-susceptibility locus on chromosome 1 (Grice 
et al., 2002).  
 
Since AN is an unstable diagnosis, studies have also used quantitative traits for 
linkage, including those related to other psychiatric disorders, personality, and 
temperament in eating disorders. Devlin et al used two quantitative traits, drive 
for thinness (DT) from the Eating Disorders Inventory (EDI), and obsessionality 
from the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), in 196 multiplex 
families with an AN proband (note: the same sample as Grice et al (Grice et al., 
2002)) for genome-wide quantitative trait linkage (Devlin et al., 2002). Using a 
novel method that incorporates covariates, they found several regions of 
suggestive linkage: one close to genome-wide significance on chromosome 1 for 
a combined drive-for-thinness–obessionality phenotype, another on 
chromosome 2 for obessionality only, and a third region on chromosome 13 for 
drive for thinness (DT) only (Devlin et al., 2002).  
 
Linkage studies have also been used to examine BN (Bulik et al., 2003), using 
microsatellite markers in 308 multiplex families with EDs identified through a 
proband with BN; the highest nonparametric multipoint maximum LOD score 
(MLS) was 2.92, on chromosome 10p. A symptom marker of BN, self-induced 
vomiting, was also used as a linkage phenotype in a subset of families with at 
least two affected relatives reporting this, which produced the highest MLS 
(3.39) at the same locus on chromosome 10p, indicating this region may harbour 
susceptibility alleles for BN. Interestingly, this region on chromosome 10 was also 
associated with obesity (Hager et al., 1998). As patients with BN pre-morbidly 
tend to have a higher BMI, the chromosomal region might point to a gene 
relevant for both body weight regulation and eating disorders. Linkage analyses 
of behavioural phenotypes related to EDs, such as obsessionality, age at 
menarche, anxiety, lifetime minimum body mass index (BMI), concern over 
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mistakes, and food-related obsessions have also been conducted (Bacanu et al., 
2005). Significant linkage was found for minimum BMI at chromosome 4 
(4q21.1), for concern over mistakes at chromosome 16 (16p13.3) and 
chromosome 14 (14q21.1), and for food-related obsessions (14q21.1) (Bacanu et 
al., 2005). No significant loci were found for AN and overlap between the AN and 
BN cohorts was minimal for substantial linkage signals (Bacanu et al., 2005). 
The candidate gene approach examines genes which are suspected of being 
involved in a disease, because the function of the gene product suggests that it 
could be related to the pathophysiology of the disease. For example, in type 2 
diabetes (T2D), two candidate genes from the insulin pathway have been 
successfully examined for association with the disease (Prokopenko et al., 2008). 
The main flaw of candidate gene studies is the low prior probability of 
association, since for most diseases, the task of selecting the correct candidate 
gene from the 30,000 or so human genes is very difficult, even when there is 
detailed knowledge of pathophysiology, since the function of most genes is 
poorly characterised. Because of this, but also because of other issues such as 
statistical power and poor genetic coverage, candidate gene studies have had 
limited success (Tabor et al., 2002,Kim et al., 2011). For example, despite 
hundreds of candidate gene studies in T2D, only two have stood the test of time: 
the Pro12Ala variant in the PPARG gene, involved in insulin action, and the 
Glu23Lys variant in KCNJ11 gene, involved in β-cell dysfunction (Prokopenko et 
al., 2008). 
 
In psychiatric disorders candidate gene studies are even more difficult as there is 
even less information on pathophysiology, thus it is more difficult to select good 
candidate genes. However there have been some successes: attention deficit 
hyperactivity disorder (ADHD), which is commonly treated by dopaminergic 
system drugs such as methylphenidate, has been associated with genes from the 
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dopamine system, particularly the dopamine D4 and D5 receptor genes DRD4 
and DRD5 (Thapar et al., 2007). There has been a series of candidate gene 
studies in EDs, which examined neurotransmitter or other pathways related to 
behaviour, such as the serotonin and dopamine systems, the neuropeptides 
implicated in eating behaviour (also see paragraph 1.1 No r ma l  r e g u l a t i on  o f  
e a t i ng  be hav io u r , page 20), or genes associated with obesity (Pinheiro et al., 
2010,Rask-Andersen et al., 2010b,Scherag et al., 2010). Few if any of these 
candidate-gene association studies have replicated genetic association. Some 
findings remain interesting if controversial, in particular agouti-related protein 
(AgRP) (Vink et al., 2001), brain derived neurotrophic factor (BDNF) (Ribases et 
al., 2003,Ribases et al., 2004), and the serotonin, dopamine, and opioid receptor 
types (Collier et al., 1997,Gorwood et al., 2002,Ziegler et al., 1999,Bergen et al., 
2003,Brown et al., 2007,Kiezebrink et al., 2010,Bergen et al., 2005,Dmitrzak-
Weglarz et al., 2007).  
 
Brandys et al examined several genetic variants associated with body mass index 
(BMI), identified by genome-wide studies of obesity, for association with AN, in a 
sample of 267 AN patients and 1,636 population controls (Brandys et al., 2010). 
They found no evidence that genetic variants regulating BMI in the general 
population are significantly associated with susceptibility to AN. One variant not 
included in these analyses was the Val66Met variant in the BDNF protein. 
However in a later meta-analysis Brandys et al tested the evidence for 
association with this variant specifically; this functional single nucleotide 
polymorphism (SNP) (also identified as rs6265), is a missense variation; the two 
different alleles of the BDNF Val66Met variant (note: 66 refers to the location of 
the variant in the protein), guanine (G) and adenine (A), lead to two different 
amino acids, Valine (Val) and Methionine (Met), and they lead to a different 
protein structure of BDNF (Noble et al., 2011). This variant is a strong candidate 
in the aetiology of EDs; in obesity, genome-wide association (GWA) studies found 
significant association, with the Val66 allele increasing the likelihood of higher 
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BMI (Thorleifsson et al., 2009). Meta-analyses by Brandys et al in a sample of 
2,767 AN cases and 3,322 controls were non-significant for association with AN, 
and the authors concluded that the BDNF Val66Met is not associated with AN, at 
least not at (currently) detectable levels (Brandys et al., 2011).  
 
The most extensive candidate gene study of AN done thus far studied over 5,000 
SNPs in 182 genes using a sample of 1,085 AN cases and 677 controls (Pinheiro et 
al., 2010). Pinheiro et al selected the SNPs on the basis of previous association 
data, gene expression in the brain, biological plausibility, and markers from 
regions linked to AN in family based linkage studies (Pinheiro et al., 2010). After 
accounting for multiple testing, there were however no statistically significant 
associations (Pinheiro et al., 2010). The authors state that their results 
nevertheless include a number of potentially interesting findings, including the 
receptor of the proglucagon-derived gut peptide (GLP2R), the phenylalanine 
hydroxylase (PAH) gene, and a small-conductance calcium-activated potassium 
channel (KCNN3), expressed in the brain. For KCNN3, a repeat polymorphism in 
the gene has previously been associated with AN (Koronyo-Hamaoui et al., 
2004,Koronyo-Hamaoui et al., 2002). Larger samples will however be required to 
verify these results.  
Since these studies, advances in genotyping technologies have allowed the 
development of several genome-wide association (GWA) studies; these studies 
analyse hundreds of thousands genetic variations at once, and do not rely on 
assumptions, or hypotheses, on the underlying aetiology of a disorder (Corvin et 
al., 2010). Two very important concepts in GWA studies are linkage disequilibrum 
(LD) and multiple testing, because they are very important for the interpretation 
of the results of this thesis, this paragraph will start with a detailed explanation 
on them, followed by an overview of results achieved thus far through use of this 
relatively new genome-wide genetic association method. Because only one small 
1 .3 . 4 .  G en om e - w i d e  a s s o c i a t i o n  ( GW A )  s t u d i e s  
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scale GWA study on AN has been published thus far (Wang et al., 2011), which 
found no significant results after correction for multiple testing, parallels will be 
drawn with other complex disorders and traits, such as other psychiatric 
disorders, body mass index, human intelligence, and height.  
Genetic variants in the DNA are not independent of each other, especially when 
they are located closely together (in the DNA) they tend to be inherited together 
(in their review on the genetics of height, McEvoy and Visscher elegantly discuss 
the basics of genetic variants and inheritance (McEvoy and Visscher, 2009)). One 
paternal and one maternal copy of the DNA are transmitted to the offspring via 
so called ‘gametes’ i.e. the sperm and the egg cell. During the generation of the 
gametes the DNA ‘recombines’, through the process of ‘crossover’. This 
recombination generates a new unique combination of DNA (Lichten et al., 
2011). In the human genome, there are two to three crossover events between 
each pair of chromosomes in the formation of gametes. There are obvious 
constraints to this process, because genomic integrity needs to be maintained; 
aberrant crossovers would have deleterious outcomes, with severely 
problematic recombination being lethal for the embryo, and less severely 
problematic recombination being associated with developmental disabilities and 
disease (Coop and Przeworski, 2007). Recombination is not completely at 
random, there are so-called ‘recombination hotspots’ (i.e. ‘exchange sites’) in the 
DNA, it has been estimated that there are approximately 25,000 such hotpots in 
the human DNA (Coop and Przeworski, 2007).  
 
This process of recombination and crossover causes the chromosomes to be 
shuffled into new combinations. Over the course of many generations, as 
crossover events accumulate, chromsomes become increasingly different 
between families; divergence increases over multiple generations, and between 
populations and ethnicities. Within families, (sub)populations, and ethnicities, 
1 .3 . 4 . 1 .  L i nka g e  d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g
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there is however significant overlap of genomic regions; the more closely related 
individuals are, the more equal their DNA is. This relatedness can be very 
problematic for genetic research; if controls are not sampled from exactly the 
same population as the cases, it can cause spurious genetic associations. In 2003 
the International HapMap project (HapMap, 2003) set out to map common 
patterns of genetic variation in the population by genotyping the DNA of 
individuals from various ethnicities. They calculated the pairwise correlation 
between any two genetic loci (i.e. DNA base pairs; I refer to these as ‘genetic 
variants’) in a given population; these data can be looked up e.g. via their online 
genome browser: http://hapmap.ncbi.nlm.nih.gov or through software tools 
such as Haploview (Barrett et al., 2005). 
 
When two genetic variants occur together in the genome more often than 
expected by chance we say they are in ‘linkage disequilibrium (LD)’, i.e. they are 
correlated in the given population; when one genetic variant is found in an 
individual (from the given population) it is very likely the correlated genetic 
variant will be present in this individual as well. Strongly correlated genetic 
variants are said to be in ‘strong LD’, and when genetic variants do not occur 
together more often than expected by chance they are said ‘not to be in LD’. 
Short genomic regions that are in strong LD are referred to as haplotype blocks; 
they are comprised of genetic variants in strong pairwise LD, i.e. haplotypes are 
‘blocks’ of DNA inherited together across many generations (Browning and 
Browning, 2011). Since haplotypes are the focus of Chapter 2 of this thesis they 
will be discussed in more detail in the next chapter (paragraph 2.1 Li t e r a tu re  
b ackg r ou nd , page 59). Figure 4 and Figure 5 illustrate recombination 
processes, and linkage disequilibrium.  
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Figure 4: The principle of linkage disequilibrium - generation 1 
In gamete formation the chromosomes are ‘shuffeled’ into new combinations through a 
process of recombination and crossover. Over the course of many generations, as 
crossover events accumulate, chromsomes become increasingly different between 
families (also see Figure 5). Linkage disequilibrium (LD) refers to the extent of correlation 
between any two genetic variants in a population; complete LD (indicated by black 
blocks) indicates that the two variants are strongly correlated, i.e. they always occur 
together, and no LD (indicated by white blocks) indicates that the two variants do not 
occur together in the population more often than expected by chance.  
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Figure 5: The principle of linkage disequilibrium - generation 2 
This figure illustrates that over the course of many generations the levels of LD between 
any two genetic variants in the genome can vary (with darker blocks indicating higher 
LD). Recombination does not occur completely at random, there are several 
‘recombination hotspots’ (Coop and Przeworski, 2007). The International HapMap 
project has mapped common patterns of LD in different ethnic populations (HapMap, 
2003).  
Genome-wide association (GWA) studies have cleverly made use of the concept 
of linkage disequilibrium (LD); per ‘block’ of DNA only one genetic variant needs 
to be genotyped to be able to infer (i.e. impute) the rest of the block based on 
pairwise LD. This principle is called ‘tagging’; where key genetic variants are 
genotyped to efficiently capture the majority of common genetic variation within 
a region. It has been estimated that approximately 500,000 tags are needed to 
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cover all genetic variants in the human genome (Cichon et al., 2009); hence the 
genotyping of these tags is referred to as genome-wide genotyping. This 
immediately also clarifies the limitations of genome-wide studies, a) the ‘tag’ is 
strongly correlated with the ungenotyped genetic variations but not fully, thus 
any true disease associations would be diluted (or underestimated) if the 
pairwise correlation between the genotyped tag and the ungenotyped disease 
variant is e.g. 0.8 instead of 1.0, b) rare variants, only occurring in some 
individuals or some subgroups of the population, can not be inferred using this 
method, c) when testing 500,000 genetic variants for association, many variants 
will be associated with the disease or trait of interest by chance and it has 
proven to be very challenging to filter the true positives from the false positives, 
i.e. ‘to separate the wheat from the chaff’.  
 
Because ‘genetic variants’ and ‘genome-wide assocation’ are quite abstract 
concepts I wanted to attempt an analogy to clarify them. Let’s say we are 
interested in the difference between commuters from Blackfriars train station in 
London (our cases) and commuters from London Bridge train station (our 
controls). We decide to study 1,000 individuals and we record 500,000 colours 
(our SNPs) per individual, namely eye colour, skin colour, hair colour, coat colour, 
wallet colour, purse colour, shoe colour, sock colour, etcetera, etcetera, 
etcetare. It will not be surprising that – by chance – some of the colours will 
appear at different frequencies between the commuters at Blackfriars and the 
commuters at London Bridge, e.g. London Bridge commuters may wear red socks 
significantly more often than Blackfriars commuters. The example of coloured 
socks may not be as ridiculous as it may sound; it is not unlikely that the average 
commuter at Blackfrairs, e.g. a banker working in the City of London, wears black 
socks more often than the average commuter at London Bridge, perhaps a nurse 
from the nearby Guy’s hospital who tends to wear white socks. The colour of the 
socks may thus be a good ‘tag’ for the profession of the commuter (let’s say our 
‘disorder’ of interest). The quality of the tag is however important; success 
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depends on how well the tag tags the cause. In the example, sock colour may 
significantly be associated with the profession of the commuter (bankers wear 
black socks more often than nurses), but the effect size of sock colour in relation 
to profession, or the predictive value of sock colour when screening commuters, 
may be poor.     
 
For the study of genetics of eating disorders it is important to note that a) a 
single nucleotide polymorphism (SNP), studied in genome-wide association 
(GWA) studies, is merely a ‘tag’ of common genetic variation in LD with the 
tagging SNP; i.e. the tagging SNP is not necessarily the causal genetic variant, and 
b) human assesement of the biological plausibility of the association is vital to 
‘separate the wheat from the chaff’.   
In 2005 Klein and colleagues published the first genome-wide association (GWA) 
study (Klein et al., 2005); they tested genome-wide genetic variations in 96 cases 
and 50 controls for asscociation with age-related macular degeneration, a major 
cause of blindness in the elderly. They genotyped 103,611 SNPs of which the 
association of two SNPs passed a conservative Bonferroni correction for multiple 
testing (Klein et al., 2005). One of the two associated SNPs was missing in 21 out 
of 150 individuals, and its distribution violated the Hardy Weinberg Equilibrium 
(the latter will be explained in detail in the next chapter, paragraph 2.5.3 
R e f e r e n c e  p o p u l a t i o n ,  a n d  Ha rd y  W e i n b e r g  Eq u i l i b r i um , page 82), which 
clearly indicated that this was a spurious result caused by technical genotyping 
errors (Klein et al., 2005). Klein et al went on to resequence the genomic region 
of the other associated SNP, which included the gene ‘complement factor H 
(CFH)’ (a key regulator of the complement system of innate immunity), and 
found a total of 50 genetic variations in the region, of which three were non-
synonymous (i.e. variations potentially affecting the protein functionality). Of 
these three non-synonymous SNPs a tyrosine-histidine variation was found to be 
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most strongly associated with the phenotype, and considered the ‘causal 
variant’, i.e. the variant causing the initial association, and the variant posing a 
risk factor in the development of age-related macular degeneration (Klein et al., 
2005). Klein et al proved biological plausibility of this association by showing that 
various components of the complement cascade were present in affected eyes of 
patients, leading to the hypothesis that age-related macular degeneration results 
from an aberrant inflammatory process that includes inappropriate complement 
activation (Klein et al., 2005).  
 
This spectacularly successful approach was rapidly copied by other researchers in 
other fields of science. Since 2005 more than 700 GWA studies have been 
published, more than 1500 genetic variations have successfully been associated 
with 101 human diseases and 124 traits (including height, and body weight or 
body mass index) (Kim et al., 2011), and the technique, data management, and 
statistical analyses of these fast amounts of data have been improved 
continously. Unfortunately not all studies were as successful as the one by Klein 
et al (Klein et al., 2005), hence in 2009 the Psychiatric GWAS Consortium 
Coordinating Committee published guidelines on GWA studies in psychiatry 
specifically (Cichon et al., 2009). The authors concluded a) that most genetic 
variation between any two individuals consisted of common (present in more 
than 5% of the population) single nucleotide polymorphisms (SNPs), and b) that 
most new findings were variants with a small increase in risk (relative risk 
between 1.12 and 1.2), and c) given the risk of false positive results, as a 
consequence of multiple testing, a genome-wide significance threshold of 
approximately 5 x 10-8 (5.00E-08) should be honoured (Cichon et al., 2009). 
Hence GWA studies would have to be performed using large sample sizes, of 
8,000 to 12,000 cases and controls, or more (Cichon et al., 2009). This daunting 
number of cases required for analyses has not held back researchers; large-scale 
world-wide collaborations have been initiated and the first successful results 
have been published, or will be published shortly (State and Levitt, 2011,Kim et 
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al., 2011) (note: the Genetic Consortium for Anorexia Nervosa (GCAN) will 
publish their first results in 2012).  
  
The proof of principle of the genome-wide technique comes from the results of 
the genetic studies of human height. It will be no surprise, even without 
calculations of heritability estimates, that height is a heritable trait (McEvoy and 
Visscher, 2009). Which genes accounted for this heritability was however not 
exactly known. GWA studies have now identified more than 50 genes or regions 
of the DNA associated with height (McEvoy and Visscher, 2009), and many of 
these genes are known to be involved in the development of bone and cartilage; 
they thus have obvious links to the regulation of observed height. Also, rare 
mutations in some of these genes had been linked to severe monogenic stature 
disorders, again supporting a role for the associated genes in normal height 
regulation (McEvoy and Visscher, 2009). Interestingly however, only 5 to 10% of 
the heritability of height has been explained so far (McEvoy and Visscher, 
2009,Visscher et al., 2011). With height having a less debated and more obvious 
heritability than most psychiatric disorders, this is encouraging for genetic 
studies of psychiatric disorders; i.e. it illustrates the difficulty of identifying 
genetic variants underlying any trait, and should encourage researchers in the 
field of psychiatry not to give up on such a promising method, despite the 
daunting sample sizes and the negative results (Visscher et al., 2011).  
The heritability estimates of disorders and traits have been the main driving 
force behind genetic studies, i.e. the increased prevalence of disorders among 
first degree relatives of probands, and the general resemblance between 
relatives, have prompted researchers to hunt for the genes that may underly 
disorders or traits (also see paragraph 1.3.1 He r i t a b i l i t y , page 37). The fact that 
only a small percentage of the heritability estimates have been explained, after 
analysing the DNA of thousands of cases (and spending much time and money), 
1 .3 . 4 . 3 .  U nd e t e c t e d  h e r i t a b i l i t y  a n d  g e n e t i c  a r c h i t e c t u r e
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has been used to critise genome-wide studies, and genetic studies in general. 
The success of these studies (also see pararagraph 1.3.4.2 W h e r e  i t  a l l  b e g a n , 
page 50) is apparently overlooked by these critics. Indeed much of the 
heritability is unexplained as yet, but it does not imply that genetic studies have 
failed.  Much has been learned about the genetic architecture of complex 
disorders and traits through these ‘failed’ studies, and many important new 
insights have been gained (Manolio et al., 2009,State and Levitt, 2011,Visscher et 
al., 2011,Day and Loos, 2011). For the genetic studies of EDs this actually 
presents an opportunity; based on the results of other psychiatric disorders, and 
other complex traits (such as body mass index), appropriate technologies and 
sample sizes can be chosen to optimise the chances of high-confidence results.  
 
There are many possible reasons for the missing or, probably more appropriate, 
undetected (Yang et al., 2011,Lango et al., 2010,Davies et al., 2011,Visscher et 
al., 2011) heritability. These reasons include imprecise phenotyping, inadequate 
accounting for shared environment in twin estimates of heritability, common 
genetic risk factors with (very) small effect sizes, rare genetic risk factors, gene-
gene interactions, gene-environment interactions, epigenetics, and an 
underestimated effect size due to causal variants being in less than full LD with 
the tagging variant (Manolio et al., 2009,Hebebrand et al., 2010,Kim et al., 
2011,Davies et al., 2011,Visscher et al., 2011,Day and Loos, 2011). All of these 
factors are probably involved, but the rare versus common genetic risk factors 
have been one of the most debated topics (Uher, 2009,Visscher et al., 2011). 
Uher argues that mental illnesses associated with (strong) reproductive 
disadvantage are likely to have a large contribution from rare variants of recent 
origin (Uher, 2009), and indeed in autism (associated with strong decreased 
reproductive fitness (State MW and Levitt, 2011)) there are a substantial number 
of well reported cases resulting from de novo (new, i.e. recent) mutations, and 
more than 300 rare autism spectrum related genetic variations have now been 
identified (State and Levitt, 2011). However, as State and Levitt also point out, it 
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is incredibly challenging to identify genes for behavioural, cognitive, and 
emotional phenotypes; neurodevelopmental processes are regulated by 
thousands of genes, with different functions at different timepoints in the 
development and functioning of the human brain (Rakic, 2009,State and Levitt, 
2011). For example, the genes found to be associated with autism tend to 
converge on alterations in the assembly and functioning of synapses (i.e. 
neuronal connections), and given the general non-specific function of these 
genes it is not surprising that the mutations associated with autism have also 
been found in individuals with more general non-specific social disabilities, 
language delay, selective mutism, and anxiety (reviewed by State and Levitt 
(State and Levitt, 2011)). Moreover, because of the importance of key processes 
such as synaptic functioning (i.e. the core process of brain functioning), there is 
much redundance in the biological processes involved, notably supported by the 
fact that these rare autism-related mutations also occur in non-affected 
individuals, including non-affected relatives (State and Levitt, 2011).  
 
The negative selective pressure on the genetic risk factors underlying disorders 
with strong reproductive disadvantage as Uher describes it (Uher, 2009) may 
however not correlate with the forces that have shaped human genetic variation 
throughout human evolution (Manolio et al., 2009,Visscher et al., 2011). Manolio 
et al (Manolio et al., 2009) describe for example that type 1 diabetes, also 
associated with poor reproductive fitness prior to the discovery of insulin 
therapy, has been successfully associated with common genetic risk variants 
when large sample sizes were analysed (Barrett et al., 2009). Visscher et al 
(Visscher et al., 2011) agree with Uher that most causal variants are expected to 
be rare, and that mutations with a large effect on the incidence of disorders such 
as schizophrenia and anorexia nervosa (AN) have a negative effect on fitness, 
and that selection will thus eliminate these variants, or at least keep them at a 
low frequency in the population (Visscher et al., 2011). However Visscher et al 
also explain that mutations can have an effect on many phenotypes, and the 
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direction of the effect is not always the same for all traits, and has not always 
been the same throughout human evolution (Visscher et al., 2011), arguably the 
best example of this is the genetic mutation that increases the risk for sickle cell 
anaemia, but decreases the risk for malaria (Williams and Obaro, 2011). Despite 
the debate all researchers appear to agree that both common and rare variants 
are expected to be important in the aetiology of disease, and that unequivocal 
empirical evidence – yet to be obtained – will demonstrate to which extent 
either of the genetic risk variants contribute to the aetiology of complex 
disorders including EDs (Uher, 2009,Manolio et al., 2009,State and Levitt, 
2011,Kim et al., 2011,Visscher et al., 2011). It is however clear that, given the 
results in the field of body mass index (Day and Loos, 2011), human height 
(Lango et al., 2010), human intelligence (Davies et al., 2011), and psychiatry in 
general (Cichon et al., 2009), that a polygenic genetic architecture consisting of 
many genetic risk factors each with a very small effect size (odds ratios in the 
range of 1.1 to 1.2) is a likely possibility for the genetic architecture of EDs.  
It is clear that genetic risk factors are relevant in the aetiology of eating disorders 
(EDs). There is an increased prevalence of EDs in first degree relatives of 
sufferers, and twin studies estimate that approximately 50% of the phenotypic 
variance is accounted for by genetic factors. Which genetic risk factors cause the 
liability to EDs has however not yet been established. Therefore, the aim of this 
thesis was to identify the genes underlying the liability to EDs.  
 
Over the past years several genetic studies of EDs have been conducted. Most of 
them have focussed on candidate genes and on anorexia nervosa (AN). 
Unfortunately the results were typically non-significant or non-replicated. For 
this reason more recent studies have tried to increase sample sizes and look at 
genes across the genome. The results of these larger-scale genetic studies have 
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not yet been confirmed; hence the aim of Chapter 1 of this thesis was to 
replicate the results of the most extensive genetic studies of AN done thus far.   
 
Because of the complexity of the clinical presentation of EDs – and of psychiatric 
disorders in general – it has been suggested to focus on endophenotypes rather 
than clinical diagnoses. An endophenotype is a intermediate phenotype; it 
bridges between the complex clinical presentation and the underlying aetiology 
by ‘breaking’ the disorder up into manageable ‘pieces’ which can be studied on 
their own. Identifying genetic risk factors for endophenotypes has been 
hypothesized to be more straightforward and more successful (Gottesman and 
Gould, 2003). Drive for thinness (DT), bulimia (B), and body dissatisfaction (BD) 
as measured by the Eating Disorder Inventory (EDI) (Garner, 1983) are candidate 
endophenotypes for EDs. Therefore, Chapter 3 and Chapter 4 of this thesis focus 
on the range of DT, B, and BD scores in females from a general population 
sample. When studying endophenotypes, or traits, it is important to take note of 
the context in which they were measured. In Chapter 3 therefore the correlates 
of the DT, B, and BD scores in this population were discussed, and specifically the 
relation between the scores and body mass index was addressed.  
 
Genetic risk variants for a disorder have an effect on biological processes by 
affecting normal gene functioning. Many different genetic variants could 
theoretically affect the same biological process, for example mutations affecting 
a receptor-ligand, mutations affecting a receptor, and mutations affecting an 
effector, could all attenuate a process of signal transduction. Hence, from a 
biological point of view it is plausible that different genetic risk variants 
cumulatively cause a disorder. The effects of individual genetic risk variants could 
even be too small to pick up in reasonable sample sizes without aggregating 
them into genes and pathways and testing their combined effect (Cantor et al., 
2010). For this reason Chapter 4 focussed on secondary genome-wide genetic 
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analyses: individual genetic variants were combined per gene and per pathway, 
and their combined effect was tested for association with the DT, B, and BD 
scores.  
 
The overall conclusion and discussion of the results from the different studies in 
this thesis was presented in Chapter 5, including an outline of future directions 
for the genetic studies of eating disorders. 
 





M o l e c u l a r  g e n e t i c  a n a l y s i s  o f  A n o r e x i a  N e r v o s a  
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M o l e c u l a r  g e n e t i c  a n a l y s i s  o f  A n o r e x i a  N e r v o s a  
Genetic studies on Anorexia Nervosa (AN) have mainly focussed on candidate 
genes up until now. The results of these studies have not been consistently 
replicated although some associations remain interesting (also see paragraph 
1.3.3 C a nd i d a t e  g e n e  s t u d i e s , page 42). As recommended by the Psychiatric 
GWAS Consortium Coordinating Committee (Cichon et al., 2009) individual 
research groups are now combining their efforts in order to obtain large enough 
sample sizes to gain the statistical power needed to identify genetic risk factors 
for AN. This is because most new findings in other psychiatric disorders or 
complex traits have been variants associated with a small increase in risk 
(relative risk 1.12 to 1.2) (Cichon et al., 2009,Yang et al., 2011,Kim et al., 
2011,Davies et al., 2011,Visscher et al., 2011).  
 
Researchers in the field of eating disorders (EDs) are also adopting large-scale 
genetic association methods. Examples of multisite collaborative study groups 
organized for the purpose of genetic studies in EDs include: the Japanese Genetic 
Research Group for Eating Disorders (JGRED), the Price Foundation Genetic 
Studies of Eating Disorders, and the Genetic Consortium for Anorexia Nervosa 
(GCAN). The results of their collaborations have been published recently and 
include both case-control study designs (Nakabayashi et al., 2009,Pinheiro et al., 
2010,Wang et al., 2011) as well as within-case study designs (Root et al., 2011). 
The genome-wide study by the GCAN consortium is currently in the final phase of 
analyses and is expected to be published in 2012. Large-scale genetic studies can 
be complemented by meta-analyses of existing data. Brandys et al performed 
two such studies for AN (Brandys et al., 2011) (also see paragraph 1.3 Genetics of 
2. Molecular genetic analysis of Anorexia Nervosa  
2 . 1 .  L i t e r a tu re  bac kg ro un d  
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eating disorders, page 37) and (Brandys et al., Anorexia nervosa and the 
Val158Met polymorphism of the COMT gene: meta-analysis and new data, in 
press).   
 
This chapter of the thesis was designed to replicate the results of some of the 
most extensive collaborative studies done on AN thus far; namely, the most 
significantly associated haplotypes from a large-scale candidate gene study of AN 
(Pinheiro et al., 2010); one of the top hits from the first genome-wide association 
(GWA) study by Wang et a (Wang et al., 2011)); and the most recent meta-
analysis by Brandys et al (Brandys et al, in press).   
Pinheiro et al conducted the most extensive hypothesis-driven candidate gene 
study of AN done thus far (Pinheiro et al., 2010); they studied 5,151 SNPs in 182 
genes, selected on the basis of previous association, gene expression in the 
brain, biological plausibility, and markers from regions linked to AN in family 
based study designs (also see 1.3 Genetics of eating disorders, page 37). After 
accounting for multiple testing there were however no significant results 
(Pinheiro et al., 2010). In order to increase their sample size and statistical 
power, our group was asked to replicate some of their top findings, specifically 
their top haplotypes (personal communication). Pinheiro et al defined haplotype 
blocks for the 5,151 SNPs in their study by using the TAGGER method in 
Haploview 4.0 (Pinheiro et al., 2010). This algorithm creates haplotype blocks 
when 95% of informative comparisons are in strong linkage disequilibrium (LD), 
i.e. it creates blocks of SNPs that are likely to have been inherited together (also 
see paragraph 1.3.4.1 L i nka g e  d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , page 
45). The blocks tested for association with AN ranged in size from two SNPs to 79 
SNPs, none of the haplotypes were significant following correction for multiple 
testing, but the top 25 haplotypes were published as Supplementary material 
(Pinheiro et al., 2010)). The haplotypes chosen for replication were three-SNP 
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haplotypes from two genes, namely phenylalanine-4-hydroxylase (PAH) and 
solute carrier family 18 A1 (SLC18A1) (see Table 2).  
 
A three-SNP haplotype (i.e. a haplotype consisting of three SNPs) could 
theoretically occur in eight combinations (see Table 3 for an example), in which 
case it would be analysed as having seven degrees of freedom (DF). Not all 
combinations are equally common though, and in haplotype analyses a zero-
frequency threshold can be set, i.e. very rare haplotype combinations can be 
considered ‘non-occuring’, in which case the DF will be less than seven (e.g. the 
top haplotype by Pinheiro et al was analysed with three DF i.e. only four 
haplotype combinations were considered, see Table 2). It is important to note 
that the ‘phase’ of the haplotypes is estimated; each chromosome has two 
strands of DNA (a paternal and a maternal strand), and a haplotype is a block of 
DNA that is inherited on a single strand of DNA (Browning and Browning, 2011). 
For technical reasons, from raw genotyping data, it can not be determined from 
which DNA strand any allele originates, hence haplotype combinations are 
inferred; their frequency is estimated (Browning and Browning, 2011).  
 
Table 2: Results of Pinheiro et al for replication (adapted from (Pinheiro et al., 2010)) 
Three haplotypes out of the top 25 published haplotypes (Pinheiro et al., 2010) were 
chosen for replication. Haplotype #1 is located in the gene PAH, haplotypes #9 and #17 
are located in SLC18A1 (also see Table 6, page 65). Results were communicated to us 
personally prior to publication, but some changes were made to the manuscript 
resulting in slightly different results in the published paper. By this time my laboratory 
work had commenced, hence only three published haplotypes (#1, 9, and 17) could be 
replicated. Degrees of freedom (DF) indicates that not all possible haplotype allele 
combinations were observed; four haplotype combinations were tested for haplotype 
#1 and #9 (DF = 3), and five combinations for haplotype #17 (DF = 4). 
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Table 3: Example theoretical combinations of a three-SNP haplotype 
A SNP has two alleles (e.g. A or T), thus a three-SNP haplotype can theoretically occur in 
eight different combinations. Generally not all combinations are equally common, and 
thus in haplotype association analyses only the number of observed combinations is 
taken into account, with sometimes a set ‘zero-frequency threshold’ for very rare 
haplotypes.  
The top result from the first genome-wide association (GWA) study of AN was 
communicated to us personally prior to publication (personal communication). 
However the authors added more cases to their sample prior to final publication, 
resulting in slightly different results in their published paper (Wang et al., 2011); 
by this time my laboratory work had already commenced, hence only the 
number four SNP (rs2383378, A-kinase anchor protein 6 (AKAP6) gene, see Table 
4) of the published paper (Wang et al., 2011) was included in this chapter. None 
of the SNPs tested by Wang et al reached genome-wide significance (Wang et al., 
2011); the p value in Table 4 is the p value uncorrected for multiple testing 
(Wang et al tested ~600,000 markers for association with AN (Wang et al., 2011), 
a Bonferroni threshold for multiple testing, with α set at 0.05, would be 0.05 / 
600,000 = 8.3E-08).   
 
Table 4: Results of Wang et al for replication (adapted from (Wang et al., 2011)) 
This SNP (rs2383378) was initially the top result with a p value of 3.8E-07 (personal 
communication), however prior to publication more samples were added and the results 
changed slightly; in the published paper this SNP is the number four SNP overall (Wang 
et al., 2011). MAF refers to Minor Allele Frequency, i.e. the allele of the SNP which 
occurs least frequently in the population.  
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Brandys et al published a negative result, their data and meta-analysis indicate 
that the SNP rs4680 of the catechol-O-methyltransferase (COMT) gene is not 
associated with AN (Brandys et al, in press) (see Table 5). The two different 
alleles of this SNP (adenine (A) and guanine (G)) lead to a different amino-acid in 
the protein-product of the gene at position 158, also known as a “misssense” or 
“nonsynonymous” polymorphism. The A allele of the SNP is the Methionine 
(Met) allele, and the G allele is the Valine (Val) allele, hence the SNP is also 
known as the Val158Met polymorphism of the COMT gene. The Met allele 
causes the COMT protein to be less stable, resulting in lower protein activity, and 
this particular polymorphism has been associated with several psychological 
disorders including substance abuse, schizophrenia, obsessive-compulsive 
disorder (OCD), and bipolar disorder (see (Hosak, 2007) for a general review, and 
(Rask-Andersen et al., 2010a) for an ED specific review). Brandys et al analysed 
data from a Dutch (Leiden and Utrecht) cohort and performed a meta-analysis on 
2,021 cases and 2,848 controls (Brandys et al, in press). The results of the 
Utrecht cohort were suggestive of a dominant genotypic effect of the Met-allele 
(genetic dominance indicates that one or two copies of the allele increase the 
risk equally, i.e. only one copy is sufficient to increase the risk), but the meta-
analysis indicated that overall there was no association (meta-analysis dominant 
genotypic effect p= 0.18, see Table 5, Brandys et al, in press).  
 
Table 5: Results of Brandys et al for replication (Brandys et al, in press) 
The meta-analysis by Brandys et al provides evidence that the Val158Met variant of the 
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COMT gene is not associated with AN. The only indication of association of this variant 
was under the dominant model of genetic effect in the Utrecht cohort (OR 1.42, p=0.03, 
in bold), however this effect was non-significant in the Leiden cohort, nor was it 
significant in the meta-analysis (Brandys et al, Anorexia nervosa and the Val158Met 
polymorphism of the COMT gene: meta-analysis and new data, in press).  
The SNPs and haplotypes of interest were tested for association with AN using 
both a case-control and a within-case study design. The case-control analyses 
included a sample from London (United Kingdom), and sample from Vienna 
(Austria). The within-case analyses included samples from London, Vienna, and 
Utrecht (The Netherlands). The within-case study design tested association with 
lowest adult lifetime body mass index (BMI) following the criteria outlined by 
Bulik et al in 2005 (Bulik et al., 2005) and Root et al in 2011 (Root et al., 2011), 
and additionally within-case analyses on highest adult lifetime BMI were 
conducted because the results of Chapter 3 of this thesis indicate that highest 
adult lifetime BM is a predictor of disordered eating (see paragraph 3.5 R e s u l t s , 
page 127). Haplotype SNPs were present as single SNPs as well as haplotype 
results, though it should be noted that they were only published as haplotypes 
associated with AN, not as single SNPs. My laboratory work was commenced 
following personal communication of the results, however prior to publication 
the authors made some amendments to their work and for this reason only nine 
out of initially 26 selected SNPs were published (see Table 6) (Pinheiro et al., 
2010,Wang et al., 2011,Brandys et al., in press). The methods section will include 
all 26 SNPs since the genotyping method analyses 26 SNPs in parallel, however in 
the results section only the nine published SNPs will be presented; an overview 
of all SNP results will be presented in the Appendix (see page 232).   
2 .2 .  A im  an d  ou t l i n e
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Table 6: Overview of SNPs for replication  
Three haplotypes published by Pinheiro et al (Pinheiro et al., 2010) will be tested for 
association with AN; one haplotype from chromosome 12, and two (partly overlapping) 
haplotypes from chromosome 8.  
The AN cases examined in this study were recruited from three different 
locations: London (United Kingdom (UK)), Utrecht (The Netherlands) and Vienna 
(Austria). Approval from the local ethical committees was in place and informed 
consent was obtained from all study participants. Cases were included in the 
study if they fulfilled the following criteria (which match the criteria of the 
Genetic Consortium for Anorexia Nervosa (GCAN)): 
o Inclusion: Cases with a lifetime diagnosis of AN (restricting or binge/purge 
subtype) excluding amenorrhoea (based on DSM-IV, assessed by 
structured clinical interviews). The DSM-IV amenorrhea criterion was 
omitted because the use of oral contraceptives and uncertain menstrual 
history make this criterion difficult to assess, moreover it has been shown 
that it does not increase the diagnostic specificity (Gendall et al., 
2006,Poyastro et al., 2007). 
o Exclusion: Any medical or psychiatric condition that may confound the 
diagnosis of AN including psychotic disorders, severe learning disabillities, 
2 .3 .  M e th od s  
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and other medical and neurological conditions causing weight or appetite 
loss. 
UK controls were recruited as controls for the Bipolar Association Case-Control 
Study (BACCS) and screened for absence of lifetime psychiatric disorders (mean 
age 32 years, 40:60 male:female ratio). Austrian controls were recruited as 
controls for a childhood migraine study (mean age 10 years, 50:50 male:female 
ratio, (Wober-Bingol et al., 2011)); they were screened for migraine but not for 
eating disorders. A concern on using controls not screened specifically for eating 
disorders is the potential loss of power due to inclusion of controls with latent 
eating disorder diagnoses, however this loss of power is minimal given the low 
lifetime prevalence of AN (0.6%, (Jacobi et al., 2004b,Hudson et al., 
2007,Swanson et al., 2011)). No controls were available for the Utrecht sample; 
the Utrecht sample was thus only part of the within-case analyses. All cases and 
controls were of Caucasian (central and western European) ancestry. 
DNA was extracted from blood and from cheek swab samples using an in-house 
variation of the phenol-chloroform extraction (cases and controls from London 
and Vienna (Freeman et al., 1997,Freeman et al., 2003)), Nucleon BACC II kits by 
GE Life Sciences (London cases), a salting-out procedure (Utrecht cases, (Miller et 
al., 1988)), and Genecatcher kits by Invitrogen (Utrecht cases).  
Genotyping was done using the Sequenom iPlex Gold reaction. The iPlex Gold 
reaction is a universal method for detecting insertions, deletions, substitutions, 
and other polymorphisms in DNA. The first step of the iPlex Gold reaction is a 
polymerase chain reaction (PCR) which amplifies the DNA region of interest. 
Next, any unincorporated nucleotides (i.e. DNA building blocks; 
deoxyribonucleotide triphosphates (dNTPs); A, T, C and G) are neutralised using 
shrimp alkaline phosphatise (SAP). The SAP cleaves off a phosphate molecule 
2 .3 . 2 .  D N A ex t r a c t i o n
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converting the dNTPs to dNDPs, this inactivates them and prohibits further 
reaction. Next, iPlex Gold reaction cocktail (primer, enzyme, buffer, and mass-
modified nucleotides) is added to the amplified DNA. This reaction will 
incorporate a mass-modified nucleotide into the exact site of interest (i.e. the 
location of the SNP); the two different alleles of the SNP will then be 
distinguishable by their mass. The amplified DNA and iPlex Gold reaction cocktail 
are thermocycled (discrete, pre-programmed steps in which the temperature of 
the reaction is raised and lowered alternately) to process the reaction. In the 
reaction mixture, all four nucleotides -A, T, C, and G- (mass-modified) are 
present.  
 
In the final step the products of the iPlex Gold reaction are desalted and 
transferred onto a SpectroCHIP by the MassARRAY nanodispenser machine. The 
SpectroCHIP is then analyzed by the MassARRAY mass spectrometer using time-
of-flight (TOF) analysis; the DNA particle will ‘fly’ through the mass spectrometer 
with higher mass DNA ‘flying’ more slowly than lower mass DNA. Each allele of 
each SNP is designed to have a different mass; they will thus all ‘fly’ through the 
mass spectrometer at a different speed and pass the detector of the mass 
spectrometer at a different time. Each time a DNA particle passes the detector a 
peak will appear on the mass spectrum, with higher peaks indicating more DNA. 
Since the mass of each SNP is known the location of its corresponding peak on 
the mass spectrum is known too. Per SNP three distinct peaks can arise; one for 
each allele and one for the primer peak (the latter will only be present in case 
the iPlex Gold reaction failed). Figure 6 shows the details of the iPlex Gold 
reaction. 


















Figure 6: Sequenom iPlex Gold reaction  
Following DNA amplification any in the amplified DNA (PCR product) left-over 
unincorporated dNTPs (i.e. DNA building blocks: A, T, C and G) were inactivated by SAP 
treatment. Next, the iPlex Gold reaction incorporates a mass-modified nucleotide into 
the exact site of interest (i.e. SNP site), rendering allele-specific DNA products with 
distinguishable masses. After mass spectrometry time-of-flight analyses (MALDI-TOF) 
three distinct peaks can arise per SNP, one for each allele and one for the primer peak 
(the latter will only be present in case the iPlex Gold reaction failed) (the image was 
obtained from (Gabriel et al., 2009)).  
The Sequenom iPlex gold reaction can analyse 26 SNPs in parallel. The design of 
the Sequenom panel must be such that each allele and each primer peak have a 
distinct mass, and that primers do not overlap in sequence as this would cause 
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unspecific binding. Figure 7 and Figure 8 show the design of the current study; 
there are three possible peaks (i.e. masses) per SNP, and 26 x 3 = 78 peaks in 
total.   
 
Figure 7: Sequenom panel design of the current study 
Each peak represents allele 1, allele 2, or the primer peak of a SNP (number of SNPs is 
26, total number of peaks is 26 x 3 = 78). The mass is expressed in units of Dalton (Da).  
 
Figure 8: Sequenom panel - zoom of the 5700 Da region 
This zoom-in of the Sequenom panel shows five out of 78 peaks: rs1390939 (primer, 
5591 Da), rs4633 (allele 1, 5748 Da), rs4633 (allele 2, 5764 Da), rs12728678 (primer, 
5797 Da) and rs1390939 (allele 1, 5838 Da).   
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A total of 2,304 samples were run on Sequenom, they were run on six 384 well 
plates in four batches. The plates included within and between plate and batch 
duplicates and negative controls (NTCs) (see Table 7).    
Type of sample n  individuals n  samples 
Unique samples 1,066 1,066 
NTCs - 119 
Other technical controls - 209 
Duplicates 221 442 
Triplicates 119 357 
Quadruplicates 22 88 
Quintuplicates 1 5 
Sextuplicates 3 18 
Total 1,432 2,304 
Table 7: Overview of samples run on Sequenom 
In total 2,304 samples were run on Sequenom including negative controls (NTCs) and 
duplicate samples for quality control purposes, these were samples of in total 1,432 
unique individuals (cases and controls from London, Utrecht and Vienna).  
In total 119 negative controls (NTCs) were included across all plates. Negative 
controls should be negative i.e. not have genotype calls, it is a quality control 
measure used to assess the quality of the laboratory work. Genotype calls in the 
NTCs would be an indication of DNA contamination; if this were the case 
genotyping results would be unreliable. NTCs consisted of double distilled water 
(ddH20) instead of DNA and were treated exactly the same as the DNA samples. 
The error percentage was calculated by dividing the number of genotype calls by 
the total number of possible calls. From the error percentage per plate it 
becomes clear plate 6 is unreliable, as the error percentage is much higher than 
the other plates (36,92% vs a mean of 8%, see Table 8) and thus all samples from 
plate 6 have been excluded from analyses (n=58, see paragraph 2.4.3 Ov e r v i e w  
o f  s am p l e  e x c l u s i o n s , page 76). Other technical controls (n=209, see Table 7) 
were samples without DNA with only iPlex Gold reaction ingredients, e.g. primer, 
2 .4 .  S am p l e  q u a l i t y  c o n t r o l
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enzyme, buffer, or mass-modified nucleotides. These were included on plate 6, 
and will not be considered further due to the high NTC error percentage on this 
plate. The mean error percentage across all samples, excluding plate 6, is 8% 
(ranging from 0 – 80%, most right column Table 8). Even though the error 
percentage is high there is no sign of DNA contamination; if there would be DNA 
contamination the high error rate would be consistent across SNPs (as happened 
on plate 6); all 26 SNPs were analysed at the same time and thus all SNPs would 
be affected equally by contamination. Looking in detail at the mass spectra of the 
NTCs it is apparent that the high error rate is caused by a marker specific design 
problem; the primer peak of some SNPs is located very closely to the allele peak 
location of another SNP, causing the primer peak to mistakenly be identified as 
an allele; this problem will be discussed in detail in paragraph 2.5 S N P qua l i t y  
c o n t r o l , page 77.    
 
Table 8: Negative control (NTC) error percentage, per SNP, per plate 
SNPs are sorted on error percentage, high error rates are shown in grey. Error rates 
were consistently high on plate 6 indicative of DNA contamination; results of plate 6 are 
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thus unreliable and were excluded from analyses. The mean error percentage across 
samples, excluding plate 6, is 8% (most right column, also see paragraph 2.5, page 77). N 
refers to the number of NTCs.  
In total 221 duplicate pairs, 119 triplicates, 22 quadruplicates, one quintuplicate, 
and three sextuplicates were analysed (see Table 7). This included within and 
between plate duplicates, exact duplicates (i.e. DNA from the same individual, 
the same blood tube, the same plate well), and regular duplicates (i.e. DNA from 
the same individual but from a different blood tube; either because two blood 
tubes were taken at the same occasion, or because the individual donated blood 
for research on multiple occasions). Duplicate samples were included as a quality 
control measure; genotype calls should match exactly between duplicates across 
plates. The number of duplicates included in the current study was higher than 
average for pragmatic reasons, a) to ensure even distribution of case and control 
samples from the different countries across plates, and b) to not leave any 
genotyping slots unused (Sequenom plates were filled completely).  
 
The duplicate error percentage was calculated by dividing the number of 
mismatching duplicate genotypes by the total number of possible mismatching 
duplicate genotypes (idem for triplicates, etc). The duplicate error percentage on 
plate 6 was calculated separately because of the high NTC error percentage on 
this plate. The duplicate error percentage of plate 6 is only slightly higher than 
the mean duplicate error percentage of the other plates (1.32% vs 0.77%, see 
Table 9). This could be explained by the fact that a possible contamination would 
affect NTCs but not necessarily DNA samples because the original DNA would be 
in excess, plate 6 was nevertheless excluded from analyses. The mean duplicate 
error percentage excluding plate 6 is 0.77%, which is within the 1% technical 
error percentage of the Sequenom technique. The SNP with the highest 
duplicate error is also the SNP with the highest NTC error (rs4633; 5.43% and 
80% respectively) (this will be discussed in detail in paragraph 2.5 S NP  qua l i t y  
2 . 4 . 2 .  D up l i c a t e s
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c o n t r o l , page 77). For the other SNPs there is no apparent relation between 
duplicate error rate and NTC error rate (see Table 9).  
 
Table 9: Duplicate error percentage per SNP 
Plate 6 was calculated separately because of the high NTC error percentage on this 
plate. Overall the duplicate error rates are normal, only rs4633 has a high duplicate 
error rate (5.84% excluding plate 6, upper row). Total number of possible mismatches 
was 26 SNPs x 221 pairs = 5,746. The duplicate error rate excluding plate 6 was 0.77%. 
The NTC error percentage excluding plate 6 (most right column) was included for easy 
comparison of error rates on SNPs.  
In total there were 28 out of 221 duplicate pairs with mismatching genotypes 
(number of mismatches per pair ranged from 1 to 12; total number of possible 
mismatches was 26 SNPs x 221 pairs = 5,746). Most mismatching samples only 
mismatched on one out of 26 genotypes. Of the samples mismatching on 
multiple genotypes all but two mismatches could be explained by the fact that 
one of the samples had many missing genotypes, i.e. one of the samples 
apparently contained little DNA. A sample can contain little DNA either because 
its DNA concentration is very low (in case two different blood samples from the 
- 74 - 
same individual were included, of which one had a low DNA concentration) or 
because of standard limitations of the laboratory work equipment used (given 
the small volume of DNA used for analyses, one microliter, some samples will 
have a lower DNA concentration by chance e.g. due to the occasional small air 
bubble). Even though the duplicate error percentage is within the technical error 
percentage of the technique, mismatching samples were examined in detail in 
order to ensure a high quality result of analyses. Two samples stood out for 
having many mismatching genotypes while there was no apparent difference in 
DNA concentration; sample MR151:01 (12 mismatches, London case sample) and 
AN185 (9 mismatches, Utrecht case sample); these two samples were excluded 
from analyses. As a general rule for duplicates the sample with the least missing 
genotypes was chosen for analyses, assuming this sample had the best DNA 
quantity and/or quality. 
 
The overall triplicate error percentage is comparable to the duplicate error 
percentage (1.14%, see Table 10). The SNP with the highest triplicate error 
percentage is also the SNP with the highest duplicate error percentage and NTC 
error percentage (rs4633; 12.61%, 5% and 80% respectively). For the other SNPs 
there is no apparent relation between error percentages.  
- 75 - 
 
Table 10: Triplicate error percentage per SNP 
Plate 6 was calculated separately because of the high NTC error percentage on this 
plate. Overall the triplicate error percentage is normal (mean triplicate error rate 
excluding plate 6 is 1.14%), only rs4633 stands out for having a high error percentage 
(12,61%, upper row). The NTC error percentage, and the duplicate error percentages 
were included for easy comparison of error rates on SNPs.  
In total 12 out of 119 triplicate pairs mismatched (excluding SNP rs4633); the 
number of mismatches per pair ranged from 1 to 6. All mismatches could be 
explained by the fact that one of the samples either had many missing genotypes 
(as discussed for duplicates) or was run on plate 6. One sample stands out for 
having mismatching genotypes and many missing genotypes on all three 
Sequenom runs (sample EDE355, London case sample), because genotype calls 
might not be reliable when many genotype calls are missing this sample has been 
excluded from further analyses. This was the only sample excluded based on 
triplicate mismatching. As for the duplicates; as a general rule for triplicates the 
sample with the least missing genotypes was chosen for analyses. The same 
holds true for the quadruplicate, quintuplicate and sextuplicate pairs that were 
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included (see Table 7); three quadruplicates and one quintuplicate were 
mismatching (excluding SNP rs4633) and all mismatches could be explained by 
the fact that one of the samples had many missing genotype calls - thus none 
have been excluded.  
Samples on plate 6 were excluded because of the high NTC error percentage on 
this plate (see 2.4.1 N eg a t i v e  c o n t r o l s  and Table 8); 57 unique samples and 1 
duplicate sample were run on plate 6, these were all cases from the Utrecht 
sample apart from one sample from Vienna. Note: plate 6 did also contain 
London and Vienna case and control samples, however of these samples a 
duplicate sample on a different Sequenom plate was available. The samples 
MR151:01 and AN185 were excluded for having unexplained duplicate 
mismatches, and triplicate sample EDE355 was excluded since it had 
mismatching genotype calls and many missing genotype calls on every run. There 
were 38 samples with missing genotype calls on more than half of the SNPs 
(more than 13 out of 26 SNPs), these samples were excluded from further 
analyses because DNA quantity or quality apparently was poorly. Nine samples 
were excluded because they did not originate from central or western Europe 
(this included the mismatching EDE355). And finally three samples were excluded 
because they were related; GAN3301 was excluded because her sister 
participated in the study, and EHE4962 and AN551 were excluded because they 
had participated in multiple studies and were thus known under different ID 
codes of which the one with the most missing genotype calls was excluded. Total 
number of excluded samples was 110 (7.7%), 1,322 samples were tested for 
association with AN (see Table 11 for details).  
2 .4 . 3 .  O v e r v i e w  o f  s am p l e  e x c l u s i o n s
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Table 11: Overview of exclusions, and final sample for analyses 
In total 26 SNPs were run on Sequenom. From the sample quality control it 
became clear that three SNPs had a high NTC error rate (above 10%, see Table 8, 
page 71); of these rs6355 and rs2383378 did not have elevated duplicate and 
triplicate error rates (<2%, see Table 10). The SNP rs4633 had a very high NTC 
2 .5 .  S N P q ua l i t y  c o n t r o l  
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error rate (80%), as well as elevated duplicate and triplicate error rates (5% and 
12.61% respectively, see Table 10). If the inflated error rate was caused by DNA 
contamination it would have been consisted across SNPs, since it is not this 
appears to be a marker specific problem related to the Sequenom panel design. 
Indeed the error rate of rs4633 can be explained by a shift in mass of the primer 
peak of rs12728678. The C allele of rs4633 is expected at 5,764 Dalton (Da), the 
primer of rs12728678 is expected at 5,797 Da (also see Figure 8, page 69). Mass 
spectra of NTCs show that this primer peak is missing where the C allele of 
rs4633 is called, indicating that the mass of this primer has turned out slightly 
lower than anticipated (see Figure 9, Figure 10 and Figure 11), and this explains 
the high NTC error rate of rs4633. Supportive of this assumption is the fact that 
the call of rs4633 in NTCs is always a C, and never a T allele.  
 
The genotype call for rs4633 will thus be reliable in samples with good DNA 
quantity and quality, because after a successful iPlex Gold reaction no primer 
peaks will be present (also see paragraph 2.3.3, page 66). Apparently for the 
mismatching duplicate and triplicate samples the DNA quality or quantity was 
low on one of the samples resulting in an incomplete iPlex Gold reaction and left-
over primer for rs12728678 which mistakenly was interpreted as the C allele of 
rs4633 (see Figure 9, Figure 10 and Figure 11). Since samples with obvious poor 
DNA quantity or quality (i.e. missing genotype calls on more than 13 out of 26 
SNPs, see 2.4.3, page 76) will be excluded from analyses the genotype call of 
rs4633 will generally be reliable, but the SNP will nevertheless be excluded at 
this point. Rs4633 was one of the SNPs communicated to us personally prior to 
publication, but it was not part of the published associations to AN in the end 
(also see paragraph 2.2 A im  an d  ou t l i ne , page 64), thus at this point in time 
there would be no reason to repeat the laboratory work on this particular SNP.  
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Figure 9: Mass spectrum of rs4633 - control DNA sample, well A2, Sequenom plate 1 
This is the spectrum of a London control DNA sample heterozygote for rs4633; a peak is 
visible at both 5,748 Dalton (Da) (T allele) and 5,764 Da (C allele). There is no peak at 
5,477 Da (primer of rs4633) nor at 5,797 Da (primer of rs12728678), indicating that the 
iPlex Gold reaction worked well.  
 
Figure 10: Mass spectrum of rs4633 – NTC, well L14, Sequenom plate 1 
In this NTC of plate 1 there is an unexpected peak at 5,764 Da – resulting in the call of a 
C allele for rs4633. Slightly heavier than the C allele is the primer for rs12728678 at 
5,797 Da (also see Figure 8, page 69) – this peak is missing in this graph (most right grey 
line). The primer of rs12728678 appears to have turned out slightly lower than 
anticipated, causing the primer peak to be mistakenly interpreted as the C allele of 
rs4633 (also see Figure 11). The primer peak for rs4633 is visible on the left side of the 
graph at 5,477 Da – as expected in an NTC.  
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Figure 11: Missing primer peak for rs12728678 – NTC well L14 Sequenom plate 1 
An alternative explanation for the called C allele of rs4633 and the missing primer peak 
for rs12728678 is that the NTC was contaminated with DNA. If this were the case than 
we would expect to see a genotype call for rs12728678, which is not the case (see the 
two dotted lines most right, there are no peaks). This figure shows that both the primer 
peak and the genotype peaks of rs12728678 are missing, supportive of the assumption 
that the mass of the primer of rs12728678 turned out slightly lower than anticipated 
causing it to be mistakenly interpreted as the C allele of rs4633.  
Missingness of genotype calls per SNP was calculated on samples passing sample 
quality control (n= 1,322, see Table 11) by dividing the number of missing 
genotypes by the number of samples. Six SNPs had missing genotype calls on 
more than 10% of the samples, this concerned three SNPs published as a 
haplotype associated with AN by Pinheiro et al (Pinheiro et al., 2010) (in italic, 
see Table 12). The mean missingness resulted from missingness in the case 
sample and the Vienna control sample; apart from rs17210001 (bottom row, 
Table 12) none of the SNPs had high missingness in the London control samples. 
In order to check whether missingness was related to case/control status, 
country of origin, DNA source and/or DNA extraction method mean missingness 
(across all 26 SNPs) was calculated per sample (see Table 13). The London control 
sample (from blood) had the lowest mean missingness (3%), and the Utrecht 
case sample had the highest mean missingness (15%) but there is no apparent 
relationship between caseness and missingness (see Table 13). DNA from cheek 
swab samples extracted by the in-house method of Freeman et al (Freeman et 
2 .5 . 2 .  M i s s i n g n e s s
- 81 - 
al., 1997,Freeman et al., 2003) did not have an apparent higher missingness 
compared to DNA extracted from blood in this sample. No SNPs will be excluded 
from analyses based on missingness, however the results of the haplotypes 
should be interpreted with care. 
 
Table 12: Missingness per SNP in cases and controls 
Six SNPs have a missingness above 10% (in italic), they have a high missingness in cases 
and in Vienna controls but not in London controls. SNPs shaded in grey were published 
in relation to AN by Brandys et al (in press) and by Wang et al (Wang et al., 2011), SNPs 
in bold were associated with AN as haplotypes by Pinheiro et al (Pinheiro et al., 2010). 
Rs4633 (top row, in grey) was excluded from analyses due to a design problem with the 
Sequenom panel, none of the other SNPs will be excluded from analyses but results of 
the haplotypes should be interpreted with care.  
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Table 13: Missingness per country, case/control status, DNA source, and DNA extraction 
method (n= 26 SNPs) 
Control samples are shaded in grey. The London control sample had the lowest mean 
missingness (3%), the Utrecht case sample had the highest mean missingness (15%) but 
there is no apparent relationship between caseness and missingness (see Table 12 for 
details per SNP). DNA extracted from cheek swab samples does not have an apparent 
higher missingness compared to DNA extracted from blood.  
The genotype frequencies were compared to genotypes frequencies of a 
reference population for Europe, namely the HapMap reference population CEU: 
Utah residents with Northern and Western European ancestry (HapMap, 2003). 
The genotype frequencies match ± 10% (control sample only (n=674), maximum 
genotype frequency difference is 0.095, see Table 15). The details of the 
unpublished SNPs are presented in the Appendix (see Table 52, page 231). A final 
quality control measure is a test of the Hardy Weinberg Equilibrium (HWE); the 
HWE assumes that allele and genotype frequencies remain constant in a normal 
population (i.e. a normally sized population in which there is random mating). 
True deviations from HWE are very rare, thus in genetic studies it is used as a 
technical quality control measure i.e. significant deviations from HWE would 
indicate genotyping was erroneous. Since a true disease allele could theoretically 
cause a deviation from HWE it is calculated in controls only.  
 
Allele frequencies were calculated from observed genotype frequencies (i.e. the 
frequency of A and B was calculated from the observed AA, AB, and BB 
frequencies), expected genotype frequencies were calculated based on allele 
2 .5 . 3 .  R e f e r e n c e  p o p u l a t i o n ,  a n d  Ha r d y  W e i n b e r g  Eq u i l i b r i um  
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frequencies, and the difference between observed and expected genotype 
frequencies was tested by a chi-square test with one degree of freedom (see 
Table 14 for calculation details). One of the published SNPs is borderline 
significant for the HWE test (p=0.05, rs7820517, in bold Table 15, published as 
part of a haplotype (Pinheiro et al., 2010)), but since its genotype frequencies 
match the HapMap frequencies it will not be excluded from analyses. The results 
of this haplotype should however be interpreted with care.  
 
Table 14: HWE calculation details 
The table gives the calculation details for the two homozygote genotypes. The expected 
heterozygote genotype frequency is calculated by multiplying the two allele frequencies 
squared, followed by multiplying it by the total number genotypes (i.e. individuals) in 
the sample.  
 
Table 15: HWE and HapMap frequencies of the published SNPs 
SNPs shaded in grey were published by Brandys et al (in press) and by Wang et al (Wang 
et al., 2011), the other SNPs were part of the haplotypes published by Pinheiro et al 
(Pinheiro et al., 2010). Details of the unpublished SNPs are presented in the Appendix 
(see Table 52, page 231). One SNP is suggestive of violating the HWE (upper row, in 
italic), but its genotype frequencies match the HapMap frequencies ± 10%. No SNPs will 
be excluded based on HWE or HapMap frequencies, but the results of the haplotypes 
should be interpreted with care.   
Since only nine of the initially 26 selected SNPs were published only the 
published SNP results will be discussed in the chapter (also see paragraph 2.2 
2 .5 . 4 .  O v e r v i e w  o f  SN P  e x c l u s i o n s  
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A im  an d  ou t l i n e , page 64), the other SNPs will be presented in the Appendix 
(see Table 53 to Table 59, page 232). None of the nine published SNPs will be 
excluded from analyses based on error rates, missingness, HWE, or HapMap 
frequencies, but the results of all three haplotypes should be interpreted with 
care since all haplotypes contain one or more SNPs with either a high 
missingness (above 10%, see Table 12, in italic) or a SNP borderline significant for 
violation of the HWE (rs7820517, see Table 15).  
Case-control and within-case genotypic and allelic associations were tested by 
maximum-likelihood inference (Unphased software, version 3.4.1 (Dudbridge, 
2008)). The Unphased method compares the probability of the observed 
distribution to occur under the hypothesis of true association versus the 
probability of the observed distribution to occur under the null-hypothesis. The 
case-control results are practically equal to a standard chi-square test, but 
Unphased, in contrast to chi-square, can still accurately test for association in 
case the allele counts are very low (below five counts). Haplotype analyses were 
also performed by maximum-likelihood inference (Unphased software, version 
3.4.1 (Dudbridge, 2008)). The window size was fixed at three SNPs, i.e. only the 
specific combination of the three SNP haplotype published by Pinheiro et al 
(Pinheiro et al., 2010) was tested. Individuals with missing genotypes were 
excluded list-wise per haplotype. No frequency threshold was applied, i.e. if a 
haplotype combination was observed in the sample it was part of the analyses 
even if it was very rare.  
 
Power calculations were conducted using the Genetic Power Calculator by 
Purcell et al ((Purcell et al., 2003)) with the following variables: 367 cases and a 
control:case ratio of 2, prevalence AN 0.6% (Jacobi et al., 2004b,Hudson et al., 
2007,Swanson et al., 2011), genotype relative risks based on an additive genetic 
model (i.e. the risk of the homozygote genotype is the squared risk of the 
2 .5 . 5 .  S t a t i s t i c a l  m e t h o d s  
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heterozygote genotype), risk allele frequency was based on the control allele 
frequency (n= 674), α = 0.05, and power = 80%). Lastly, multiple testing was 
taken into account by using a Bonferroni correction of α = 0.05 divided by the 
number of tests.  
Individual phenotype data were available for cases only, summary age and 
gender data of controls were presented in paragraph 2.3.1 Sam p l e  c o l l e c t i o n , 
page 65. All cases were female apart from one; the male case was part of the 
Utrecht case sample. The male case was slightly younger than average (18 vs 26 
years old), his current and lowest adult lifetime body mass index (BMI) were 
close to the sample mean, and his highest adult lifetime BMI was slightly lower 
than average (18.5 vs 21.9) (age of onset was missing).  
Age was missing for 265 out of 648 cases, it ranged from 13 to 64 with a mean of 
26 years old (n=383, stdev=10.7, see Figure 12).  
2 .6 .  D at a  de sc r i p t i o n
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Figure 12: Distribution of age - AN cases 
 
2 .6 . 2 .  A g e  o f  o n s e t  
Age of AN onset was missing for most cases (405 out of 648), it ranged from 10 
to 40 with a mean of 16 years old (n=243, stdev=3.8, see Figure 13).  
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Figure 13: Distribution of age of onset - AN cases 
2 .6 . 3 .  A n or e x i a  N e r v o s a  s u b t y p e  
For 153 cases (24%) information on subtype was missing. There were 296 (46%) 
cases of the restricting subtype and 199 (31%) cases of the binge/purge subtype. 
AN cases of all subtypes were analysed as a single group.  
2 .6 . 4 .  C u r r e n t  B M I  
Current BMI was missing for 136 out of 648 cases, it ranged from 9.4 to 33.2 with 
a mean of 17.6 (n=512, stdev=2.8, see Figure 14).  
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Figure 14: Distribution of current BMI - AN cases 
 
2 .6 . 5 .  L o we s t  a d u l t  l i f e t im e  B M I  
For four cases their reported lowest adult lifetime BMI (i.e. lowest BMI) was 
higher than their current BMI and these lowest BMI data points were thus 
excluded. In total 146 out of 648 lowest BMI data points were missing. Lowest 
BMI ranged from 8.2 to 20.1 with a mean of 14.5 (n=502, stdev= 2.2, see Figure 
15). Note: 36 cases reported a lowest adult lifetime BMI above 17.5 (one of the 
diagnostic criteria for AN); for which they, strictly speaking, should be excluded. 
However, because lowest adult lifetime BMI was self-reported, and diagnosis 
was made by structured clinical interviews based on DSM-IV (also see paragraph 
2.3.1 Sam p l e  c o l l e c t i o n , page 65) cases were not excluded.  
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Figure 15: Distribution of lowest BMI - AN cases 
2.6.6.  H i gh e s t  a d u l t  l i f e t im e  B M I  
For five cases their highest adult lifetime BMI (i.e. highest BMI) was lower than 
their current BMI and these highest BMI data points were thus excluded from 
analyses. In total 205 out of 648 highest BMI data points were missing. Highest 
BMI ranged from 14.5 to 46.2 with a mean of 21.9 (n=443, stdev=3.5, see Figure 
16). 
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Figure 16: Distribution of highest BMI - AN cases 
Of the SNPs from the published haplotypes by Pinheiro et al (Pinheiro et al., 
2010) one SNP was suggestively associated with AN (rs1801153, p= 0.08, see 
Table 16). Note: they were published as a haplotype association with AN, not as 
single SNPs (also see paragraph 2.2 Ai m  a nd  ou t l i n e , page 64). When taking 
multiple testing into account none of the SNPs were significantly associated; 
when testing this many SNPs an association of this significance would be 
expected by chance. The top SNP published by Wang et al (Wang et al., 2011) 
was not associated with AN in the current sample (p= 0.59, see Table 17), 
however the current sample was underpowered to pick up effects with odds 
ratios smaller than 1.3 for heterozygote genotypes (1.69 for homozygote 
genotypes, also see paragraph 2.5.5 S t a t i s t i c a l  m e t h o d s , page 84). The results 
2.7.  Results case-control analyses  
2 .7 . 1 .  G en o t y p i c  a n d  a l l e l i c  a s s o c i a t i o n  
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of the unpublished SNPs are presented in the Appendix (see Table 53 and Table 
54, page 232). 
 
Table 16: Results case control analyses - Pinheiro et al 
One SNP of the top haplotype SNPs (Pinheiro et al., 2010) was suggestive associated 
with AN (genotype p value=0.08, in bold), however when taking multiple testing into 
account none of the SNPs were significantly associated with AN. Some SNPs had a high 
percentage of missingness: see Table 12, page 81 for details on missingness.  
 
Table 17: Results case control analyses - Wang et al 
The top SNP from Wang et al (Wang et al., 2011) was not associated with AN in the 
current sample, however the current sample was underpowered to detect small effects 
(OR < 1.3).  
Brandys et al published a negative result (Brandys et al, Anorexia nervosa and 
the Val158Met polymorphism of the COMT gene: meta-analysis and new data, in 
press), and the results of the current sample supported this (p= 0.27, see Table 
18). The odds ratio (OR) of the current sample was comparable to the results of 
the Utrecht cohort published by Brandys et al (1.11 vs 1.14; see Table 18 vs Table 
5, page 63), and it was slightly higher than the mean OR of the published meta-
analysis (OR 1.03, see Table 5, page 63). Note: the Utrecht cases were part of 
both the current study and the published study by Brandys et al, but the Utrecht 
- 92 - 
samples were not part of the results in Table 18 since they were only part of the 
within-case study (also see paragraph 2.2 A im  an d  ou t l i ne , page 64). Brandys 
et al presented a suggestive dominant effect of the Met-allele for the Utrecht 
cohort (p= 0.03, see Table 5, page 63) which was not replicated in their meta-
analysis (p= 0.18), the current sample supports the meta-analysis results; there is 
no sign of a dominant effect (see Figure 17).  
 
Table 18: Results case control analyses - Brandys et al 
The results of the current study were supportive of the results published by Brandys et 
al; rs4680 was not associated with AN (Brandys et al, Anorexia nervosa and the 
Val158Met polymorphism of the COMT gene: meta-analysis and new data, in press). The 
A allele is the Methionine (Met) allele.  
 
Figure 17: No dominant effect Met-allele (rs4680) COMT gene 
In the Utrecht cohort of Brandys et al the Met-allele (A-allele) was suggestively 
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associated using a dominant genetic model, i.e. the presence of one or two A alleles (AA 
or AG, indicated by A) was significantly associated with AN compared to no A alleles 
present (GG) (p= 0.03 Table 5, page 63). In the current sample there was no sign of a 
possible dominant genetic effect; the Met-allele (A allele) was not more prevalent 
among cases than among controls (77% vs 78%).  
None of the haplotype combinations showed a sign of association with AN in the 
current sample, p values of overall associations were 0.37, 0.68, and 0.44 
respectively (see Table 19 to Table 21).  
 
Table 19: Result haplotype rank 1 - Pinheiro et al 
Haplotype combinations are in the order (rs1801153 - rs1718312 - rs12831013). The 
haplotype combination with the highest odds ratio (OR) is indicated in italic. There was 
no sign of association between any of the haplotype combinations and AN.  
 
Table 20: Result haplotype rank 9 - Pinheiro et al 
Haplotype combinations are in the order (rs987778 - rs2173114 - rs7820517). The 
haplotype combination with the highest odds ratio (OR) is indicated in italic. There was 
no sign of association between any of the haplotype combinations and AN.  
2 .7 . 2 .  H ap l o t y p i c  a s s o c i a t i o n  
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Table 21: Results haplotype rank 17 - Pinheiro et al 
Haplotype combinations are in the order (rs2173114 - rs7820517 - rs7836907). The 
haplotype combination with the highest odds ratio (OR) is indicated in italic. There was 
no sign of association between any of the haplotype combinations and AN.  
2.8.  Results within-case analyses – lowest BMI 
2 .8 . 1 .  G en o t y p i c  a n d  a l l e l i c  a s s o c i a t i o n  
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Of the SNPs from the published haplotypes by Pinheiro et al (Pinheiro et al., 
2010) one SNP was suggestively associated with case-only lowest adult lifetime 
BMI (rs1718312, p= 0.02, see Table 22). Note: this is not the same SNP 
suggestively associated with AN in the case control analyses (see Table 16, page 
91). However, when taking multiple testing into account none of the SNPs were 
significantly associated (Bonferroni threshold is α = 0.05 divided by nine SNPs is 
0.006). The results of the SNPs from the haplotypes needed to be interpreted 
with care since several of the SNPs had a high missingness or were suggestive of 
violating the HWE; however there were no problems with rs1718312 (see Table 
12 and Table 15). The top SNP published by Wang et al (Wang et al., 2011) was 
also not associated with lowest BMI in the current sample (p= 0.76), nor was the 
SNP published by Brandys et al (p= 0.20) (see Table 22). The results of the 
unpublished SNPs are presented in the Appendix (see Table 55, page 234). 
 
Table 22: Results within-case analyses - lowest BMI 
One SNP is suggestive of association (rs1718312, genotypic p= 0.02, in bold), see Figure 
18 for details. However, taking correction for multiple testing into account none of the 
SNPs were associated with AN (Bonferroni correction threshold is 0.006).  
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Figure 18: Suggestive association between rs1718312 and lowest BMI 
The genotype of rs1718312 was suggestively associated with lowest BMI (p= 0.02, see 
Table 22), however when taking multiple testing into account there is no significant 
association; a difference like this would be expected by chance when testing nine SNPs 
for association. In this sample the individuals with a CC genotype had a higher lowest 
BMI (n= 78) compared to individuals with a CT or TT genotype (n= 269, and n= 244 
respectively).  
There is no sign of overall association of the haplotypes with case-only lowest 
BMI in the current sample; p values of overall associations were 0.47, 0.57, and 
0.24 respectively. The haplotype combination C-A-T (haplotype rank 17 Pinheiro 
et al, see Table 2, page 61) was however suggestively associated (p= 0.03, see 
Table 23), but when taking multiple testing into account it is not significant; p 
values like this would be expected by chance when testing this many 
2 .8 . 2 .  H ap l o t y p i c  a s s o c i a t i o n  
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associations. The results of the other haplotypes are presented in the Appendix 
(see Table 57 and Table 58, page 235).  
 
Table 23: Results within-case association - lowest BMI - haplotype rank 17 Pinheiro et al 
The haplotype combination C-A-T (rs2173114 - rs7820517 - rs7836907) was suggestively 
associated with lowest BMI, however when taking multiple testing into account there is 
no significant association.   
2 .9 . 1 .  G en o t y p i c  a n d  a l l e l i c  a s s o c i a t i o n  
None of the SNPs showed a sign of association with case-only highest adult 
lifetime BMI (see Table 24), rs1801153 has the lowest p value (genotype p value= 
0.12). The results of the unpublished SNPs are presented in the Appendix (see 
Table 56, page 235). 
 
Table 24: Results within-case analyses - highest BMI 
There is no sign of association of the SNPs with highest BMI.  
2.9.  Results within-case analyses – highest BMI
- 98 - 
2 .9 . 2 .  H ap l o t y p i c  a s s o c i a t i o n  
There is no sign of overall association of haplotypes with case-only highest BMI in 
the current sample; p values of overall associations were 0.20, 0.27, and 0.87 
respectively. The haplotype combination T-A-G (haplotype rank 1 Pinheiro et al, 
see Table 2, page 61) was however suggestively associated (p= 0.05, see Table 
25), but when taking multiple testing into account it is not significant. The same 
holds true for the haplotype combination A-C-T (p= 0.04, haplotype rank 9 
Pinheiro et al, see Table 26). The results of the other haplotype are presented in 
the Appendix (see Table 59, page 236). 
 
Table 25: Results within case association - highest BMI - haplotype rank 1 Pinheiro et al 
The haplotype combination T-A-G (rs1801153 - rs1718312 - rs12831013) was 
suggestively associated with lowest BMI, however a p value like this would be expected 
by chance when testing this many associations.  
 
Table 26: Results within-case association - highest BMI - haplotype rank 9 Pinheiro et al 
The haplotype combination A-C-T (rs987778 - rs2173114 - rs7820517) was suggestively 
associated with lowest BMI, however a p value like this would be expected by chance 
when testing this many associations.  
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The case control single nucleotide polymorphism (SNP) results indicate that one 
out of nine tested SNPs was suggestively associated with AN (rs1801153, 
genotypic p value = 0.08, allelic p value = 0.35, Table 16). When testing nine SNPs 
for association however, a result like this would be expected to arise by chance; 
it does not pass a Bonferroni correction for multiple testing. Moreover, this SNP 
had not been associated with AN as a single SNP, but as part of a haplotype (also 
see Table 2) (Pinheiro et al., 2010).  
 
The top SNP found to be associated with AN in the first genome-wide association 
(GWA) study of AN by Wang et al (rs2383378, (Wang et al., 2011)) did not 
replicate in the current sample (genotypic p value = 0.84, allelic p value = 0.59, 
Table 17), however the current sample was underpowered to detect variants 
with small effect sizes (odds ratio below 1.5 for heterozygote genotypes, and 
below 2.25 for homozygote genotypes - given a minor allele frequency of 0.38 
and a disease prevalence of 0.6%). In hindsight, I have to agree with the – 
somewhat uncomfortable – conclusion of Kim et al (Kim et al., 2011); that 
underpowered studies are not worth undertaking. There is (now) a large body of 
evidence indicating that common genetic risk factors underlying complex 
disorders such as EDs probably have a very small effect, somewhere the region 
of 1.1 to 1.2 (Cichon et al., 2009,Visscher et al., 2011), however – to my defence 
– this evidence was only unfolding as I was already conducting my laboratory 
work. The genotype data of this study could be used however in future meta-
analyses. For this particular SNP (rs2383378) unfortunately there was an inflated 
negative control error rate; 59% of negative controls (which contain no DNA) had 
a genotype call for this SNP (Table 8, page 71), indicative of (technical) erroneous 
genotype calling. If the negative control rate had been inflated for all SNPs it 
2.10.  Conclusion and discussion 
2 .1 0 . 1 .  C a s e - c o n t r o l  a n a l y s e s  
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would be an indication of DNA contamination (also see paragraph 2.4 S am p l e  
q u a l i t y  c o n t r o l , page 70), which was not the case. The duplicate and triplicate 
error rates were normal for this SNP; 2% and 0.84% respectively (221 samples 
were run in duplicate, and 119 samples were run in triplicate, for quality control 
purposes; the error rate was calculated by dividing the number of mismatching 
duplicates/triplicates by the number of possible mismatches). Furthermore, the 
genotype distribution of this SNP matched the distribution of the reference 
population, and it did not violate the Hardy Weinberg Equilibrium (also see 
paragraph 2.5.3 R e f e r e n c e  p o p u l a t i o n ,  a n d  Ha rd y  W e i n b e r g  Equ i l i b r i um , 
page 82), hence it was not excluded from analyses in this chapter. I nevertheless 
found the inflated negative error rate worrying, and I would want to repeat the 
laboratory work prior to any meta-analyses. I did also genotype this particular 
SNP with a different technique; a TaqMan technique (McGuigan and Ralston, 
2002), which is based on fluorescence rather than mass spectrometry. However 
the results were unusable, because the homozygote and heterozygote genotypes 
of rs2383378 did not cluster, indicative of technical genotyping problems with 
the TaqMan technique (data not shown). This is however a relatively common 
problem and repeating either the Sequenom or the TaqMan method would be 
needed before it could be concluded that this particular SNP is difficult to 
genotype.  
 
The Val158Met polymorphism of the COMT gene has been associated with AN, 
though not unequivocally (Brandys et al, in press). Brandys et al conclude from 
their meta-analyses that the polymorphism is not associated with AN, and the 
results of this thesis support this conclusion; the odds ratio in the London and 
Vienna case and control sample was more equal to that of the Utrecht cohort 
(1.11 vs 1.14, Table 18), but the results were non-significant (genotypic p value 
0.47, allelic p value 0.27). There was no sign of a possible dominant effect of the 
Met allele in this sample (also see Figure 17), which also supports the conclusion 
of Brandys et al (Brandys et al, in press).  
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The three selected haplotypes of the study by Pinheiro et al (Pinheiro et al., 
2010) did not replicate in the current sample (p values of overall association 
were 0.37, 0.68, and 0.44 respectively). Haplotypes are however difficult to 
assess due to current technological limitations; actual (i.e. phased) haplotypes 
can not be measured directly, because raw genotyping data does not distinguish 
between maternally and paternally derived chromosomes. Thus when an 
individual is heterozygote for a SNP it can not be determined from which 
parental chromosome the allele came; the genotype data is said to be 
‘unphased’. The phase can not be measured directly, but is assigned using 
probablities of haplotypes based on LD and known haplotype structures 
(Browning and Browning, 2011). The problem with this method is however that 
minor inaccuracies in the estimation of haplotype frequencies can lead to 
spurious results (Curtis and Gurling, 2006,Curtis and Xu, 2007), and for this 
reason current genetic studies (like the genome-wide GCAN study for anorexia 
nervosa) tend to avoid haplotypes. As Browning and Browning point out 
(Browning and Browning, 2011), haplotype estimation can be improved by 
improving LD information through genotyping larger panels of individuals from 
different ethnicities, for which progress is being made as part of the 1000 
Genomes project (1000 Genomes, 2010).  
Lowest and highest adult lifetime body mass index (BMI) was tested for 
association with genetic variants previously (suggestively) associated with AN 
(Pinheiro et al., 2010,Wang et al., 2011,Brandys et al., in press). One out of nine 
tested SNPs was suggestively associated with lowest adult lifetime BMI; 
rs1718312 (genotypic p value = 0.02, allelic p value = 0.10 see Table 22). The CC 
genotype of this SNP had a higher lowest adult lifetime BMI compared to the CT 
and TT genotypes (15.2 versus 14.3 and 14.4, see Figure 18). A difference like this 
is however expected to arise by chance when testing nine SNPs for association; 
2 .1 0 . 2 .  W i th i n - c a s e  a n a l y s e s  
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the result does not pass a Bonferroni correction for multiple testing. Similarly 
one haplotype combination was suggestively associated with lowest adult 
lifetime BMI (p = 0.03, the combination C-A-T of haplotype rank 17 (Pinheiro et 
al., 2010), also see Table 4, page 62) however again when taking multiple testing 
into account it is not significant. Unfortunately Pinheiro et al (Pinheiro et al., 
2010) only published the overall significance of the haplotypes instead of the 
significance of the specific haplotype combinations, hence it is unclear from the 
paper which haplotype combination (e.g. C-A-T) was most strongly associated to 
the phenotype in their sample. No SNPs were associated with highest adult 
lifetime BMI, but two haplotype combinations were suggestively associated; the 
combination T-A-G of haplotype rank 1 Pinheiro et al (Table 2, page 61, (Pinheiro 
et al., 2010)) (p = 0.05, see Table 25), and the combination A-C-T haplotype rank 
9 Pinheiro et al (Table 2, page 61) (p = 0.04, see Table 26), however again the 
results do not pass a multiple testing correction.  
 
The lack of association with lowest and highest adult lifetime BMI could indicate 
that these are not quantitative traits reflective of the underlying genetic liability 
for AN; the true underlying traits for EDs are unknown as yet. The non-significant 
results of this thesis support the results of the study by Root et al (Root et al., 
2011), who also tested the association between genetic variants and quantitative 
traits relevant for AN (testing the same genetic variations and the same sample 
as (Pinheiro et al., 2010), who only performed case control analyses). Root et al 
found no significant results (after correction for multiple testing) for association 
with lowest adult lifetime BMI, nor for association with any of the other traits 
tested, including age at menarche, drive for thinness, body dissatisfaction, trait 
anxiety, concern over mistakes, and the anticipatory worry and pessimism 
versun uninhibited optimism subscale of the harm avoidance scale (Root et al., 
2011).  
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The current study was underpowered to detect variants with small effects on 
lowest and highest adult lifetime BMI, similarly as to what was discussed for the 
results of the case control analyses (paragraph 2.10.1, page 99). If there were 
genetic risk variants underlying lowest and highest adult lifetime BMI in AN 
cases, and we assumed they had similar effect sizes as the genetic variants 
underlying current BMI (Day and Loos, 2011), a sample size of at least 100,000 
individuals would be needed in order to have enough power to detect them (Day 
and Loos, 2011). For the studies of current BMI, a total of four waves of data 
collection have lead to the robust discovery of at least 50 genetic loci (reviewed 
by Day et al (Day and Loos, 2011)); in the fourth wave a meta-analysis of 46 
studies (123,865 individuals) was conducted, of which the resulting top 42 SNPs 
were taken forward for replication in 125,931 additional individuals (Speliotes et 
al., 2010). Day and Loos show that the gene with the largest effect size (FTO) was 
discovered first, i.e. it was the lowest hanging fruit (Day and Loos, 2011). Per FTO 
risk allele BMI increases by 0.39 kg/m2, which is equal to approximately 1.1 
kilogram for someome 1.70m tall (represented by the black bar, see Figure 19 
(Day and Loos, 2011)). The discovery of the genetic risk variant with the second 
most strong effect size (located near MC4R, the second bar from the left, see 
Figure 19) needed a much larger sample size, not only because its effect size was 
lower than FTO but also because its risk allele occurs less frequently in the 
population (Day and Loos, 2011). These results clearly demonstrate that the 
study I conducted was underpowered, and that much larger sample sizes would 
be needed.  











Figure 19: The lowest hanging fruit (Day and Loos, 2011) 
The genetic studies on body mass index (BMI) indicate that the gene with the largest 
effect on BMI (FTO, also see paragraph 1.1 No rm a l  r e g u l a t i on  o f  e a t i ng  
b eha v i ou r , page 20) was discovered first, i.e. it was the lowest hanging fruit. After 
four waves of data collection (n=125,931) 50 genetic risk variants have now robustly 
been associated with BMI. The effect size of the risk variants is expressed in the increase 
in body weight (gram) per risk allele for an individual 1.70m tall (the figure was obtained 
from reference (Day and Loos, 2011)).  
The most important limitations of the study presented in this chapter were the 
relatively small sample size (at least given the current knowledge on the genetic 
architecture of complex disorders, also see paragraph 1.3.4.3 Un d e t e c t e d  
h e r i t a b i l i t y  a n d  g e n e t i c  a r c h i t e c t u r e , 52), and the fact that relatively few 
genetic variations were tested for association. Several studies now demonstrate 
that genetic variants cumulatively cause phenotypic variance in complex traits; 
Lango Allen et al show that hundreds of genetic variants are involved in the 
regulation of human height (Lango et al., 2010), Li et al, and Hebebrand et al 
present the cumulative effects of the genetic risk loci for BMI (Li et al., 
2010,Hebebrand et al., 2010), and Davies et al predicted human intelligence 
scores based on the cumulative effect of genome-wide SNPs (Davies et al., 2011). 
2 .1 0 . 3 .  L im i t a t i o n s  a n d  f u t u r e  d i r e c t i o n s  
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Since several genetic risk variants have now robustly been associated with BMI, 
and it presents a nice example of where the genetics of eating disorders may 
head towards in the future. Li et al illustrate how the mean BMI increases in a 
linear fashion with the number of genetic risk alleles (see Figure 20, (Li et al., 
2010). On average the mean BMI increases with 0.15 kg/m2 per additional 
genetic risk variant, and individuals with 17 or more genetic risk variants had a 
BMI that was 1.53 kg/m2 greater than that of individuals with 6 or less genetic 
risk variants (Li et al., 2010). In a more recent paper Hebebrand et al update this 
calculation after more risk variants for BMI had been established, and they show 
that individuals with 38 or more genetic risk variants had a BMI 2.73 kg/m2 
greater than individuals with 21 or less genetic risk alleles (Hebebrand et al., 
2010). This example illustrates the challenges of genetic research in eating 
disorders; it will be very difficult to assess a difference in the order of magnitude 
of “0.15kg/m2” per genetic risk variant expressed in liability for AN, because – at 
least currently – there are no unequivocal measurements of severity of illness for 










Figure 20: Increase in BMI per genetic risk variant (Li et al., 2010) 
Mean BMI increases linearly with the number of genetic risk variant; on average 0.15 
kg/m2 per genetic risk variant.  





D i s o r d e r e d  e a t i n g  i n  r e l a t i o n  t o  b o d y  m a s s  i n d e x  
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D i s o r d e r e d  e a t i n g  i n  r e l a t i o n  t o  b o d y  m a s s  i n d e x  
This chapter will present the results of the Eating Disorder Inventory (EDI) 
questionnaire in a sample of 3,624 healthy female twins from the United 
Kingdom (UK). The mean age of the sample was 57 years, which is higher than 
most samples in the field of eating disorders; hence the literature introduction 
will provide some background on disordered eating in this age group. This 
chapter will not include genetic analyses, but it partly serves as an extensive 
introduction to the next chapter; Chapter 4 Genome-wide gene analyses (page 
154), which will discuss the genome-wide genetic analyses of the EDI in this 
sample.  
The Eating Disorders Inventory (EDI) was developed by Garner, Olmsted, and 
Polivy in 1983 (Garner et al., 1983), and it aimed to measure behavioural and 
psychological traits in anorexia nervosa (AN) and bulimia nervosa (BN) (also see 
paragraph 1.2 Ea t in g  d i so r de r s , page 27, for the definition AN and BN, and 
their clinical presentation). The original version of the EDI comprised 64 items, 
but it was revised in 1991 to 91 items (EDI-2, Garner, 1991), and revised again in 
2004 (EDI-3, Garner, 2004). In the last revision the items remained the same as 
for the EDI-2, but the internal structure was altered. In all EDI versions the 
respondents are asked whether an item applies to them “always”, “usually”, 
“often”, “sometimes”, “rarely”, or “never”. The 91 items are grouped in 
subscales, and the responses to the items can be added up per subscale. Three 
subscales specifically assess attitudes towards weight, body shape, and eating; 
the drive for thinness (DT), bulimia (B), and body dissatisfaction (BD) subscales; 
these are also known as the Eating Disorder Risk Scales. The other subscales 
assess more general psychological characteristics, such as: low self-esteem, 
personal alienation, interpersonal insecurity, interpersonal alienation, 
3. Disordered eating in relation to body mass index
3 .1 .  L i t e r a t u r e  b a c k g r o u n d  
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interoceptive deficits, emotional dysregulation, perfectionism, ascetiscism, 
interoceptive awareness, and maturity fears. For the current study the general 
psychological characteristics were not assessed; only the items of the Eating 
Disorder Risk Scales; DT, B, and BD, were included in the self-report 
questionnaire that was sent to the participants (which will be discussed in more 
detail in paragraph 3.4 D a ta  d e s c r i p t i o n , page 113). In the most recent version 
of the EDI, the EDI-3, the Eating Disorder Risk Scales were unchanged apart from 
the addition of one item from the EDI-2 ‘interoceptive awareness’ scale to the 
‘bulimia’ and the ‘body dissatisfaction’ scales (Garner, 2004), the exact questions 
and their corresponding subscales are presented in the Appendix (Table 60, page 
237).  
 
The EDI Eating Disorder Risk Scales DT, B, and BD, have been suggested as 
endophenotypes of eating disorders (EDs) (Stice and Shaw, 2002,Bulik et al., 
2007a,Wilksch and Wade, 2009). An endophenotype basically is an 
‘intermediate’ phenotype; it bridges between the complex clinal presentation 
and the underlying aetiology, i.e. it ‘breaks’ the disorder up into manageable 
‘pieces’ which can be studied on their own; complex disorders can be 
disentangled in this way. The endophenotype concept has been suggested to 
lead to more straight forward, and more successful genetic analyses (Gottesman 
and Gould, 2003). Flint and Munafo however argue that endophenotypes may 
not have a more simple genetic architecture at all (Flint and Munafo, 2007). 
Moreover, Walters and Owen stress that, even though the endophenotype 
concept is very appealing, in reality endophenotypes may be state-dependent, or 
they may associate with the disease but not with the disease causing genes 
(Walters and Owen, 2007); stressing the need for very careful examination of 
endophenotypes. Several within- and between- disorder endophenotypes have 
been suggested for EDs (reviewed by Bulik et al (Bulik et al., 2007a), and by 
Treasure (Treasure, 2007)). Drive for thinness and body dissatisfaction have been 
studied more than the bulimia subscale of the EDI, and they have proven to be 
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among the most robust endophenotypes for EDs (Bulik et al., 2005,Bulik et al., 
2007a,Stice and Shaw, 2002,Wilksch and Wade, 2009), though it should be noted 
that EDI is not the only method used to assess drive for thinness and body 
dissatisfaction (Tury et al., 2010). Note: only when specifically the drive for 
thinness, bulimia, and body dissatisfaction subscales of the EDI are discussed the 
abbreviations DT, B and BD will be used, in all other situations the abbreviations 
will not be used. Several studies have demonstrated that DT and BD are 
moderately heritable (Rutherford et al., 1993,Klump et al., 2000,Keski-Rahkonen 
et al., 2005) (Boraska et al, submitted), and DT and BD have been included as 
behavioural covariates in genetic analyses of EDs (Devlin et al., 2002,Root et al., 
2011).  
 
When interpreting the results of the EDI it is important to take note of the 
context in which the questionnaire was administered, because the scores may 
not represent the same thing in different samples, like samples from different 
cultures, different age groups, or different settings (e.g. clinical or community 
based). Podar and Allik conducted a large-scale cross-cultural comparison of the 
EDI literature in 2009 (Podar and Allik, 2009), their sample included 43,722 
individuals from 25 countries across all continents. Out of the 310 samples Podar 
and Allik included a 136 were general population samples, 159 were clinical ED 
samples, and 15 were special samples (including ballet dancers, and specific 
psychiatric, and obesity samples) (Podar and Allik, 2009). The mean age was 21 
years for individuals with AN, 25 years for individuals with BN, and 19.7 years for 
individuals from the general population (Podar and Allik, 2009). The mean body 
mass index (BMI) for the general population samples was 21.6 (with a standard 
deviation of 1.9) (Podar and Allik, 2009). Podar and Allik found, based on the 
mean scores of the subscales of the EDI, that the pairwise intercorrelation of the 
subscales suggested two main factors which accounted for 67% of the total 
variance; three personality scales loaded strongly on the first factor, and the 
Eating Disorder Risk scales DT, B, and BD, loaded strongly on the second factor 
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(Podar and Allik, 2009), which is in agreement with the intended distinction 
between eating behaviour attitudes and general psychological characteristics 
(Garner, 1983,Garner, 1991,Garner, 2004). This factor structure held true for 
both the general population as the clinical sample across cultures, indicating that 
the meaning of the scales is comparable between the general population and 
individuals with a clinical ED (Podar and Allik, 2009).  
 
The sample I analysed in this chapter is of older age and higher BMI than the 
samples in the study by Podar and Allik (Podar and Allik, 2009). Even though EDs 
are typical for adolescent females (also see 1.2.1 P r e v a l e n c e  a n d  i n c i d e n c e , 
page 29), disordered eating and weight and shape concerns do occur in older 
women as well (Lewis and Cachelin, 2001,Mangweth-Matzek et al., 2006,Bedford 
and Johnson, 2006,Slevec and Tiggemann, 2011). No differences in prevalence of 
body dissatisfaction were found between women of younger and older age 
groups (Webster and Tiggemann, 2003,Bedford and Johnson, 2006), but Webster 
and Tiggemann note that body dissatisfaction had less impact on the self-esteem 
of women who were older (Webster and Tiggemann, 2003).  
 
The EDI scores tend to increase with body mass index (BMI) (Mangweth-Matzek 
et al., 2006,Packianathan et al., 2002). It should however be noted that this trend 
was observed in clinical samples, but not in the general population samples of 
the study by Podar and Allik (Podar and Allik, 2009); however the general 
population samples in the study by Podar and Allik were young, mean age 19.7 
years (standard deviation 3.9), and had a low normal BMI, 21.6 (standard 
deviation 1.9). The mean BMI in the UK in 2007 for women was 26.8, and was 
generally higher in older age groups (Health Survey for England, 2007). 
Packianathan et al aimed to identify a normative range of EDI scores in an obese 
predominantly female UK sample with a mean age of 42 years (note: these were 
not patients seeking bariatric surgery) (Packianathan et al., 2002). They found 
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that most subscale scores were within the range of a normal population, except 
for DT and BD, which were elevated among obese individuals (Packianathan et 
al., 2002). Figure 21 shows the median raw scores of the EDI-2 of 100 unselected 
obese patients referred to an obesity clinic by their general practitioners, 
compared to a normative range of EDI scores in healthy college-aged females, 
and a normative range of EDI scores in eating disorder patients (see Figure 21). 
The obese sample scored significantly higher compared to the healthy women on 
the DT and on BD subscales; and 83% of the obese sample had a BD score above 
the normative range for eating disorders (half of the obese sample scored the 
maximum BD score) (Packianathan et al., 2002). This relationship between body 
dissatisfaction and BMI was also found in more recent studies on weight and 
shape concerns of older women (Mangweth-Matzek et al., 2006,Slevec and 









Figure 21: Normative range of the EDI (Packianathan et al., 2002) 
In light grey the normative range of EDI scores in eating disorder patients is shown 
(labelled ‘Eating Disorder norm’); in dark grey the normative range of EDI scores in 
healthy college-aged females is shown (labelled ‘Female College Students norm’); and 
the black squares represent the median raw scores of the EDI subscales in the obese 
group (n = 100). The obese group scores higher on Drive for Thiness (DT), and Body 
Dissatisfaction (BD); the BD scores of most obese individuals are higher than the eatind 
disorder normative range (half of the obese samples scored the maximum BD score) 
(Packianathan et al., 2002).  
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This aim of this chapter was to present the distribution and correlates of the 
drive for thinness (DT), bulimia (B), and body dissatisfaction (BD) eating disorder 
risk scales, as assessed by the Eating Disorder Inventory (EDI) (Garner, 2004), in a 
general population sample, with a specific focus on the relation with body mass 
index. The first part of this chapter tested the hypothesis that a higher current 
BMI was related to a higher DT, B, and BD score. The second part of this chapter 
aimed to test which BMI predicts DT, B, and BD scores best; namely current BMI, 
lowest adult lifetime BMI, highest adult lifetime BMI, or the combined BMI 
history of an individual. Note: any causal direction of these relationships, e.g. 
whether disordered eating preceded an increase in BMI or the other way around, 
could not be ascertained from this study.  
Analyses were performed using regression and multiple regression methods, and 
do not include twin modelling for heritability analysis. Twin relatedness was 
accounted for by multilevel analyses using Generalised Estimating Equations 
(GEE) in SPSS Statistics software version 17.0, with the twin family identifier as 
the subject effect and an indication of proband and non-proband as within-
subject effect. Variables were entered into the model by forced entry. Cases with 
missing values were excluded list-wise.  
The relationship between disordered eating as assessed by the Eating Disorder 
Inventory (EDI)-3 – Eating Disorder risk scales drive for thinness (DT), bulimia (B) 
and body dissatisfaction (BD) self report questionnaires (Garner, 2004) and self 
reported current BMI was tested by multiple regression, with BMI as dependent 
variable and individual EDI scales as independent (predictor) variables adjusted 
for age. EDI scales were regressed individually with BMI, as well as together; i.e. 
with the scores of all three EDI scales as covariates. All associations between EDI 
3.2.  Aim and outline
3 .3 .  S ta t i s t i c a l  me th od s  
3 .3 . 1 .  D i s o r d e r e d  e a t i n g  a n d  c u r r e n t  B M I  
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and BMI were regressed with age as a covariate, because each EDI scale was 
significantly associated with age (scores significantly decrease with age, data 
presented in the Appendix, page 238), and because age was significantly 
associated with BMI (BMI increases with age, data presented in the Appendix, 
Figure 66, page 241). Even though the relationship between the EDI scores and 
age was not the main objective of this chapter, a short comment was written on 
the significant association between both in the conclusion and discussion of this 
chapter (paragraph 3.6.5 R e l a t i o n s h i p  b e t w e e n  E D I  s c o r e s  a n d  a g e , page 
151), because literature had indicated there were no differences between 
women of younger and older age groups (Webster and Tiggemann, 2003,Bedford 
and Johnson, 2006).  
I tested whether lowest BMI and/or highest BMI predicted EDI scale scores 
better than current BMI by multiple regressions, with the individual EDI scales as 
dependent variables and lowest, current, and highest BMI as independent 
(predictor) variables adjusted for age. BMIs were regressed individually with the 
EDI scales, as well as combined in order to test which BMI measure was the best 
predictor of disordered eating as assessed by the EDI questionnaire.  
A total of 4,050 individuals (3,624 females and 426 males) recruited by the St 
Thomas' UK Adult Twin Registry took part in this study. They completed the 
Autumn 2008 questionnaire which can be found online at 
http://www.twinsuk.ac.uk/phenotypes.html. This questionnaire included 162 
questions on several topics including eye surgery, education, work experience, 
social behaviour, nutritional supplements, eating behaviour, height and weight, 
physical appearance, lifestyle, diabetes and genetic testing. Of these data 41 
questions were available for analyses (see Table 60, page 237 in the Appendix for 
an overview); 38 of these questions – namely the questions considering EDI and 
BMI – were analysed in the current chapter. Available questions on breakfast 
3.3.2. Disordered eating and BMI history 
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frequency and waist circumference were excluded since they were beyond the 
scope of the current chapter. The sample consisted predominantly of females 
(90%), and for this chapter only females were included (n=3,624). The sample 
consisted of 780 monozygotic (MZ) twin pairs, 614 dizygotic (DZ) twin pairs and 
836 single twins (of who 389 have an MZ and 446 have a DZ twin). The single 
twins are either single because their twin did not fill out the Autumn 2008 
questionnaire or because their twin was male and was excluded from analyses 
for that reason.  
The age ranged from 18-92 with a mean age of 57 years (n=3,624, stdev=12.9, 
see Figure 22). The distribution of age shows a negative skew; the sample 
contains relatively few individuals older than 80 years old, at least fewer than 
expected based on a normal distribution with a mean age of 57; this is skew is 
probably a life expectancy effect, and individuals older than 80 years are 
probably less likely to participate in any study.     
3 .4 . 1 .  A g e  
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Figure 22: Distribution of age – TwinsUK (females) 
Body mass index (BMI) was calculated from self-reported current weight and 
height (kilogram/meter2). For some individuals weight was given in both 
kilograms (kgs) and stones/lbs. Where weight was provided in both units, 
preference was given to the data in stones/lbs (as this is most commonly used in 
the United Kingdom (UK) and thus may be more reliable). For eight individuals 
the standard and metric weight was more than 5kgs apart and they were 
excluded based on the assumption that one or both of the measurements were 
erroneous (n=8). An additional four current weight measurements were 
excluded because they were too low (ranging from 4.5 to 5.8kgs) and thus invalid 
(n=4). For height again standard and metric measurements were available for 
some individuals. For five individuals these measurements were more than five 
centimetres (cms) apart and they were thus excluded (n=5). An additional three 
measurements were excluded because they were too low (ranging from 0.07 to 
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0.27 meters, n=3). Distributions of height and weight are presented in the 
Appendix (see Figure 67 and Figure 68, page 242). In total this resulted in the 
exclusion of 24 current BMIs, an additional 197 height and/or current weight 
measurements were missing, rendering a total number of missing BMIs of 221. 
Valid BMIs range from 7.3 to 73.2 kg/m2 with a mean of 25.5 (n=3,403, 
stdev=4.9) (see Figure 23). The distribution of current BMI shows a positive skew; 
there are more high BMIs than expected based on a normal distribution with a 
mean of 25.5 (see Figure 23). According to the WHO guidelines a BMI below 18.5 
is considered underweight, a BMI between 18.5 and 25 is normal range, between 
25 and 30 pre-obese and above 30 obese. In the current sample 85 individuals 
(2%) would be classified as underweight, 1,780 (52%) as normal range, 1,037 
(31%) as pre-obese, and 501 (15%) as obese. Compared to the latest UK Health 
Survey results in 2007 the current sample contains relatively many women with 
normal range BMIs and relatively few women classified as obese (see Figure 24, 
Health Survey for England, 2007).  
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Figure 23: Distribution of current BMI – TwinsUK (females) 
There are relatively many high BMIs in the sample based on a normal distribution of the 
sample mean. The proportion of high BMIs (>35) is however less than the proportion of 
high BMIs in the UK generally based on the latest UK Health Survey results for women 
(see Figure 24).  
 
Figure 24: TwinsUK BMI compared to UK BMI (females) 
The graph was adapted from the WHO website (http://apps.who.int/bmi). UK data 
(females) is from the 2007 Health Survey for England (Health Survey for England, 2007). 
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The sample contains relatively many individuals with normal range BMIs and relatively 
few obese individuals compared to the UK population.  
For one individual the standard and metric lowest adult lifetime weight (i.e. 
lowest weight) measurements were more than 5kgs apart, and this 
measurement was thus excluded (n=1). An additional two measurements were 
excluded because they were too low (3.1 and 3.6kgs, n=2), and 14 
measurements were excluded because the lowest weight was more than 5kgs 
higher than the current weight (ranging from 5.4 to 49kgs difference, n=14). A 
minor difference between lowest adult lifetime and current BMI was allowed 
accounting for slight differences between standard and metric measurement 
calculations (maximum difference allowed between lowest and current weight 
was -4.5kgs or -1.6 BMI units). The distribution of lowest weight is presented in 
the Appendix (see Figure 69, page 243). In total 198 lowest adult lifetime BMIs 
(i.e. lowest BMIs) were missing due to invalid and/or missing height and lowest 
weight measurements. Lowest BMI ranged from 8.5 to 44 with a mean of 20.7 
(n=3,426, stdev=3.1) (see Figure 25). For 844 individuals their lowest BMI was 
within 2 BMI units from their current BMI, 296 individuals were currently more 
than 10 BMI units heavier than their lowest BMI.  
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Figure 25: Distribution of lowest adult lifetime BMI – TwinsUK (females) 
For three individuals their given highest weight in kgs was more than 5kgs 
different from their given highest weight in stones/lbs and their measurements 
were thus excluded (n=3). A further 35 measurements were excluded because 
their highest weight was more than 5kgs lower than their current weight. In total 
232 highest BMIs were missing because of invalid and/or missing height and 
highest weight measurements. The distribution of highest weight is presented in 
the Appendix (see Figure 70, page 243). Highest BMI ranged from 12.8 to 69.7 
with a mean of 27.2 (n=3,392, stdev=5.4) (see Figure 26). For most individuals 
their highest BMI is not more than 2 BMI units higher than their current weight 
(n=2,177), for 38 individuals their highest BMI is more than 10 BMI units heavier 
than their current BMI and for 523 individuals their highest BMI is more than 10 
BMI units heavier than their lowest BMI. There were 82 individuals who only 
reported their highest weight and not their current weight, however the total 
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number of current BMIs reported still outnumbers the number of highest BMIs 
reported (3,403 vs 3,392).  
 
Figure 26: Distribution of highest adult lifetime BMI – TwinsUK (females) 
Twenty-five questions from the EDI-3 Eating Disorder Risk scales Drive for 
Thinness (DT), Bulimia (B), and Body Dissatisfaction (BD) (Garner, 2004) were 
part of the self report TwinsUK Autumn 2008 questionnaire (see the Appendix 
for the exact questions, Table 60, page 237). The responses were scored one to 
six instead of zero to four to ensure a more normal and informative distribution, 
but in order to be able to compare the scores to the literature the mean 
following traditional scoring will be presented as well. In addition the mean EDI-1 
and EDI-2 scores will be calculated by deleting the question “When I am upset, I 
worry that I will start eating” from the B scale, and the question “I feel bloated 
after eating a normal meal” from the BD scale. In Finland the EDI questionnaire 
was also administered to a twin cohort (Keski-Rahkonen et al., 2005), they 
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however excluded the question “I like the shape of my buttocks” from the BD 
scale (personal communication). In order to be able to compare the BD scores to 
the Finnish study a mean “Finnish-BD” score was calculated as well. If an 
individual had not completed all questions of the EDI scale they were excluded 
from analyses, as missing answers would artificially lower the scale score (the 
proportion of missingness was 4.8%, 3.8% and 6.5% for the DT, B and BD scales 
respectively). Figure 27 shows the number of individuals skipping one or more 
EDI questions (see Figure 27). Missingness of answers was not random; it was 
significantly associated with the mean score of the question with more missing 
answers for questions with higher mean scores (linear regression: r-square 
0.303, p=0.004, n=25 questions, see Figure 28). The questions least and most 
often skipped, controlling for the mean score of the question, are shown in Table 
27. There is no apparent relationship between skipping EDI questions and 
current BMI (see Figure 29).   
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Figure 27: Number of individuals skipping EDI questions 
Most individuals skip only one question per EDI scale, very few people skip more than 
one question. Which question is skipped relates to the mean score of the question (see 
Figure 28).  
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Figure 28: Missingness of answers to EDI questions is not random 
The number of missing answers per EDI question significantly increases with increasing 
mean score of the EDI question (r-square= 0.303, p=0.004, n=25 questions).  
 
Table 27: EDI questions skipped least and most often 
N predicted is the number of missing answers predicted based on the mean score of the 
question.  
- 124 - 
 
Figure 29: No apparent relationship between current BMI and skipping EDI questions 
The interpolation line shows the mean current BMI per number of missing answers. 
Note: there were three people who skipped all twenty-five EDI questions however for 
these individuals there were no valid BMI data.  
Drive for thinness (DT) was assessed by seven self-report questions from the EDI-
3 Eating Disorder risk scale (Garner, 2004) (see the Appendix Table 60, page 237 
for the exact questions). For 178 individuals one or more answers of the DT scale 
were missing and they were thus excluded from analyses (4.8%). The scores 
range from 7 to 42, with a mean of 17.7 (n=3,448, stdev=7.1) (see Figure 30). 
EDI-1 and EDI-2 calculations are equal to the EDI-3 calculation for DT, but 
following traditional scoring (Garner, 2004) the mean is 5.9 (stdev=5.6). 
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Figure 30: Distribution of DT score – TwinsUK (females) 
Bulimia (B) was assessed by eight self-report questions from the EDI-3 (see the 
Appendix Table 60, page 237 for the exact questions). For 138 individuals one or 
more answers of the B scale were missing and they were thus excluded from 
analyses (3.8%). The scores range from 8 to 48, with a mean of 12.3 (n=3,486, 
stdev=4.9) (see Figure 31). With traditional scoring (Garner, 2004) the mean is 
1.8 (stdev=3.2), and with EDI-1 and EDI-2 scoring the mean is 10.8 (stdev=4.2). In 
Chapter 4 this EDI scale was analysed as a dichotomous trait with the 75% 
percentile, 12, as a threshold.  
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Figure 31: Distribution of B score – TwinsUK (females) 
Body Dissatisfaction (BD) was assessed by ten self-report questions from the EDI-
3 (see the Appendix Table 60, page 237 for the exact questions). For 237 
individuals the answer to one or more questions of the BD scale was missing and 
they were thus excluded from analyses (6.5%). The scores range from 10 to 60, 
with a mean of 34.1 (n=3,387, stdev=11.5) (see Figure 32). With traditional 
scoring (Garner, 2004) the mean is 15.8 (stdev=10.1), with EDI-1 and EDI-2 
scoring the mean is 31.6 (stdev=11.2), and the mean Finnish-BD score (see 
paragraph 3.4.5 Ea t i n g  D i s o r d e r s  I n v e n t o r y , page 120) is 27.8 (stdev=10).  
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Figure 32: Distribution of BD score – TwinsUK (females) 
The EDI Eating Disorder Risk scales Drive for Thiness (DT), bulimia (B), and body 
dissatisfaction (BD) scores are all significantly associated with current BMI 
(controlling for age, p<0.001), with higher scores predicting higher current BMIs 
(see Table 28 and Figure 33 to Figure 35). BD explains most variation in current 
BMI; it has the highest standardized coefficient (beta) (0.53, see Table 28). This 
means that when predicting current BMI, one standard deviation increase in BD 
score increases the current BMI with 0.53 standard deviations.  
3 .5 .  R e s u l t s   
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Table 28: Results predicting current BMI by EDI-3 scales adjusted for age 
The results are grouped per EDI scale; DT, B, and BD. The variables column shows that all 
analyses were adjusted for age. The third column, labelleled ‘B’, indicates the correlation 
coefficient between the EDI scale and current BMI; SE B is the standard error of this 
coefficient. Beta is the standardised coefficient (the coefficient divided by the standard 
deviaton); the strength of association of the different EDI scales be compared to each 
other based on the beta values, because the beta does not depend on the unit of 
measurement. The Wald Chi-square is also known as the Wald statistic, or simply ‘chi-
square’. The p value is the p value adjusted for age (the p value of age is adjusted for the 
EDI scale, and it can be seen that age is significantly associated to current BMI). Note: 
the p value 0.00E+00 indicates that the p value was lower than the lowest p value that 
could be displayed by SPSS (p < 1.00E-15), i.e. these p values were highly significant. All 
three EDI-3 scales are significantly associated with current BMI, but BD explains most 
variation in BMI as indicated by the highest beta value (0.53, indicated in italic).  
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Figure 33: Current BMI increases with increasing DT scores 
The left Y axis and the bars indicate the mean current BMI (± one standard error of the 
mean (SE)) per DT score. The right Y axis and the line show the distribution of DT scores, 
i.e. the number of individuals per DT score.   
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Figure 34: Current BMI increases with increasing B scores 
The left Y axis and the bars indicate the mean current BMI (± one standard error of the 
mean (SE)) per B score. The right Y axis and the line show the distribution of B scores, i.e. 
the number of individuals per B score. There are very few individuals with high bulimia 
(B) scores.   
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Figure 35: Current BMI increases with increasing BD scores 
The left Y axis and the bars indicate the mean current BMI (± on standard error of the 
mean (SE)) per BD score. The right Y axis and the line show the distribution of BD scores, 
i.e. the number of individuals per BD score.   
The different EDI scales are however moderately correlated (see Table 29), and 
from the combined multiple regressions it becomes apparent that they partly 
explain the same variation in current BMI. When the three EDI scales are 
regressed together to predict current BMI BD explains most unique variation in 
current BMI (beta=0.51, p<0.001), B also significantly contributes to the model 
(beta=0.10, p=1.84E-04), but DT does not (p=0.206) (see Table 30).  
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Table 29: Correlations of the EDI-3 scales 
Partial correlations adjusted for age. The strongest correlation is between DT and BD 
(0.623, in bold), but there is also considerable correlation between DT and B, and B and 
BD.  
 
Table 30: Results predicting current BMI by all EDI-3 scales combined 
Beta (in bold) is the standardised correlation coefficient; i.e. the coefficient based on 
which the variables can be compared, as beta does not depend on the unit of 
measurement. The unstandardised coefficient (B) and standard error of the 
unstandardised coefficient (SE B) are shown as well. When all EDI scales are controlled 
for BD explains most unique variation in current BMI (beta=0.51, indicated in italic), B 
also has a significant contribution (beta=0.10, in italic), but DT does not significantly 
contribute to the model. Note: the p value 0.00E+00 indicates the p value was lower 
than the lowest p value that could be displayed in SPSS, i.e. this association is highly 
significant.  
Current BMI can be predicted significantly better using the EDI-3 Risk scale 
scores than when using the current BMI mean as a ‘best guess’, however the 
difference between the predicted and observed current BMI still has a large 
range (see Table 31). BD is the best predictor of current BMI, and adding B and 
DT to the model only improves the model marginally. The standard deviation of 
the raw residuals is however smallest for the model including all three EDI-3 
scales (see Table 31), and this model will thus be considered the best model to 
predict current BMI. The residuals are normally distributed (see Figure 36), and 
characteristics of the outliers (± two standard deviations of the mean) are 
presented in Table 32. Only 3.8% of the cases have a residual value ± two 
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standard deviations, and 1.2% of the cases have a residual value ± three standard 
deviations, which is within 0.5% of what would be expected for an ordinary 
sample indicating that the assumption of normally distributed errors for 
regression models has not been violated. The negative outliers (i.e. individuals 
for whom the observed current BMI was much lower than the predicted) have a 
lower lowest and current BMI (17.0 and 16.6 versus 20.6 and 25.0 respectively, 
see Table 32); the positive outliers have higher lowest, current, and highest BMI 
(see Table 32). The model thus performs well predicting current BMIs in the 
normal range, but performs less well to predict very low and very high current 
BMIs. Figure 37 shows that current BMI was more often underestimated than 
overestimated, which is a result of the fact that the sample contained more high 
BMIs than low BMIs (see distribution of current BMI Figure 23, page 117). The 
variance in residuals slightly increases for increasing BD scores indicating that the 
prediction of current BMI gets slightly less accurate with higher BD scores (see 
Figure 37). For 60% of the individuals the prediction of current BMI is ± 8.5 BMI 
units of the observed current BMI (see Figure 37). 
 
Table 31: Raw residuals per model predicting BMI 
All models were adjusted for age. BD is the best predictor of current BMI, adding B and 
DT to the model only improves the model marginally. The standard deviation (Stdev) of 
raw residuals is smallest for the model including all three EDI-3 scales, and this will thus 
be considered the best model to predict current BMI (stdev=4.19, in bold). The raw 
residuals (observed current BMI minus predicted) range from -23.40 to +48.88.  
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Figure 36: Distribution of standardised residuals for the model predicting current BMI 
The residuals are normally distributed and no more than 5% of the cases have a residual 
value more than 2 standard deviations away from the sample mean.  
 
Table 32: Characteristics of outliers for the model predicting current BMI 
The outliers are of approximately equal age, and have slightly elevated EDI-3 scores 
compared to rest of the sample (in italic). Negative outliers (-2 stdev, n=19) have lower 
mean lowest and current BMIs (middle column, in bold) and the positive outliers (+2 
stdev, n=118) have higher lowest, current, and highest BMI (most right column, in bold).  
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Figure 37: Residual values of the model predicting current BMI per BD score 
Raw residuals were plotted with BD score because it was the most important predictor 
of the model. The dotted lines indicate a range of two standard deviations from the 
mean. There are more positive residuals than negative residuals, i.e. the current BMI 
was more often underestimated than overestimated. The characteristics of the outliers 
are given in Table 32. The variance in residual values appears to increase slightly for 
higher BD scores, indicating that the prediction of current BMI is less accurate for higher 
BD scores.  
3.5.2. Disordered eating and BMI history 
I tested whether lowest and/or highest BMI would predict disordered eating as 
assessed by the EDI-3 scales better than current BMI. Lowest, current and 
highest BMI are however correlated, with current and highest BMI being highly 
correlated (0.909, see Table 33). Indeed when predicting DT based on all BMIs 
only highest BMI explains a significant proportion of unique variation (see Table 
34), combining highest BMI with only lowest or only current BMI gives the same 
result (data not shown) thus the best model to predict DT scores is based on 
highest BMI only adjusted for age (beta=0.38, see Table 34). Figure 38 shows the 
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relationship between lowest, current, and highest BMI with DT scores. The 
results for predicting B follow the same pattern, only highest BMI explains a 
significant proportion of unique variation in B scores (see Table 35 and Figure 
39).  
 
Table 33: Correlations for lowest, current, and highest BMI 
Partial correlations adjusted for age. Current and highest BMI are very strongly 
correlated (0.909, indicated in bold). Lowest and current BMI, and lowest and highest 
BMI are moderately correlated.    
 
Table 34: Results prediction DT by BMI history 
All analyses were adjusted for age. The columns B and SE B represent the unstandarised 
coefficients, and standard errors of the unstandardised coefficients, of association. Beta 
is the standardised coefficient. Lowest, current, and highest BMI are correlated and 
partly explain the same variation in DT scores. Only highest BMI explains a significant 
proportion of unique variance in DT scores (upper model, in italic), its beta of 0.38 
(lower model, in bold) indicates that when predicting DT one standard deviation 
increase in highest BMI increases DT by 0.38 standard deviations.  
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Figure 38: Mean lowest, current, and highest BMI per DT score 
The circles indicate the mean current BMI per DT score; the upper line of the bar 
indicates the mean highest BMI and the lower line of the bar indicates the mean lowest 
BMI per DT score. With increasing DT scores the means of the BMIs increase as well, 
which is most prominent in highest BMI. Missingness is not related to BMI (see most 
right bar, and 3.4.5 Ea t i n g  D i s o r d e r s  I n v e n t o r y , Figure 29, page 124).  
 
Table 35: Results prediction B by BMI history 
All analyses were adjusted for age. Lowest, current, and highest BMI partly explain the 
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same variation in B scores. Only highest BMI explains a significant proportion of unique 
variance in B scores (upper model, in italic), its beta of 0.34 (lower model, in bold) 
indicates that when predicting B one standard deviation increase in highest BMI 
increases B by 0.34 standard deviations.  
 
Figure 39: Mean lowest, current, and highest BMI per B score 
The circles indicate the mean current BMI per B score; the upper line of the bar indicates 
the mean highest BMI and the lower line of the bar indicates the mean lowest BMI per B 
score. The BMIs increase with increasing B scores, however among the higher B scores 
there is more variation in BMI, which can be explained by the fact that there were very 
few individuals with high B scores in the sample (see Figure 31, page 126). Missingness is 
not related to BMI (see most right bar, and Figure 29, page 124).  
For BD lowest, current, and highest BMI all significantly contribute to the 
prediction of BD scores (p<0.005, see Table 36 and Figure 40). In contrast to the 
results for DT and B current BMI, not highest BMI, explains most variance in BD 
scores. Based on this model an individual’s BD score can be predicted by 
multiplying their age, lowest -, current -, and highest BMI by the corresponding 
unstandardised coefficient (B, Table 36) and adding them to the unstandardised 
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coefficient of the intercept (B=8.97, see Table 36). Table 37 provides an example 
of this calculation.  
 
Table 36: Results prediction BD by BMI history 
All analyses were adjusted for age. Beta is the standardised coefficient. The BMIs explain 
more variation in BD than in the other EDI-3 scales; i.e. the beta values are higher for BD 
than for DT or B (see Table 34 and Table 35). Current BMI explains most variation in BD 
scores (beta=0.50), but both lowest and highest BMI significantly contribute to the 
model (p<0.005, in italic). Based on this model an individual’s BD score can be predicted 
by multiplying their age, lowest -, current -, and highest BMI by the unstandardised 
coefficients value (B) and adding them to the intercept B value (see Table 37 for an 
example).  
 
Table 37: Example calculation of predicted BD score by BMI history 
B is the unstandardised correlation coefficient. The BD score can be predicted by 
multiplying an individual’s variable values by the corresponding unstandardised 
coefficient (B) of the model. Participant #83212 was chosen randomly, for this person 
the predicted BD score was calculated by multiplying the her scores by the 
unstandardised coefficients (B) of the model and adding them to the intercept; the 
predicted BD score was only 1.19 BD units lower than the observed BD score (raw 
residual=1.19, in italic).   
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Figure 40: Mean lowest, current, and highest BMI per BD score 
The circles indicate the mean current BMI per BD score; the upper line of the bar 
indicates the mean highest BMI and the lower line of the bar indicates the mean lowest 
BMI per BD score. The BMIs increase with increasing BD scores, most prominently for 
current and highest BMI. Missingness is not related to BMI (see most right bar, and 
Figure 29, page 124).  
In general BD is most accurately predicted out of the EDI-3 scales (see Table 38). 
The EDI-3 scores can be predicted significantly better based on their BMI than 
when using the scale mean as a ‘best guess’, however the prediction is not 
equally accurate for all individuals; there are subgroups for whom the prediction 
is not as good as it is for the majority of the sample. For DT this is apparent from 
the fact that the standardised residuals are not normally distributed; there are 
more cases with negative residual values than predicted based on a normal 
distribution and there are relatively many outliers with high positive residuals 
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(see Figure 41). The number of individuals with residual values ± two and three 
standard deviations from the sample mean is however not larger than 5% and 
1% respectively, which are the expected percentages for a normally distributed 
sample. The characteristics of the outliers ± two standard deviations from the 
sample mean are given in Table 39; negative residual outliers have a higher mean 
current and highest BMI (n=10) and positive residual outliers stand out for having 
elevated EDI-3 scores (n=159, see Table 39). Figure 42 shows the subgroup of 
individuals with high positive residual values (dotted circle, see Figure 42); they 
have a normal range highest BMI and high positive residual values indicating that 
their observed DT score was much higher than their predicted score. The mean 
DT score significantly increases with increasing highest BMI, and on average 
people with normal range highest BMIs have low DT scores, but this does not 
hold true for this subgroup of individuals. Omitting this subgroup from the 
sample would normalise the distribution of standardised residuals and increase 
the predictive ability of the model for the rest of the sample.  
 
Table 38: Raw residuals of the models best predicting the EDI-3 scale scores 
The best model to predict DT and B scores is based on highest BMI adjusted for age, in 
contrast to BD for which the model based on lowest, current, and highest BMI is the 
better model. The range of raw residuals (i.e. observed minus predicted score) is 
however considerable. BD can be predicted most accurately; it has the lowest standard 
deviation (Stdev, 4.46, bottom row).  
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Figure 41: Distribution of standardised residuals – DT model based on BMI history 
The distribution of standardised residuals deviates from normality; there are more 
negative residuals than expected based on a normal distribution and there are outliers 
with high positive residual values.  
 
Table 39: Characteristics outliers - model DT based on BMI history 
The outliers are of approximately equal age. Negative outliers (-2 stdev, n=10) have 
higher mean current and highest BMIs (middle column, in bold), and the positive outliers 
(+2 stdev, n=159) have elevated EDI-3 scores (most right column, in bold).  
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Figure 42: Raw residuals DT model based on BMI history 
There is a subgroup of individuals for whom the DT score is underestimated (indicated 
by the dotted circle); based on their highest BMI their DT score was predicted to be 
lower than it actually was. Dotted lines indicate two standard deviations; for 60% of the 
sample the predicted DT score was ± 13 units of the observed score.  
The standardised residuals of the B scores are normally distributed (see Figure 
43). Characteristics of the cases most different from the sample mean, i.e. 
individuals for whom the model predicted the B score least accurately, are given 
in Table 40; it concerns individuals with lower and higher than average EDI-3 
scores. Residuals are equally distributed on each increment of the predictor 
variable; however the prediction is fairly inaccurate with the predicted B score 
deviating from the observed score with ± 9.4 for approximately 60% of the 
sample (see area within dotted lines, Figure 44).  
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Figure 43: Distribution of standardised residuals - model B based on BMI history 
The standardised residuals for the prediction of B are normally distributed.  
 
Table 40: Characteristics outliers - model B based on BMI history 
Negative and positive residual value outliers stand out for having low and high scores 
respectively on all EDI-3 scales (most prominent differences in bold).  
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Figure 44: Raw residuals - model B based on BMI history 
The residuals are equally positive and negative at each increment of the predictor 
variable highest BMI. Dotted lines indicate two standard deviations from the mean of 
the sample.  
The standardised residuals of the model predicting BD are not normally 
distributed; as for DT there are more cases with negative residual values than 
predicted based on a normal distribution and there are relatively many outliers 
with high positive residuals (see Figure 45). The number of cases with residual 
values ± two standard deviations from the sample mean is not larger than 5%, as 
expected for an ordinary sample. The number of cases ± three standard 
deviations is 1.7% of the sample, which is still within 1% of what would be 
expected for a normally distributed sample. The characteristics of the outliers 
are given in Table 41; negative residual outliers have much higher mean current 
and highest BMI (n=8) and positive residual outliers have much higher EDI-3 
scores than the rest of the sample (n=145, see Table 41). As for DT there appears 
- 146 - 
to be a subgroup of individuals for whom the model is a poor fit, Figure 46 shows 
that this subgroup consists of individuals with normal range current BMIs but 
high positive residual values; i.e. for these individuals the predicted BD score is 
much lower than the observed score (indicated by a dotted circle, see Figure 46). 
The mean BD score does significantly increase with increasing current BMI (also 
see Figure 35, page 131), and on average people with normal range current BMIs 
have low BD scores, however this does not hold true for this subgroup of 
individuals. Omitting this subgroup from the sample would normalise the 
distribution of standardised residuals and increase the predictive ability of the 
model for the rest of the sample. 
 
Figure 45: Distribution standardised residuals - model BD based on BMI history 
The distribution of standardised residuals deviates from normality, which appears to be 
caused by a subgroup of individuals for whom the predicted BD score is much lower 
than the observed score (also see Figure 46).  
- 147 - 
 
Table 41: Characteristics outliers - model BD based on BMI history 
Negative residual value outliers have much higher current and highest BMIs, and 
positive residual value outliers have much higher EDI-3 scores than the rest of the 
sample (most prominent differences in bold).  
 
Figure 46: Raw residuals - model BD based on BMI history 
Raw residuals were plotted with the predictor which had the most influence on the BD 
model: current BMI (beta=0.50, see Table 36, page 139). BD scores are predicted more 
accurately than DT and B scores (stdev raw residuals=4.5). The subgroup of individuals 
for whom the model is a poor fit is indicated by a dotted circle; their BD scores are 
underestimated.  
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This thesis confirms that EDI scores are generally higher in individuals with a 
higher body mass index (BMI) (Packianathan et al., 2002,Mangweth-Matzek et 
al., 2006,Slevec and Tiggemann, 2011). The results are not in line with the 
conclusion of Podar and Allik that this relationship only exists in clinical eating 
disorders samples, and not in general population samples (Podar and Allik, 
2009). The sample size of the study by Podar and Allik is unparalleled (n = 43,722 
individuals; Podar and Allik performed meta-analyses of the literature available 
on EDI), however the mean age of their general population sample (i.e. thus of 
the literature on EDI on the general population overall) was low; 19.7 years 
(standard deviation 3.9), and the mean BMI was also low; 21.6 (standard 
deviation 1.9). By comparison the mean BMI of the general population in the UK 
is very high; 26.8 for women (Health Survey for England, 2007). The mean BMI of 
the sample described in this chapter is comparable to the general UK population 
(also see Figure 24, page 117).  
 
The relationship between each of the EDI Eating Disorder Risk scale scores, DT, B, 
and BD, and BMI are highly significant (p < 1.00E-15), and the correlation 
coefficients are moderately strong (standardised correlation coefficients (beta): 
0.34, 0.32, and 0.53 for DT, B, and BD respectively). Individuals with low DT 
scores (below 13) have a mean BMI in the normal weight range (BMI between 20 
and 25), and individuals with higher DT scores (13 and above) have a mean BMI 
in the overweight range (BMI above 25). The same holds true for the bulimia (B) 
scores; the mean BMI of individuals with low B scores (below 10) are in the 
normal weight range, and individuals with higher B scores (10 and above) are in 
the overweight range. As also indicated by the standardised correlation 
coefficient (beta) value, the relation with BMI is strongest for BD; individuals with 
3.6.  Conclusion and discussion 
3 .6 . 1 .  H i gh e r  ED I  s c o r e s  r e l a t e  t o  h i g h e r  B MI s  
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low BD scores (below 35) are in the normal weight range, individuals with 
moderate BD scores (between 35 and 50) are in the overweight range (BMI 
between 25 and 30), and individuals with high BD scores (50 and above) tend to 
be obese (BMI above 30). This finding that a high BMI is associatied with high BD 
scores is in line with the findings of Packianathan et al, who specifically studied 
the EDI scores of obese individuals; Packianathan et al found that their obese 
sample had a BD scores above the normative range of the general population, 
and, notably also above the normative range of the clinical eating disorders 
population (also see Figure 21, page 111). Individuals with missing EDI scores; 
because they skipped one or more questions on the questionnaire (also see 
paragraph 3.4.5 Ea t i n g  D i s o r d e r s  I n v e n t o r y , page 120), did not stand out for 
having very high or very low BMIs, their BMI was equal to the mean BMI of the 
sample.  
Highest adult lifetime BMI, rather than current BMI, was the most important 
predictor of DT and B scores. For BD current BMI was the most important 
predictor, however highest adult lifetime still explained a significant proportion 
of variance in BD scores when current BMI was controlled for. This result may 
hold important implications for the assessment of disordered eating behaviour; 
e.g. highest adult lifetime BMI, or more general BMI history, could be used as a 
proxy, or a risk factor, of disordered eating in the general population; e.g. to 
select individuals at risk for disordered eating in a classic two-stage study design 
as recommended by Hoek et al (Hoek and van Hoeken, 2003). Highest adult 
lifetime BMI is easy to assess, and individuals do not appear less willing or able to 
report their highest adult lifetime BMI compared to their current BMI on self-
report questionnaires (data presented in Chapter 3, page 119). Whether higher 
EDI scores truly represent more disordered eating in individuals with higher BMIs 
would need to be ascertained in future studies, because most studies of the EDI 
3 .6 . 2 .  B M I  h i s t o r y  p r e d i c t s  E DI  s c o r e s  b e t t e r  t h a n  c u r r e n t  BM I  
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questionnaire thus far have focussed on individuals with low normal range BMIs 
(Podar and Allik, 2009).  
The relationship between BMI and DT, B, and BD scores did not hold true for 5% 
of the sample (approximately 150 out of 3,000 individuals). These individuals 
presented with high DT, B, and BD scores, without having, or ever having had, a 
high BMI. This percentage of individuals is approximately equal to the estimated 
prevalence of eating disorder not otherwise specified (EDNOS) in the general 
population (Hoek and van Hoeken, 2003,Wade et al., 2006,Machado et al., 
2007,Keski-Rahkonen et al., 2007,Swanson et al., 2011), and could indicate that 
this group of outliers could consist of individuals at risk for eating disorders (EDs), 
with clinical EDs, or with a history of EDs. This finding points out that it is 
important to view disordered eating behaviour in the context of individual 
current BMI, and individual BMI history. For example, a high body dissatisfaction 
score could represent very different underlying behavioural and psychological 
traits in an individual with a normal range BMI who has never been overweight, 
versus an individual with a normal range BMI who has been obese in the past, 
versus an individual who is currently obese. Whether this subgroup of individuals 
with high DT, B, and BD scores, without ever having had a high BMI, truly 
represents a group with possible disordered eating behaviour cases would have 
to be ascertained through (semi-)structured clinical interviews, but it is 
nevertheless a finding worthy of follow-up.   
The strengths of the current study include: a large sample size (n = 3,624), and a 
sampe unselected for age and BMI as opposed to a selected cohorts (Lewis and 
Cachelin, 2001,Mangweth-Matzek et al., 2006), or separately sampled cohorts 
(Packianathan et al., 2002,Bedford and Johnson, 2006). The two most important 
limitations of this study are the generalisability of the EDI scores in relation to 
eating disorders, and the dimensionality of the EDI subscales. It remains to be 
3 .6 . 3 .  D i s o r d e r e d  e a t i n g  i n  t h e  c o n t e x t  o f  B M I  h i s t o r y  
3 . 6 . 4 .  S t r e n g t h s  a n d  l im i t a t i o n s  
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ascertained whether individuals with high EDI scores truly represent individuals 
with disordered eating in this sample; the results by Podar and Allik do indicate 
that the meaning of the scales is comparable between the general population 
and individuals with a clinical ED (Podar and Allik, 2009), however ideally 
individuals with high scores would be followed up and assessed by (semi) 
structured clinical interviews for eating disorders. The suggested factor structure, 
i.e. the subscales, of the EDI has been questioned (Garcia-Grau et al., 2010). 
Garcia-Grau et al suggest a different factor structure, e.g. by combining the drive 
for thinness (DT) and body dissatisfaction (BD) items; because they demonstrate 
that the questions of these two subscales load onto the same factor (Garcia-Grau 
et al., 2010). The results of this thesis support this finding, by demonstrating that 
DT and BD appear to explain the same variance in current BMI (Table 30). Hence, 
future studies may want to run analyses on observed rather than suggested 
factor structures.  
Studying the EDI scores across age groups was not the main objective of this 
chapter, however I nevertheless wanted to write a short comment on the results 
– which were presented in the Appendix (see Figure 63, Figure 64, and Figure 65, 
page 238). Even though EDs occur most frequently among adolescent females 
(also see paragraph 1.2.1 P r e v a l e n c e  a n d  i n c i d e n c e , page 29) weight and shape 
concerns, and disordered eating are also prevalent among older women 
(Mangweth-Matzek et al., 2006,Slevec and Tiggemann, 2011), and specifically 
body dissatisfaction levels were found to be equal between younger and older 
age groups (Slevec and Tiggemann, 2011,Bedford and Johnson, 2006,Mangweth-
Matzek et al., 2006). The current study supports this finding; even though the EDI 
scores significantly decrease with age (data presented in the Appendix, page 
238), the correlation coefficients of these associations are very small 
(unstandardised coefficients are -0.081 (±0.01), -0.10 (±0.01), and -0.068 (±0.02), 
for DT, B, and BD respectively), indicating that the effect of age on the EDI scores 
3 .6 . 5 .  R e l a t i o n s h i p  b e t w e e n  E DI  s c o r e s  a n d  a g e  
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is minor. For example for BD this indicates that when age increases with one unit 
(one year) BD decreases with 0.068 units, thus on average women 30 years older 
(e.g. 50 years old versus 20 years old) score only (0.068*30=) 2.04 units lower on 
the BD scale (arguably negligible on a scale of 10 to 60, also see Figure 32, page 
127). In line with the literature the BD scores decrease least with age (visualised 
in Figure 65, page 240). The small effect of age on EDI scores was significant in 
the current sample as a result of the large sample size, and it explains why other 
studies (with smaller samples) found no significant differences between the age 
groups; this results of this thesis are in line with the literature, concluding that 
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G e n o m e - w i d e  g e n e  a n a l y s e s  
Genome-wide genetic studies differ from candidate gene studies in that they do 
not rely on hypotheses or assumptions on the underlying biological mechanism 
of disease, which is highly advantageous when the pathophysiology is largely 
unknown, as is the case in eating disorders (EDs). In genome-wide studies 
genetic variants (usually single nucleotide polymorphisms (SNPs)) are genotyped, 
which are spread throughout the genome based on knowledge of linkage 
disequilibrium (LD). Thanks to LD only a proportion of SNPs, ‘only’ approximately 
500,000 SNPs, need to be genotyped to tag most (about 80%) of common 
genetic variation (note: rare genetic variation can not be detected). The principle 
and the limitations of this relatively new genome-wide association (GWA) 
technique were explained in more detail in paragraph 1.3.4.1 L i nka g e  
d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , page 45.  
 
Genes are thought to be the functional units of the human genome, and disease 
causing genetic variants should somehow influence gene function, e.g. by 
affecting the level of protein expression or the protein structure (i.e. protein 
functionality) (Cantor et al., 2010,Lehne et al., 2011,Huang et al., 2011a). The 
fact that most diseases are multifactorial is inherent to the natural complexity of 
biology; all biological functions in the human body are a result of a complex 
interplay between many proteins (and the environment). The design of each 
protein is laid out in the DNA code, similarly as to how a manual describes the 
assembly of e.g. new furniture. Figure 47 illustrates the main aspects of protein 
functionality that can be affected by genetic mutations, 1) mutations in the 
regulatory region of the protein can affect the amount of protein that is 
4. Genome-wide gene analyses 
4.1.  Literature background 
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produced, these regulatory regions are usually located flanking the protein-
coding region (generally within ± 100kb distance (Fu et al., 2011,Huang et al., 
2011a)), 2) mutations in the protein-coding region can attenuate or enhance the 
functionality of the protein, for example, if a mutation changes the amino-acid at 
a key location of a receptor protein it may become insensitive to its ligand, or 
remain activated upon binding, hence not function normally anymore (see Figure 
47).  
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Figure 47: Causal genetic variants in relation to gene function 
There are two main aspects of protein functionality that can be affected by genetic 
mutations; mutations in the regulatory region can affect the amount of protein that is 
produced (which would attenuate a biological process), and mutations in the protein-
coding region, which can alter the shape and functional aspects of the protein directly, 
e.g. by attenuating its capacity to bind a ligand, or to transmit a signal.  
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In the context of biological function and mechanism of disease genome-wide 
association (GWA) studies are only the first step, aimed at identifying genetic risk 
loci, which should then be followed up in secondary analyses in order to 
elucidate biological function, as was done elegantly in the first GWA study in 
2005 by Klein and colleagues (also see paragraph 1.3.4.2 W h e r e  i t  a l l  b e g a n , 
page 50, (Klein et al., 2005)). It has however proven to be very challenging to 
identify genetic risk variants which pass a genome-wide significance threshold, 
which was set at p < 5 x 10-8 (or 5.00E-08) in order to distinguish true positive 
findings from false positive findings when testing a large number of genetic 
variants for association (Cichon et al., 2009) (also see paragraph 1.3.4.1 L i nka g e  
d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , page 45). The conclusions that can be 
drawn from these challenges hold important clues on the genetic architecture of 
complex traits and disorders, in that genetic risk variants underlying these traits 
and disorders either include many genetic risk factors each with a (very) small 
effect on disease risk (odds ratios in the region of 1.1 tot 1.3, i.e. increasing the 
risk of carriers by 10 to 30% compared to the risk in non-carriers (Cichon et al., 
2009,Cantor et al., 2010)), or they result from rare genetic variants present in 
less than 1% of the population. The effect of rare genetic variants on disease can 
not be assessed yet using current genotyping methods (also see paragraph 
1.3.4.3 U nd e t e c t e d  h e r i t a b i l i t y  a n d  g e n e t i c  a r c h i t e c t u r e , page 52).   
 
Genetic risk variants underlying disease may have effect sizes too small to detect 
without assessing their aggregation into genes and pathways. Because of 
stringent genome-wide significance threshold thousands of SNPs with 
“suggestive” p values are ignored, but they may nevertheless represent true 
associations (Cantor et al., 2010,Lehne et al., 2011). Secondary analyses such as 
genome-wide gene and genome-wide pathway analyses aim to address this 
limitation of GWA studies. Several methods have been developed for this 
purpose in the past couple of years (reviewed by (Cantor et al., 2010) and by 
(Wang et al., 2010)), but as both reviews describe, pathway analyses are 
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currently still in their infancy. Cantor et al (Cantor et al., 2010) point out critical 
factors for secondary analyses, of which arguably the most important is the 
choice of the appropriate database(s) for genes and pathways; there is a growing 
list of pathways that are at varying stages of completion; a notable example of a 
newly discovered gene and pathway is FTO in the regulation of eating behaviour 
(Frayling et al., 2007) (also see paragraph 1.1 No r ma l  r e gu l a t i o n  o f  e a t i ng  
b eha v i ou r , page 20). Interestingly, and worryingly, Elbers et al found that the 
results of pathway analyses reflect the difference in pathway database 
information, and database organisation (Elbers et al., 2009). Because of these as 
yet unresolved issues Cantor et al (Cantor et al., 2010) recommend full 
transparency on the choices made when running secondary genome-wide 
analyses, preferably more than one database (and method) are used, and any 
results should be interpreted in a context-specific manner. The authors note that 
it is too early to set fixed guidelines for these analyses; any strict rules would 
hamper scientific creativity, and more time is needed before evidence-based 
guidelines can be developed further and applied (Cantor et al., 2010).  
Genome-wide association (GWA) studies on single nucleotide polymorphisms 
(SNPs) are the first step in identifying genetic risk loci. SNPs are however only 
‘tags’ of possible genetic risk variants for disease (also see paragraph 1.3.4.1 
L i nka g e  d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , page 45). Genes are thought 
to be the functional units of the human genome, and disease causing genetic 
variants should somehow influence gene function. Because biological processes 
are coordinated by many different proteins, acting together in pathways, many 
different genetic mutations could theoretically cause the same disease. 
Moreover, genetic risk variants underlying disease may have effect sizes too 
small to detect without assessing their aggregation into pathways (Cantor et al., 
2010). For these reasons this chapter focusses on secondary genome-wide 
analyses of candidate quantitative traits of eating disorders, including genome-
4.2.  Aim and outline
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wide gene and pathway analyses. Genome-wide secondary analyses are 
currently still in their infancy, hence two distinct methods were used. The aim of 
this chapter was identify genes associated with drive for thinness, bulimia, and 
body dissatisfaction as assessed by the Eating Disorder Inventory (EDI) (Garner, 
2004), as well as to appraise the value of secondary analyses over primary 
genome-wide SNP analyses.  
 
Note (also see ‘Statement of work’): The author participated in an ongoing 
collaborative project with the Wellcome Trust Sanger Institute (Cambridge), and 
the UK Adult Twin Registry (TwinsUK). The collaboration included multiple 
research lines; the author was the lead analyst for the genome-wide association 
gene (GWAG) analyses. The results of three different GWAG analyses will be 
presented in this chapter. These results are post-hoc to the GWA SNP analyses, 
which were led by Dr. Vesna Boraska (Sanger Institute) and have now been 
submitted for publication (Boraska et al, submitted).  
4.3.  Data description 
A subgroup of the sample presented in Chapter 3, page 113, recruited by the St 
Thomas' UK Adult Twin Registry (TwinsUK) took part in this study. Only twins 
who had consented to genetic analyses and completed the EDI questions were 
included in this study (also see paragraph 3.4.5 Ea t i n g  D i s o r d e r s  I n v e n t o r y , 
page 120). EDI-2 scoring was used in order to be able to replicate the study by 
Keski-Rahkonen et al (Keski-Rahkonen et al., 2005). Compared to the results of 
the previous Chapter, where EDI-3 was used, the question “When I am upset, I 
worry that I will start eating” was deleted from the bulimia (B) sub scale and the 
question “I feel bloated after eating a normal meal” was deleted from the body 
dissatisfaction (BD) sub scale. In addition the question “I like the shape of my 
buttocks” was deleted from the BD sub scale since this question had not been 
included by Keski-Rahkonen et al (personal communication; this BD score was 
labelled as Finnish-BD in Table 43); it was decided to follow the Finnish study 
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protocol exactly for replication purposes. Cases with missing answers to EDI 
questions were excluded, since missing answers would artificially lower the scale 
score and because missingness was not random (see paragraph 3.4.5, page 120).  
 
To normalize the distribution of drive for thinness (DT) scores a 1/sqrt 
transformation was applied (the transformed DT score equals: one divided by the 
square root of the original DT score), BD scores were not transformed, and both 
traits were analysed as quantitative traits with continuous scoring. B was 
analysed as a binary trait because the distribution could not be normalised since 
there were very few individuals with elevated scores; the 75% percentile point, 
12, was set as the cut-off point. Note: this is not a clinical cut-off point for 
Bulimia. The distribution of B scores was presented in Chapter 3, Figure 31, page 
126 (note: the mean B score presented there is slightly higher since EDI-3 scores 
were presented in that chapter, whereas the current chapter used EDI-2 scores, 
also see Table 43). The subgroup of individuals who consented to genetic 
analyses are not different from the general sample (see Table 42, Table 43, and 
paragraph 3.4 Da ta  d e s c r i p t i o n , page 113), therefore only the distribution of 
the DT scores will be presented here as it was transformed prior to genetic 
analyses (see Figure 48). 
 
Table 42: Sample overview genome-wide genetic analyses of the EDI 
DT and BD subscales were analyses as a continuous trait, whereas the B subscale was 
dichotomised with individuals scoring above the 75% percentile (score 12 and above) 
labelled as cases.  
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Table 43: Data description of the sample for genome-wide genetic analyses 
Individuals who consented to genetic analyses were not different from the general 
sample; the latter was described in Chapter 3, page 113. B was analysed as a 
dichotomous trait with the 75% percentile as a cut-off between cases and controls (EDI-
2 B: 12 and above, in bold). In Chapter 3 EDI-3 scoring was used, and in Chapter 4 EDI-2 
scoring was used, hence both scoring results are presented for comparison.  
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Figure 48: Distribution of DT score - transformation 1/sqrt (DT) 
Since the DT scores were not normally distributed (also see Figure 30, page 125) a 1/sqrt 
transformation was applied (the transformed DT score equals: one divided by the square 
root of the original DT score). 
Genotyping was conducted on three different Illumina arrays (317K, 610K, and 
1M). Analyses were conducted on the merged dataset and only on overlapping 
SNPs (n=283,744 SNPs). Quality control (QC) was applied to each dataset 
separately, and further QC was applied to the merged dataset (the quality 
control criteria are listed in Table 44). Alleles of the three datasets were aligned 
to HapMap2 or HapMap3 forward strand alleles, in order to make sure the 
annotation of the minor allele was equal across datasets. Since spurious 
4.4.  Methods 
4.4.1. G en o t y p i n g  p l a t f o rm s ,  a n d  q u a l i t y  c o n t r o l    
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associations could result from including individuals from different ancestries, a 
principal component analysis was performed comparing the genotypes of the 
TwinsUK sample to HapMap3 populations; for the HapMap project several 
distinct ethnic populations were genotyped, and the TwinsUK population should 
match the Utah residents with Northern and Western European ancestry (CEU 
population, The International HapMap project (HapMap, 2003)). Figure 49 shows 
that the TwinsUK sample indeed clusters with the CEU population (black and 
green data points, see Figure 49).  
 
Table 44: Quality control (QC) criteria genome-wide genetic analyses 
Subjects were excluded (i) when their DNA was of insufficient quantity or quality, (ii) 
when there was a risk of DNA contamination assessed by the average heterozygosity per 
individual; on average individuals are heterozygote for 30% of genome-wide genetic 
variations, (iii) when there was evidence of deviant ancestry assessed by Principal 
Component Analysis (PCA) comparison with individuals from various ethnicities (The 
International HapMap project (HapMap, 2003) (also see Figure 49), (iv) when there was 
evidence of relatedness or sample identity errors (e.g. duplications) assessed by pairwise 
Identity By Descent (IBD) probabilities, and (v) when the reported zygosity of twins was 
not confirmed by IBD probabilities, which could be indicative of sample identity  errors. 
SNPs were excluded (i) when their genotype distribution in the sample violated the 
Hardy Weinberg Equilibrium (indicative of a technical genotyping error, also see Chapter 
2, paragraph 2.5.3 R e f e r e n c e  p o p u l a t i o n ,  a n d  H a r d y  W e i n b e r g  Eq u i l i b r i um , 
page 82), (ii) when their Minor Allele Frequency (MAF), i.e. the frequency of the least 
frequent allele, was below 1% in the sample; quality control is more stringent for very 
rare alleles in order to reduce the risk of spurious results, (iii) when the SNP call rate (an 
indication of technical genotyping quality) was below 99% for rare SNPs, and (iv) when 
the SNP call rate was below 97% for common SNPs.   
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Figure 49: Principal Component Analysis (PCA) plot - evidence of ancestry 
The colour printed plot is presented in the Appendix (see Figure 75, page 257). The 
genotypes of the individuals from the TwinsUK sample were plotted against samples 
from various ethnicities. The black dots represent the individuals from TwinsUK; they 
cluster well with the CEU population; who have Northern and Western European 
ancestry (The International HapMap project (HapMap, 2003)).   
The author was the lead analyst for the genome-wide gene (GWAG) analyses; 
which were post-hoc analyses of the genome-wide association (GWA) SNP 
analyses, which were led by Dr. Vesna Boraska (Sanger Institute). We tested 
283,744 directly typed overlapping SNPs for association with three EDI subscales 
(DT, B, and BD) separately using the R software package GenABEL; since the 
sample was a twin sample all analyses were adjusted for family relatedness 
(Aulchenko et al., 2007,Chen and Abecasis, 2007) (Boraska, Helder, et al, 
submitted). Association analyses were restricted to individuals with complete 
phenotype information: 1,934 individuals for DT, 2,024 for B, and 1,915 for BD 
(also see Table 42, page 160). The results of the GWA SNP analyses will only be 
4 .4 . 2 .  G en om e - w i d e  S NP  ana l y s e s  
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presented briefly in this Chapter for two reasons: because the GWAG analyses 
are post-hoc it is important to be able to assess the quality of the initial analyses, 
and because the main aim of this Chapter was to appraise the added value of 
GWAG analyses compared to GWA SNP analyses.  
Genome-wide association gene (GWAG) analyses were performed using two 
different methods; VEGAS (Liu et al., 2010) and GATES (Li et al., 2011). As was 
described in the literature background introduction of this chapter many 
different gene-based association tests have been developed; one distinguishing 
factor is the technical capacity of the computer systems (central processing unit 
(CPU) and memory) needed to run the analyses (Huang et al., 2011a,Gui et al., 
2011). VEGAS and GATES are currently unique methods because a) they are fast 
since they do not require computationally intensive permutation procedures, b) 
they have no inflation of the type I error regardless of gene size and linkage 
disequilibrium (LD) patterns, c) they do not need raw individual genotype and 
phenotype data but work with SNP p values and LD information from known 
reference populations (HapMap, (HapMap, 2003)) and d) they are open access.  
The VEGAS online method defines gene boundaries as ± 50 kilo base pairs (kb) 
according to positions on the UCSC Genome browser hg18 assembly (note: gene 
boundaries could not be altered by the user), and combines SNP p values in a 
gene by converting them to upper tail chi-square test statistics with one degree 
of freedom (Liu et al., 2010). SNP p values were uploaded to the VEGAS website 
(http://gump.qimr.edu.au/VEGAS/) and gene p value results were obtained by 
email directly from the server. It is possible to include all SNPs of a gene (VEGAS-
Sum method) or a subset of SNPs (e.g. only the top SNP; VEGAS-Max method). If 
the SNPs in the gene were completely independent of each other a combined 
gene test statistic, as calculated in the VEGAS-Sum method, would have a chi-
square distribution with degrees of freedom equal to the number of SNPs. In 
4 .4 . 3 .  G en om e - w i d e  g e n e  a n a l y s e s  
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reality however most SNPs are not independent but they are in linkage 
disequilibrium (LD) (also see paragraph 1.3.4.1 L i nka g e  d i s e q u i l i b r i um ,  a n d  
m u l t i p l e  t e s t i n g , page 45). According to Liu et al, ideally, LD would be taken into 
account by computing the gene p value through permutation, however heavy 
computational requirements restrict the use of permutation. Instead Liu et al use 
a Monte Carlo approach to calculate a simulated gene test statistic based on the 
LD structure of a set of reference individuals from the HapMap phase 2 
population (Frazer et al., 2007). The simulated gene test statistic they calculate 
has been shown to have a distribution very similar to the observed gene test 
statistic under the null hypothesis; i.e. the simulated gene p value is a good 
approximation of the ‘true’ gene p-value. The simulated gene p value is the 
proportion of simulated test statistics that exceed the observed test statistic (Liu 
et al., 2010); i.e. the simulation based gene p value is the observed gene p value 
adjusted for LD. Liu et al run a number of simulations per gene, which is 
determined adaptively. In the first stage 103 simulations are performed, if the 
resulting simulation based p value is less than 0.1, 104 simulations will be 
performed; if the simulation based p value from 104 simulations is less than 
0.001, 106 simulations will be performed (Liu et al., 2010).   
The GATES method maps SNPs onto genes according to gene coordinate 
information from the National Center for Biotechnology Information (NCBI). SNP 
p values are uploaded to the Knowledge-based mining system for Genome-wide 
Genetic studies (KGG) software which can be downloaded from their website 
(http://bioinfo1.hku.hk:13080/kggweb//home.htm, product version 2.0 was 
used for the current study). Gene region length was extended with 50kb on 
either side of the gene in order to approximate VEGAS methodology. The gene p 
value is equal to the most significant SNP p value of the gene after correction for 
the number of independent SNPs in the gene; the difference between both 
methods is thus that VEGAS combines the SNPs of a gene whereas GATES 
4 .4 . 3 . 2 .  G A TE S m e t h o d  
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corrects best SNP of the gene. GATES corrects SNP p values for the number of 
independent SNPs in the gene using an extended Simes method (i.e. a Simes 
method which takes LD into account) (Li et al., 2011). The original Simes test was 
proposed by RJ Simes in 1986 as a modified Bonferroni correction for multiple 
testing; rather than using α/n as a threshold for significance Simes used j * α/n as 
a threshold, with j being the ranking number of the p value when p values have 
been ordered (Simes, 1986). This way the correction of the most significant p 
value is equal to Bonferroni correction (j = 1), but the correction of the remaining 
p values is less conservative than Bonferroni correction (Simes, 1986). The type I 
error rate is equal to α and the Simes test is advantageous over Bonferroni when 
several highly correlated tests are performed (Li et al., 2011,Simes, 1986,Sarkar, 
1997). In the GATES method the following formula is used:  
Gene p-value = Min (Me P(j) / Me (j) 
With Min indicating that the lowest SNP p value of the gene becomes the gene p value; 
Me being the number of independent SNPs (i.e. only SNPs with pairwise LD below the 
threshold) in the gene; P(j) the p value of the jth most significant SNP in the gene; Me (j) 
the number of independent p values among the top j SNPs (Li et al., 2011).   
LD information is obtained from an appropriate reference population from the 
International HapMap project (CEU population was used for the current study, 
(HapMap, 2003)), and the user can define the threshold of LD (r-square) above 
which SNPs are considered connected i.e. dependent. For the current study SNPs 
with r-square values above the (default) threshold of 0.9 were considered 
dependent; this is a very conservative threshold. Lowering the threshold would 
decrease the number of independent SNPs per gene; the best SNP of the gene 
would thus be corrected for fewer independent SNPs, i.e. it would thus be 
corrected less conservatively. Li et al demonstrate that their extended Simes 
method has more power than the VEGAS-Max test (Li et al., 2011). The GATES 
method has however less power in the case of genes with multiple independent 
disease-susceptibility loci and relatively few neutral SNPs, in which case the 
VEGAS-Sum method is superior (Li et al., 2011).   
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In summary it can be concluded that the main differences between the VEGAS 
and GATES methodologies are 1) VEGAS combines SNP test results per gene 
whereas GATES corrects the best SNP of a gene, and 2) VEGAS accounts for LD by 
simulation whereas GATES uses an LD threshold above which SNPs are 
considered dependent. The preferred method for detecting genes with one or a 
few disease-susceptibility loci and relatively many neutral SNPs is the GATES 
method (Li et al., 2011), and for detecting genes with multiple disease-
susceptibility loci it is the VEGAS-Sum method (Liu et al., 2010,Li et al., 2011). 
Since the genetic architecture of eating disorders is still largely unknown (also 
see Chapter 1 paragraph 1.3.4 Ge n om e -w i d e  a s s o c i a t i o n  ( GW A )  s t u d i e s , 
page 44), both methods were used for analyses (see Figure 50 for an overview of 
analyses).  
 
Figure 50: Flowchart overview of analyses 
Gene based p values were calculated from SNP p values using two different methods; 
VEGAS (Liu et al., 2010) and GATES (Li et al., 2011).  
Using the GATES methodology pathway analyses were also run on these data. 
The GATES pathway association method (Gui et al., 2011) (also referred to as 
GATES-Simes) calculates a pathway p value similarly as to how a gene p value is 
calculated (see paragraph 4.4.3.2 GA TE S  m e t h o d , page 166); namely by 
correcting the best gene p value of a pathway for the number of genes in the 
4 .4 . 4 .  A  n o t e  o n  g e n om e - w i d e  p a t h wa y  a n a l y s e s  
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pathway (Gui et al., 2011). Using the GATES software tool, Knowledge-based 
mining system for Genome-wide Genetic studies (KGG), pathway p values can 
also be calculated using a hypergeometric method; a distinct method (not 
specifically developed for genetic studies) which tests the probability of by-
chance enrichment of pathways by significant genes. The hypergeometric-
method (referred to as GATES-Hyper (Gui et al., 2011)) calculates a cumulative 
probability based on the population size (i.e. the number of genes; n = 30.204), 
the number of successes in the population (i.e. the number of genes with a p 
value < 0.05), the sample size (i.e. number of genes in the pathway of interest), 
and the number of successes in the sample (i.e. the number of genes in the 
pathway with a p value <0.05).  
 
A major limitation of these methods for pathway analyses (and of pathway 
analyses in general, while they are still under development (Cantor et al., 
2010,Lehne et al., 2011) is that they assume that genes are independent of each 
other, i.e. that there is no LD between genes. In reality this is not true; hence 
pathway associatons need to be carefully examined in the context of LD between 
the genes of the pathways (note: the GATES pathway methods are currently 
being updated and improved (personal communication with Miaoxin Li (Li et al., 
2011)). Because of the limitations of the methods used it was decided not to 
present the results of the pathway analyses in the chapter, but in the Appendix 
instead; the limitations were discussed in further detail in the discussion and 
conclusion of this chapter (see paragraph 4.8, page 190). The top pathways for 
drive for thinness (DT) were presented in the Appendix (see Table 66 and Table 
67, page 250).   
4 .5 .  R e s u l t s  D r i v e  f o r  Th i n n e s s  
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The top SNP associated with drive for thiness (DT) scores is rs1436174 with a p 
value of 2.31E-06, this SNP is located on chromosome one within 50kb of the 
gene cornichon homolog-3 (CNIH3). General note: gene names are listed 
alphabetically in the Appendix (see Table 61 to Table 65, page 244). None of the 
SNP p values pass a Bonferroni correction for multiple SNP testing (0.05 / 
283,744 SNPs = 1.76E-07), nor do they pass an arbitrary Bonferroni threshold for 
suggestive association: with α set at half the chance (α=0.5) a SNP is associated 
with the phenotype (0.5 / 283,744 SNPs = 1.76E-06). Figure 51 shows a plot of 
the SNP p values (ordered by chromosome and position in the chromosome), 
and the quantile-quantile (QQ)-plot which is a quality control measure for 
genome-wide association studies; observed SNP p values are plotted against an 
equal number of normally distributed p values. When running a large number of 
statistical tests (283,744 SNPs were tested for association with DT scores) the 
resulting p values will be relatively uniformly distributed, which is what is 
expected under the null hypothesis of no association with the phenotype. In the 
case of true association there would be more SNPs strongly associated to the 
phenotype than expected by chance; i.e. the only deviation from uniformity 
would be expected at the lowest p values. In general the QQ-plot should thus 
show a straight diagonal line; it provides evidence of no systematic over-
estimation of the association signal due to confounders, e.g., population 
structure or genotyping error. This is the case for DT (see Figure 51), which is 
reassuring of the quality of the QC and GWA SNP analyses.  
- 171 - 
 
Figure 51: P value and QQ plot - SNP association results DT 
Note: p values were plotted after –log10 transformation: a p value of 0.05 is thus 
plotted at –log(0.05,10)= 1.30. The top SNP, with a p value of 2.31E-06, is plotted at 5.64 
(upper left corner of the p value plot). The QQ-plot shows that the p values do not 
deviate from the diagonal, indicating that the p values are generally uniformly 
distributed. Plots were generated using R software, the ‘ppoints’ function was used to 
generate 283,744 normally distributed probability points.  
The top gene associated with drive for thinness (DT) scores according to the 
VEGAS-Sum method is brain-derived neurotrophic factor (BDNF) with a p value 
of 3.70E-05 (see Table 45). Using the VEGAS (Liu et al., 2010) definition of genes 
(the gene region plus SNPs ± 50kb) 23 SNPs are located in the BDNF gene, 11 out 
of 23 SNPs have a p value below 0.01 (see Table 46, in bold). Out of these 11 
SNPs four SNPs are in moderate LD with the strongest associated SNP (pairwise 
LD between 0.6 and 0.8, see Figure 52). The second most significant SNP is 
however not in strong LD with the top SNP (rs6265, LD < 0.6, see Table 46 and 
Figure 52), interestingly this SNP is a missense variation; the two different alleles, 
G and A, lead to two different amino acids, Valine (Val) and Methionine (Met), in 
the BDNF protein, i.e. they lead to a different protein structure of BDNF (Noble 
et al., 2011,Brandys et al., 2011). BDNF is the only gene in the top 25 genes of 
the VEGAS method also present in the top 25 of the GATES method for gene 
association (BDNF ranked 7th in GATES, see Table 47). The BDNF gene p value 
does however not pass Bonferroni correction for the number of genes tested 
4 .5 . 2 .  R e s u l t s  g e n om e - w i d e  a s s o c i a t i o n  g e n e  a n a l y s i s  -  DT 
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(0.05/17,555 = 2.85E-06), nor does it pass the threshold for suggestive 
association (0.5/17,555 = 2.85E-05). Table 45 also shows the top SNP per gene 
(according to NCBI annotation), and its rank among SNPs; the top SNP of BDNF 
was rs7116850, which was the fifth most significant SNP overall (see Table 45). 
Several genes share the same top SNP; there are only 19 unique top SNPs among 
the top 25 genes. The SNP rs756441 is an example of this; it is the top SNP of 
three different genes (see Table 45 in grey); these genes are located very closely 
together and the overlap is a result of defining gene regions as ± 50kb on either 
side (see Figure 53). The ranking of the top SNPs of the top genes (most right 
column in Table 45) shows that most genes would not have been picked up 
without the VEGAS method, e.g. if only the top SNPs (e.g. the top 250 SNPs) had 
been examined further.  
 
Table 45: Results VEGAS method - Top 25 genes DT 
BDNF is the only gene which is also present in the top 25 of the GATES method (rank 7, 
in bold). BDNF is located on chromosome (Chr) 11, and has 23 SNPs (nSNPs). Pvalue is 
the gene p value uncorrected for the number of genes tested (none of the genes pass a 
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Bonferroni correction for multiple testing). The ‘Top SNP’ is the top SNP of the gene, and 
the ‘Rank SNP’ is its rank among SNPs overall. Some genes share a top SNP, rs756441 is 
an example of this (in grey, also see Figure 53). Two genes were not part of the GATES 
gene set (indicated by #N/A).  
 
 
Table 46: Details of BDNF SNPs - DT 
There are 23 SNPs in the BDNF gene according to the VEGAS definition of genes (Liu et 
al., 2010). SNPs were ordered on position in the chromosome (BDNF is located on 
chromosome 11 (CHR 11)). Frequency refers to the risk allele frequency. The variation in 
one SNP (rs6265) is a missense variation, meaning that the two alleles of the SNP lead to 
two different amino acids in the BDNF protein, i.e. lead to a different protein structure 
of BDNF. Three SNPs are located in the intron of the gene; they are not translated into 
BDNF protein. BDNF has several SNPs suggestively associated to DT scores, p values 
below 0.01 are indicated in bold. Details on LD between the SNPs are given in Figure 53, 
page 173. BDNF is the top gene according to the VEGAS method with a p value of 3.70E-
05.  
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Figure 52: Plot of BDNF SNPs - DT 
SNPs of BDNF (± 50kb on either side) are plotted. The left Y axis indicates the –log10 p 
value of the SNPs. The right Y axis and the line in the graph indicate the recombination 
rate, i.e. the average rate of ‘reshuffling’ of parental DNA; a high recombination rate 
decreases the LD between SNPs. The top SNP in BDNF is rs7116850 (indicated by the 
large black circle). Four SNPs are in moderate LD with the top SNP (LD between 0.6 and 
0.8, indicated by large grey circles); these four SNPs are also among the lowest p values 
of the gene. Smaller circles are SNPs in low LD with the top SNP (LD < 0.6). The missense 
SNP (indicated by the triangle) is also not in strong LD with the top SNP (LD < 0.6) but 
has the second lowest p value of the gene (also see Table 46). The plot was generated 
using LocusZoom (Pruim et al., 2010). An extended plot including the complete LD 
region (LD ≥ 0.4) of the top SNP was presented in the Appendix, page 254.   
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Figure 53: Example of genes with overlapping top SNP 
The SNP rs765441 was the 52nd most significant SNP overall, and is the top SNP of three 
different genes (also see Table 45). The three genes, COL11A2, RXRB, and SLC39A7 are 
located closely together on chromosome six. Rs756441 is located most closely to 
COL11A2, but due to the gene region definition of ± 50kb it is assigned to all three 
genes. The image shows that the SNPs of these three genes almost completely overlap 
due to this definition of gene regions. The blackness of the blocks below the genes 
visualise the LD between the SNPs of the genes, with black blocks indicating complete 
LD. The image was generated using Haploview (Barrett et al., 2005).   
The top gene associated with DT scores resulting from the GATES method is 
cornichon homolog-3 (CNIH3) with a p value of 3.82E-05 (see Table 47). The gene 
p values were corrected for the number of tested SNPs within the gene, but not 
for the number of tested genes. None of the genes pass a Bonferroni correction 
for the number of genes (0.05/30,204 genes = 1.66E-06), nor do they pass the 
threshold for suggestive association (0.5/30,204 = 1.66E-05). Note: the GATES 
method uses the NCBI database of genes whereas the VEGAS method uses the 
UCSC database (also see paragraph 4.4.3 G en o m e - w i d e  g e n e  a n a l y s e s , page 
165), hence the difference in the number of genes. The top SNPs of the genes 
were all among the top 65 of most significant SNPs overall. Several genes share 
the same top SNP; there are only 14 unique top SNPs among the top 25 genes 
(rs10280445 was the top SNP of eight genes, see Table 47 in grey). BDNF is the 
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only gene present in both the VEGAS and the GATES top 25 genes, indicating that 
there were several independently associated SNPs in the gene (making it a gene 
VEGAS would pick up) and that the top SNP was strongly associated (making it a 
gene GATES would pick up) (also see Table 46 and Figure 52). CNIH3 on the other 
hand is a gene that would only be picked up by GATES; it has 24 SNPs of which 
only three SNPs have a p value below 0.01, the top SNP of CNIH3 is the number 
one most strongly associated SNP overall (see Table 47 and Figure 54).  
 
Table 47: Results GATES method - Top 25 genes DT 
CNIH3 is the top gene according to the GATES method, its top SNP is the top SNP overall 
(rs1436174, rank 1, upper row). BDNF is the only overlapping gene between the VEGAS 
and GATES methods (in bold); it is the most significant gene in the VEGAS-Sum method 
(also see Table 45). Many genes share the same top SNP (rs10280445 is an example, in 
grey); there are only 14 unique top SNPs among the top 25 genes. Fourteen genes were 
not part of the VEGAS gene set (indicated by #N/A); the VEGAS gene set was 
considerably smaller than the GATES gene set (17,555 vs 30,204 genes also see 4.4.3 
G en om e - w i d e  g e n e  a n a l y s e s , page 165).  
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Figure 54: Plot of CNIH3 SNPs - DT 
CNIH3 is a typical gene that would be picked up by the GATES method, but not by the 
VEGAS method. There are 24 SNPs in the gene of which only three SNPs have a p value 
below 0.01. Its top SNP is however the top SNP overall (rs1436174, p= 2.31E-06, 
indicated by the large black circle). The second most significant SNP of the gene is in 
moderate LD with the top SNP (indicated by the large grey circle); the other SNPs are not 
in LD with the top SNP (smaller circles). The left Y axis indicates the –log10 p value of the 
SNPs. The right Y axis and the line in the graph indicate the recombination rate. The plot 
was generated using LocusZoom (Pruim et al., 2010). An extended plot including the 
complete LD region (LD ≥ 0.4) of the top SNP was presented in the Appendix, page 255.  
4.6.  Results Bulimia 
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The top SNP associated with Bulimia (B) scores is rs2895316 with a p value of 
1.87E-06, this SNP is located on chromosome three within 50kb of the gene 
LOC100128733 (an uncharacterised or pseudo gene with no known function). 
General note: gene names are listed alphabetically in the Appendix (see Table 61 
to Table 65, page 244). None of the SNPs associated with B pass a Bonferroni 
correction for multiple SNP testing, nor do they pass a Bonferroni threshold for 
suggestive association. Figure 55 shows a plot of the SNP p values and the QQ-
plot; the p values are generally normally distributed. 
 
Figure 55: P value and QQ plot - SNP association results B 
P values are plotted after –log10 transformation; the top SNP has a p value of 1.87E-06 
and is plotted at 5.73 (upper left data point p value plot). The p values are generally 
normally distributed. Plots were generated using R software.  
The top gene associated with Bulimia (B) scores according to the VEGAS-Sum 
method is alkylation repair homolog-3 (ALKBH3) with a p value of 7.10E-05 (see 
Table 48). There are 17 SNPs in this gene of which seven have a p value below 
0.01; only one SNP is in strong LD with the top SNP (LD > 0.8, indicated by a 
square, see Figure 56). Note: the plot shows there are three more genes at this 
location; HSD17B12, LOC729799, and AG2. HSD17B12 ranked 2nd in the VEGAS 
method (see Table 8), which is expected given the defition of genes as ± 50kb; 
the SNPs annotated to ALKBH3 and HSD17B12 almost completely overlap. 
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LOC729799 was not part of the VEGAS gene set, but ranked 182nd out of 30,204 
genes according to the GATES method (data not shown), and AG2 was not part of 
either the VEGAS or the GATES gene set. The p value of ALKBH3 does however 
not pass a Bonferonni threshold for multiple gene testing, nor does it pass the 
arbitrary threshold of suggestive association (see paragraph 4.5.1 R e s u l t s  
g e n om e -w i d e  a s s o c i a t i o n  SN P  ana l y s i s , page 169) (0.5/17,555 = 2.85E-05). 
The ranking of the top SNPs of the top genes shows that most genes would not 
have been picked up without the VEGAS method, if only top SNPs had been 
examined further. Six genes were present in both the VEGAS and GATES top 25 
(see Table 48 and Table 49, in bold).  
 
Table 48: Results VEGAS method – Top 25 genes B 
The top gene according to the VEGAS method is ALKBH3, it ranked 112th according to 
the GATES method. ALKBH3 is located on chromosome (Chr) 11, there are 17 SNPs and 
its top SNP ranked 72nd overall. Six genes were also present in the top 25 of the GATES 
method (in bold). Some genes are located closely together and share the same top SNP 
(in grey an example).   
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Figure 56: Plot of ALKBH3 SNPs - B 
SNPs of ALKBH3 ± 50kb are plotted, the plot includes the complete LD region (LD ≥ 0.4) 
of the top SNP. The top SNP rs2434474 was ranked 72nd most significant SNP overall (see 
Table 48). Only one SNP is in strong LD with the top SNP (indicated by a square), this is 
the 3rd most significant SNP of the gene. Several SNPs in the gene are suggestively 
associated with B scores. The left Y axis indicates the –log10 p value of the SNPs. The 
right Y axis and the line in the graph indicate the recombination rate. The plot was 
generated using LocusZoom (Pruim et al., 2010).   
The top gene resulting from the GATES method is 5-hydroxytryptamine 
(serotonin) receptor 1A (HTR1A) with a p value of 1.33E-05, its top SNP was the 
2nd most significant SNP overall (see Table 49). The top genes do not pass a 
Bonferroni correction for multiple gene testing, but HTR1A does pass the 
Bonferroni threshold for suggestive association (0.5/30,204 = 1.66E-05). Figure 
57 shows that only one SNP of the gene has a low p value, rs1478497, which is 
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located approximately 40kb upstream of HTR1A (see Figure 57). Six genes were 
present in both the VEGAS and the GATES top 25 (see Table 49, in bold).  
 
Table 49: Results GATES method – Top 25 genes B 
The top gene according to the GATES method is HTR1A, it does not pass a Bonferroni 
correction for multiple testing but it does pass a threshold for suggestive association 
(also see paragraph 4.5.1, page 169) (0.5/30,204 = 1.66E-05). HTR1A is located on 
chromosome (Chr) five and there were five SNPs in the gene, its top SNP ranked 2nd 
overall. Some genes are located closely together and share the top SNP (an example in 
grey). Six genes were present in the top 25 of both the VEGAS and the GATES method (in 
bold). Thirteen genes were not part of the VEGAS gene set (indicated by #N/A).  
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Figure 57: Plot of HTR1A SNPs - B 
Only one SNP of the HTR1A gene (defined as ± 50kb) has a low p value, rs1478498, 
which was the 2nd most significant SNP overall (see Table 49). The other SNP are not in 
LD with the top SNP (LD < 0.6). The plot includes the complete LD region (LD ≥ 0.4) of 
the top SNP. The left Y axis indicates the –log10 p value of the SNPs. The right Y axis and 
the line in the graph indicate the recombination rate. The plot was generated using 
LocusZoom (Pruim et al., 2010).   
The top SNP associated with Body Dissatisfaction (BD) scores is rs10485408 with 
a p value of 3.21E-06, this SNP is located on chromosome six within 50kb of the 
gene MAP3K7. General note: gene names are listed alphabetically in the 
4.7.  Results Body Dissatisfaction 
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Appendix (see Table 61 to Table 65, page 244). None of the SNP p values pass a 
Bonferroni correction for multiple SNP testing, nor do they pass a Bonferroni 
threshold for suggestive association (0.5/283,744 = 1.76E-06). Figure 58 shows a 
plot of the SNP p values and the QQ-plot; the p values are generally normally 
distributed. 
 
Figure 58: P value and QQ-plot – BD 
The top SNP has a p value of 3.21E-06, which does not pass multiple SNP testing 
correction. The QQ-plot shows that the p values generally do not deviate from 
normality. Plots were generated using R software.  
The top gene for Body Dissatisfaction (BD) according to the VEGAS-Sum method 
is heterogeneous nuclear ribonucleoprotein H1 (HNRNPH1) with a p value of 
1.30E-05 (see Table 50). It does not pass a Bonferroni correction for multiple 
gene testing, but it does pass a Bonferroni threshold for suggestive association 
(0.5/17,555 = 2.85E-05). HNRNPH1 ranked 31st according to the GATES method 
(see Table 50). According to VEGAS (UCSC Genome browser hg18 assembly) 
annotation there are nine SNPs in the gene, however according to GATES 
annotation (NCBI, also see paragraph 4.4.3 G en o m e - w i d e  g e n e  a n a l y s e s , page 
165) there are five SNPs in the gene. For pragmatic reasons (it is much more 
elusive to extract SNPs per gene ± 50kb using the UCSC Genome browser) NCBI 
annotation was used to plot the SNPs of the HNRNPH1. Out of the five SNPs 
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three have a p value below 0.0006, these three SNPs are not in strong LD (LD < 
0.6, see Figure 59). The plot shows that there is another gene at this location, 
C5orf60. This gene was not part of the VEGAS gene set, but it ranked 28th out of 
30,204 genes according to the GATES method (data not shown).  
 
Table 50: Results VEGAS method – Top 25 genes BD 
HNRNPH1 is the top gene most strongly associated with BD scores, it does not pass a 
Bonferroni multiple testing correction but it does pass a threshold for suggestive 
association (0.5/17,555 = 2.85E-05). HNRNPH1 is located on chromosome five and has 
nine SNPs according to VEGAS (UCSC) annotation, its top SNP ranked 72nd of SNPs 
overall. Some genes share a top SNP (an example in grey). Three genes were also among 
the top 25 genes according to the GATES method (in bold). One gene was not part of the 
GATES gene set (indicated by #N/A). 
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Figure 59: Plot of HNRNPH1 SNPs - BD 
According to the GATES method (NCBI) five SNPs were annotated to the HNRNPH1 gene. 
Three SNPs have a p value below 0.0006. None of the SNPs are in strong LD (LD < 0.06). 
The top SNP, rs6875168, is indicated by the largest circle. There is another gene at this 
location, C5orf60. This gene was not part of the VEGAS gene set, but it ranked 28th out 
of 30,204 genes according to the GATES method (data not shown). The plot includes the 
complete LD region (LD ≥ 0.4) of the top SNP. The left Y axis indicates the –log10 p value 
of the SNPs. The right Y axis and the line in the graph indicate the recombination rate. 
The plot was generated using LocusZoom (Pruim et al., 2010).   
The top gene associated with BD scores resulting from the GATES method is 
neurochondrin (NCDN) with a p value of 8.98E-06 (see Table 51). The genes in 
the top 25 do not pass a Bonferroni correction for the number of genes tested, 
but four genes do pass the threshold for suggestive association (0.5/30,204 = 
1.66E-05); NCDN, TFAP2E, KIAA0319L, and LOC100419802. Of these genes 
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transcription factor AP-2 epsilon (TFAP2E) was also among the top 25 genes 
according to the VEGAS method (rank 6, indicated in bold, see Table 51). These 
four genes however all share the same top SNP, rs7523017, which was ranked 
third most significant SNP overall for BD (indicated in grey in Table 51). Figure 60 
shows clearly that the gene p values are all a result of this SNP p value 
(rs7523017, p= 4.50E-06); there are several small genes in the area, which all 
rank high as a consequence of the single strongly associated SNP (see Figure 60); 
in this situation it is the SNP that deserves most attention, and to a lesser extent 
the genes that ranked high as a consequence of this single SNP p value. Note: 
LOC100419802 is a pseudogene; based on its sequence it is considered not to 
code for a functional protein (but it could nevertheless have a regulatory 
function (Wang and Chang, 2011)). LOC100419802 was not part of the gene set 
based on which the plot was generated (Pruim et al., 2010), hence it is not visible 
in Figure 60.   
 
Table 51: Results GATES method – Top 25 genes BD 
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None of the genes pass a Bonferroni correction for the number of tested genes, but the 
top four genes do pass a Bonferroni threshold for suggestive association with BD. These 
four genes however all share the same top SNP, rs7523017, which ranked third of SNPs 
overall (also see Figure 60). Three genes were also among the top 25 genes according to 
the VEGAS method (in bold).  
 
Figure 60: Plot of the SNPs from the top genes GATES – BD 
This plot shows that the gene p values of the top genes for BD are a result of a single 
strongly associated SNP, rs7523017. The other four SNPs in the region are not in strong 
LD with the top SNP (LD < 0.6, indicated by the smaller circles), and they are not strongly 
associated to the phenotype either. The left Y axis indicates the –log10 p value of the 
SNPs. The right Y axis and the line in the graph indicate the recombination rate. The plot 
was generated using LocusZoom (Pruim et al., 2010). An extended plot including the 
complete LD region (LD ≥ 0.4) of the top SNP was presented in the Appendix, page 256. 
The genes in this top 25 (see Table 51) stand out for having very few SNPs per 
gene compared to the other top 25s in this Chapter. The GATES method claims 
not to suffer from an inflation of the type I error due to gene size (Li et al., 2011), 
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which is important since by chance larger genes would be associated to any 
phenotype more often. However in this case there appears to be a suggestive 
bias towards smaller genes; the GATES method corrects the best p value of a 
gene for the number of independent SNPs in a gene, smaller genes are thus 
corrected less conservatively. The association was tested by a Spearman’s rho 
test (a non-parametric statistic for a bivariate correlation on gene rank and the 
number of SNPs per gene); the number of SNPs is significantly associated with 
gene rank, however not smaller genes but larger genes tend to be ranked higher 
(p<0.001, correlation coefficient 0.046, n=30,204 genes). The impact of this 
association is however minor since the correlation coefficient is very small. This is 
illustrated in Figure 61 and Figure 62. Figure 61 shows that the mean rank 
increases with increasing number of SNPs per gene (indicated by bars), the 
distribution of genes (indicated by the line) shows though that there are very few 
large genes. Figure 62 only shows the smaller genes (100 SNPs or less per gene); 
the r-square of the number of SNPs per gene with the gene p value is very small 
(2.12E-05, see Figure 62), indicating that the deviation from zero is minimal. The 
association was tested by Spearman’s rho rather than a linear regression since 
the p values may not be completely normally distributed, which would violate 
the assumption for linear regression. The p value is significant because the 
sample size is very large, but the correlation between the gene p value and the 
number of SNPs per gene is very small (0.046, see Figure 62), hence it is unlikely 
that the number of SNPs per gene have biased the results of the gene analyses 
for BD.  
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Figure 61: The mean rank of genes relates to the number of SNPs per gene 
The left Y axis shows the mean rank of genes, and the right Y axis shows the number of 
genes – the genes are ordered on the number of SNPs per gene on the X axis. The rank 
of the gene increases with increasing number of SNPs per gene (Spearman’s rho: 
p<0.001, correlation coefficient = 0.046, n= 30,204 genes). The impact of this association 
is however minor; the correlation coefficient is very small (also see Figure 62). There are 
very few large genes; most genes have less than 50 SNPs per gene.  
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Figure 62: Scatterplot of gene p values versus the number of SNPs per gene 
The gene p value is associated with the number of SNPs per gene, with lower p values 
associated with larger genes (Spearman’s rho: correlation coefficient = 0.046, p < 0.001, 
n = 30,204 genes). The figure also shows the r-square value (2.12E-05, indicated by the 
line) in order to illustrate the minor impact of the association. Note: the association was 
not tested statistically by a linear regression but by Spearman’s rho, since the p values 
may not be completely normally distributed. Only genes with 100 SNPs or less are 
shown in this figure.  
No SNPs showed genome-wide significant association with drive for thinness 
(DT), bulimia (B), or body dissatisfaction (BD), as measured by the Eating 
Disorder Inventory (EDI), after correction for multiple SNP testing. Assuming 
there are indeed genetic variants underlying the variance in DT, B, and BD, scores 
(given the heritability estimates of the EDI (Rutherford et al., 1993,Keski-
Rahkonen et al., 2005)(Boraska et al, submitted)) these results indicate that 
either the effect sizes were small, or that the causal common variants were not 
4.8.  Conclusion and discussion
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well tagged (also see paragraph 1.3.4.1 L in ka g e  d i s e q u i l i b r i um ,  a n d  m u l t i p l e  
t e s t i n g , page 45), or that the causal variants were rare variants (not at all tagged 
by current genotyping arrays). Results from studies on height and body mass 
index (Lango et al., 2010,Yang et al., 2011,Day and Loos, 2011), indicate that 
common genetic variants did underly phenotypic variance, but that large 
samples sizes were needed (50,000 to 200,000 individuals) in order to detect 
these because the effect sizes were very small. Though obviously challenging and 
time consuming, it would most definitely be possible to increase the sample size 
for the EDI questionnaire; it is a self report questionnaire which is easily 
administrered to the general population, and Podar and Allik demonstrated 
already that analyses of large cross-cultural samples of the EDI are feasible (n = 
43,722) (Podar and Allik, 2009).   
It is still a matter of debate whether secondary analyses can be conducted when 
the SNPs do not reach genome-wide significance (p < 5.00E-08 (Cichon et al., 
2009)). The conservative side of the discussion is that the laws of probabilty 
should be honoured (Cichon et al., 2009,Kim et al., 2011); and most of the 
success has indeed resulted from increasing sample sizes rather than from novel 
analytical methods (Huang et al., 2011a,Lango et al., 2010,Yang et al., 2011,Day 
and Loos, 2011). From a biological perspective it is however not at all surprising 
that multiple different genetic risk factors could underly disease, and that the 
effects may be too small to pick up without aggregation into genes and pathways 
(Cantor et al., 2010,Lehne et al., 2011,Huang et al., 2011a), since genes are 
though to be the functional units of the human genome, and gene functions 
converge into pathways (also see the introduction of this chapter: paragraph 4.1, 
page 154). Perhaps this is even more the case in psychiatry, since 
neurodevelopmental processes are regulated by thousands of genes, with 
different functions at different timepoints in the development and functioning of 
the human brain (Rakic, 2009,State and Levitt, 2011). Moreover, because of the 
4 .8 . 1 .  S e c o n d a r y  a n a l y s e s  
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importance of these basic brain processes there is much redundance in the 
biological processes involved; i.e. the system is very able to cope with minor 
‘flaws’ (State and Levitt, 2011). The presumed genetic architecture of complex 
traits and disorders, consisting of multiple genetic risk variants each with a (very) 
small (cumulative) effect on risk (Visscher et al., 2011) (also see paragraph 
1.3.4.3 Un d e t e c t e d  h e r i t a b i l i t y  a n d  g e n e t i c  a r c h i t e c t u r e , page 52), thus is 
biologically very plausible (Cantor et al., 2010,Lehne et al., 2011,Huang et al., 
2011a).   
 
The ideal proof of principle of secondary gene and pathway analyses would be to 
successfully analyse datasets with known genetic disease risk variants, which is 
possible because many datasets are open access these days (e.g. those of the 
Wellcome Trust Case-Control Consortium (WTCCC), http://www.wtccc.org.uk, 
(WTCCC, 2007)). Both Lehne et al (Lehne et al., 2011), and Huang et al (Huang et 
al., 2011a), took this approach to test multiple gene-based methods. None of the 
methods caused any false positive gene associations, but only a few of the 
known risk genes were picked up (seven out of 39 for Crohn’s Disease (Lehne et 
al., 2011), five out of 27 for type 1 diabetes (Lehne et al., 2011), and six out of 38 
for atherosclerosis risk (Huang et al., 2011a)). Lehne et al describe that some of 
the known risk genes consistently ranked low in all three gene-based methods 
they tested (Lehne et al., 2011); for some of these genes the truly associated 
SNPs were located more than 40kb away from the gene (Lehne et al extended 
gene regions by 40kb), or the associated SNP had not been genotyped in the 
open access data, or simply did not show any association (Lehne et al., 2011). 
Huang et al included the VEGAS method in their analyses, and they note that an 
important limitation of the approach is that the sum over all SNPs of a gene 
creates a bias to find causal variants in LD blocks represented by many SNPs, and 
that VEGAS would miss true disease risk variants located in LD blocks with fewer 
SNPs (Huang et al., 2011a). The most widely used approach is taking the most 
significant SNP p value per gene as the gene p value, however only when the size 
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of the gene or pathway (i.e. the number of SNPs per gene or pathway) is 
controlled for, because otherwise by chance large genes and pathways would be 
associated with the phenotype more often (Lehne et al., 2011,Li et al., 2011).  
The results of this chapter indicate that none of the genes tested for association 
analyses with DT, B, and BD passed a threshold for multiple gene testing. It 
seems however almost more than coincidence that several previously with 
eating disorders or mental illness associated genes are among the top genes 
(including BDNF (Noble et al., 2011), GLP2R (Pinheiro et al., 2010), and HTR1A 
(Albert et al., 2011)). Any speculation about these genes would however be 
premature; larger sample sizes or independent replications would be necessary 
to verify these results. If however the results of the large scale genome-wide 
study of anorexia nervosa, currently conducted by the GCAN consortium, again 
point towards these genes (results will be published in 2012), then there may be 
enough evidence to decide to follow-up these genes, e.g. by sequencing them.  
The main aim of this chapter was to appraise the gene-based methods over SNP-
based methods. The VEGAS-Sum methodology (Liu et al., 2010) fits the 
pressumed model of genetic architecture for complex traits and disorders 
(Visscher et al., 2011) much better than the GATES methodology (Li et al., 2011), 
because VEGAS-Sum combines the SNP p values per gene whereas GATES 
corrects the best p value of a gene for the number of SNPs in a gene (also see 
paragraph 4.4.3 G en om e - w i d e  g e n e  a n a l y s e s , page 165). VEGAS-Sum is indeed 
able to prioritise genes with multiple independent suggestive association signals; 
genes ranking high according to VEGAS-Sum would mostly not have been picked 
up if only the top SNPs associated with the DT, B, and BD scores had been 
considered for follow up (see Table 45, Table 48, and Table 50). This is in sharp 
contrast with the results following the GATES methodology; the top SNPs of all 
genes ranking high in GATES were among the top 70 SNPs overall (see Table 47, 
4 .8 . 2 .  A s s o c i a t e d  g e n e s  d i d  n o t  p a s s  c o r r e c t i o n  f o r  m u l t i p l e  t e s t i n g  
4 . 8 . 3 .  A pp ra i s a l  o f  g e n e - b a s e d  m e t h o d s  
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Table 49, and Table 51). GATES gene-based methodology thus appears to add 
little to SNP-based association; it might be more straight-forward to simply 
follow up the genes of the top 100 SNPs, rather than performing gene-based 
association. Moreover, there is a slight bias towards smaller genes in the GATES 
methodology; smaller genes (with less SNPs) are corrected less conservatively 
than larger genes (see Figure 61 and Figure 62, page 189). Lehne et al also 
addressed this problem; they noted that small genes tended to be at the 
extremes of the p value distribution, i.e. the gene p value of a gene with one or 
two SNPs is dominated by these particular SNPs, in contrast to larger genes with 
more SNPs (Lehne et al., 2011). This bias is however only minor (see Figure 61 
and Figure 62, page 189), more importantly to my opinion is that the GATES 
methology (only taking the most significant SNP of the gene into consideration) is 
a poor fit for the presumed genetic architecture of complex traits and disorders 
(Visscher et al., 2011).  
The limitations of the GATES methodology were most clear for the results of the 
pathway analyses. GATES-Simes pathway analyses methodology (Gui et al., 2011) 
is similar to the gene-based methodology (Li et al., 2011), in that the best gene of 
the pathway is corrected for the number of genes in the pathway. The pathway 
most significantly associated with DT was the Glucagon Type Ligand Receptors 
pathway (data presented in the Appendix, see Table 66, page 250). GLP2R is 
however the only gene of the pathway associated with DT with a p value below 
0.05 (Table 66, page 250), moreover the top SNP of GLP2R was the second most 
significant SNP overall Table 47, page 176); it thus appears that a single SNP p 
value caused a whole pathway to be suggestively associated with the phenotype 
(note: the pathway p value did not pass a correction for multiple pathway 
testing), while there was no evidence for any of the other genes in the pathway 
to be even suggestively associated with the phenotype. Hence calculating gene 
and pathway p values by a correction of the best SNP appears to cause a risk of 
4 .8 . 4 .  L im i t a t i o n s  
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overanalysing; it would be more accurate and appropriate to only state that the 
SNP rs7218549, located on chromosome 17, near the gene GLP2R, was 
suggestively associated with DT, in stead of stating that the gene GLP2R and the 
pathway Glucagon Type Ligand Receptors were suggestively associated with DT.    
 
A major challenge in genome-wide association studies at any level, including 
SNP, gene, and pathway, is linkage disequilibrium (LD) (Cantor et al., 2010,Lehne 
et al., 2011,Huang et al., 2011a). SNPs and genes and pathways are not 
independent of each other (also see paragraph 1.3.4.1 L i nka g e  
d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , page 45). Moreover, as Huang et al 
point out, even when controlling for LD like in the VEGAS method (Liu et al., 
2010) a bias can still result from the fact that regions in LD carrying many SNPs 
will be overrepresented in the results (Huang et al., 2011a). The results of this 
thesis indicate that the extended gene regions may exaggerate this problem; 
Figure 53 (page 175) shows that genes located closely together overlap almost 
completely when gene regions are extended, and Figure 71 (presented in the 
Appendix, page 253) shows that genes located closely together may not be in LD 
with each other, but when gene regions are extended there may be significant 
LD between genes. Lehne et al circumvent this problem by excluding genes from 
the major histocompatability complex (MHC) region (known to be in strong LD) 
from their gene-based analyses (indeed the genes from both Figure 53 and 
Figure 71 are located in this region) (Lehne et al., 2011), though the issue with LD 
may be more wide spread than just the MHC region. 
As a final remark I wanted to emphasize that any output of an equation can only 
be as good as the input; i.e. when SNP p values are the input for gene and 
pathway association analyses, the results will only be as good as the SNP 
association with the phenotype. Genotyped SNPs in genome-wide association 
studies are merely ‘tags’ for a genomic region of common genetic variation (also 
4 .8 . 5 .  C on c l u d i n g  r em a rk s  
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see paragraph 1.3.4.1 L inka g e  d i s e q u i l i b r i um ,  a n d  m u l t i p l e  t e s t i n g , 
paragraph 45), and the genotyped SNPs are merely in LD with possible causal 
genetic risk variants. The very first genome-wide study conducted by Klein et al 
in 2005 is still a source of inspiration today; Klein and colleagues emphasized the 
quality of phenotyping, and provided compelling evidence for biological 
plausibility of the genome-wide significant association they found (Klein et al., 
2005).  





C o n c l u s i o n  a n d  d i s c u s s i o n  
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C o n c l u s i o n  a n d  d i s c u s s i o n  
Genetic studies of eating disorders (EDs), i.e. studies that aim to discover which 
genes are involved in the aetiology of EDs, have had limited success. Few if any, 
of these studies have identified (and replicated) robust genetic associations with 
EDs, and the results of this thesis (Chapter 2 and Chapter 4) are no exception to 
this rule. This ‘failure’ is not specific to EDs, and it has actually held important 
clues about the underlying genetic architecture of disease. Recent large-scale 
genetic studies of other complex (psychiatric) disorders and general traits such as 
human intelligence, height, and body weight, now confidently demonstrate that 
there are many genetic risk variants underlying complex disorders and traits, 
each either with a (very) small effect size, or (very) rare in the population (Cichon 
et al., 2009,Speliotes et al., 2010,State and Levitt, 2011,Davies et al., 2011,Lango 
et al., 2010). Power to detect genetic risk variants with such small effect sizes 
could be obtained by increasing samples sizes, and by focussing on disease 
related traits rather than diagnoses, which may have a more direct relationship 
with the underlying genetic risk factors. 
Several quantitative traits, or endophenotypes, have been suggested for EDs 
(reviewed by Bulik et al (Bulik et al., 2007a), and by Treasure (Treasure, 2007)). 
Endophenotypes have been suggested to lead to more successful genetic 
analyses (Gottesman and Gould, 2003), though in reality they may be equally 
complex as diagnoses (Flint and Munafo, 2007,Walters and Owen, 2007). Drive 
for thinness (DT) and body dissatisfaction (BD) are among the most robust 
endophenotypes for EDs (Bulik et al., 2005,Bulik et al., 2007a,Stice and Shaw, 
2002,Wilksch and Wade, 2009). Several studies show that DT and BD are 
5. Conclusion and discussion 
5 . 1 .  G en e t i c s  o f  e a t i n g  d i s o r d e r s  
5 .2 .  Qu an t i t a t i v e  t r a i t s  o f  e a t i n g  d i s o r d e r s  
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moderately heritable (Rutherford et al., 1993,Klump et al., 2000,Keski-Rahkonen 
et al., 2005,Boraska et al., submitted), and DT and BD have been included as 
behavioural covariates in genetic analyses of EDs before (Devlin et al., 2002,Root 
et al., 2011). When interpreting the endophenotype scores, it is important to 
take note of the context in which the (in this case) questionnaire was 
administered. The sample I analysed for Chapter 3 and Chapter 4 of this thesis 
was a general population sample, of older age and of higher BMI than a typical 
eating disorder study sample. Even though EDs are most common among 
adolescents, disordered eating and weight and shape concerns do also occur in 
women of older age (Lewis and Cachelin, 2001,Mangweth-Matzek et al., 
2006,Bedford and Johnson, 2006,Slevec and Tiggemann, 2011).  
 
The results of Chapter 3 of this thesis demonstrate that drive for thinness (DT), 
bulimia (B), and body dissatisfaction (BD) scores, as assessed by the Eating 
Disorder Inventory (EDI (Garner, 2004)) tend to be higher in individuals with a 
higher body mass index (BMI), which is in line with the literature (Packianathan 
et al., 2002,Mangweth-Matzek et al., 2006,Slevec and Tiggemann, 2011). 
Notably, highest adult lifetime BMI, rather than current BMI, was the most 
important predictor of DT and B scores. Current BMI, perhaps understandably, 
was however the best predictor for BD, though highest adult lifetime BMI still 
explained a significant proportion of unique variation in BD scores when current 
BMI was controlled for. This result may hold important implications for the 
assessment of disordered eating behaviour; highest adult lifetime BMI is easy to 
assess, and most individuals appear willing and able to report their highest adult 
lifetime BMI on self-report questionnaires (data presented in Chapter 3, page 
119). Lifetime BMI history could be used as a proxy, or a risk factor, of disordered 
eating in the general population; e.g. to select individuals at risk for disordered 
eating in a classic two-stage study design as recommended by Hoek et al (Hoek 
and van Hoeken, 2003).   
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The effect sizes of the associations between DT, B, and BD, and BMI were 
considerable (the standardised correlation coefficients (beta) were 0.34, 0.32, 
and 0.53 for DT, B, and BD respectively). Individuals with low DT scores (below 
13, EDI-3 scoring) have a mean BMI in the normal weight range (BMI between 20 
and 25), and individuals with higher DT scores (13 and above) tend to have a BMI 
in the overweight range (BMI above 25). The relation between BD and BMI is 
most strong; individuals with low BD scores (below 35, EDI-3 scoring) are 
generally in the normal weight range, individuals with moderate BD scores 
(between 35 and 50) are in the overweight range (BMI between 25 and 30), and 
individuals with high BD scores (50 and above) tend to be obese (BMI above 30).  
 
This highly significant relationship between DT, B, and BD scores and BMI does 
however not hold true for 5% of the sample (approximately 150 out of 3,000 
individuals). These individuals present with high DT, B, and BD scores, without 
having, or ever having had, a high BMI. The percentage of individuals is 
approximately equal to the estimated prevalence of EDNOS in the general 
population (Hoek and van Hoeken, 2003,Wade et al., 2006,Machado et al., 
2007,Keski-Rahkonen et al., 2007,Swanson et al., 2011), and could indicate that 
this group of outliers could consist of individuals at risk for EDs, with clinical EDs, 
or with a history of EDs. This finding again indicates that it is important to view 
disordered eating behaviour in the context of individual current BMI, and BMI 
history. Whether this subgroup of individuals with high DT, B, and BD scores, 
without ever having had a high BMI, truly represents possible disordered eating 
behaviour cases would have to be ascertained through (semi-)structured clinical 
interviews, but this is nevertheless a finding worthy of follow-up.   
Genome-wide association (GWA) studies genotype single nucleotide 
polymorphisms (SNPs) in the genome. SNPs are however merely ‘tags’ of 
possible genetic risk variants for disease; genes are thought to be the functional 
5 .3 .  G en om e - w i d e  g e n e  a n a l y s e s  
- 201 - 
units of the human genome, and disease causing genetic variants should 
somehow influence gene function. Secondary analyses, e.g. genome-wide gene 
and genome-wide pathway analyses, are post-hoc to GWA SNP analyses. It is 
currently still a matter of debate whether secondary analyses can be conducted 
when the SNPs do not reach genome-wide significance (p < 5.00E-08 (Cichon et 
al., 2009)). From a biological perspective it would however not be surprising if 
multiple different genetic risk factors could underly the same disorder, and that 
the effects of the individual genetic risk factors may be too small to be detected 
without their aggregation into genes and pathways (Cantor et al., 2010,Lehne et 
al., 2011,Huang et al., 2011a). This may be particularly relevant for psychiatric 
disorders, since neurodevelopmental processes are regulated by thousands of 
genes (Rakic, 2009,State and Levitt, 2011).  
 
Two different methods for secondary analyses of genome-wide gene associaton 
were tested in this thesis; the VEGAS-Sum method (Liu et al., 2010) which 
combines the SNP p values per gene, and the GATES method (Li et al., 2011), 
which corrects the best SNP of a gene for the number of SNPs in a gene. The 
VEGAS-Sum methodology fits the pressumed model of genetic architecture for 
complex traits and disorders better than the GATES methodology does; GATES is 
designed to detect genes with one or a few disease-susceptibility loci and 
relatively many neutral SNPs (Li et al., 2011), whereas VEGAS-Sum is geared for 
detecting genes with multiple disease-susceptibility loci (Liu et al., 2010,Li et al., 
2011), exactly the type of genetic variations expected to underly complex 
disorders such as eating disorders (Visscher et al., 2011). The VEGAS-Sum 
method is indeed able to prioritise genes with multiple independent suggestive 
association signals; genes detected by the VEGAS-Sum method would mostly not 
have been picked up using only primary GWA SNP analyses. This is in sharp 
contrast with the genes detected by the GATES method; the top SNPs of these 
genes were all among the top 70 SNPs overall, indicating that these genes would 
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have been identified if simply the top 100 SNPs was followed up without doing 
any secondary analyses.  
 
Linkage disequilibrium (LD) represents a major challenge for genome-wide 
association studies at any level, including SNP, gene, and pathway (Cantor et al., 
2010,Lehne et al., 2011,Huang et al., 2011a). Huang et al point out for example, 
that gene-based association methods like the VEGAS-Sum method, which take 
the sum over all SNPs of a gene, can create a bias towards finding causal variants 
in LD blocks carrying many SNPs, and miss causal variants in LD blocks 
represented by fewer SNPs (Huang et al., 2011a). The results of this thesis 
indicate that extended gene regions may further exaggerate this problem; genes 
located closely together may not be in LD with each other, but when gene 
regions are extended there can be significant LD between genes. Lehne et al 
circumvent this problem by excluding genes from the major histocompatability 
complex (MHC) region (known to be in strong LD) from their gene-based analyses 
(Lehne et al., 2011). Indeed the most problematic LD regions found in this thesis 
(Figure 53 and Figure 71) were located in this region, but the issue with LD may 
be more wide spread than just the MHC region. 
 
No SNPs or genes were found to be significantly associated with the Eating 
Disorder Inventory (EDI) (Garner, 2004) risk scales drive for thinness (DT), bulimia 
(B), or body dissatisfaction (BD) after correction for multiple testing. This is in line 
with other complex traits, such as human intelligence (Davies et al., 2011), height 
(Lango et al., 2010), and body mass index (Day and Loos, 2011); very much larger 
samples sizes were required to detect any genetic risk variants underlying these 
traits (in the region of tens of thousands of samples, rather than the 
approximately two thousand samples analysed in this thesis). Increasing the 
sample size is however not a guarantee for success. The EDI scales were chosen 
as candidate endophenotypes for eating disorders; i.e. simpler phenotypes than 
- 203 - 
the complex diagnoses, meant to lead to more straight forward, and more 
successful genetic analyses (Gottesman and Gould, 2003). Whether the EDI 
scales are good endophenotypes for eating disorders, and whether they truly 
associate with eating disorder causing genetic variants (Flint and Munafo, 
2007,Walters and Owen, 2007) however remains to be ascertained. The results 
of this thesis are – despite the lack of significance – very encouraging, because 
among the top genes were several previously implicated in the aetiology of 
eating disorders (including BDNF (Noble et al., 2011), GLP2R (Pinheiro et al., 
2010), and HTR1A (Albert et al., 2011)). In 2012 the results of the first large scale 
genome-wide study of anorexia nervosa by the GCAN consortium are expected 
to be published. If these genes are again among the top results, there would, to 
my opinion, be enough suggestive evidence to decide to follow them up, e.g. 
through sequencing studies. 
The complex clinical presentation of eating disorders, the presumed underlying 
molecular biology, and the statistical analyses methods to test causal 
relationships, are all challenging fields of science on their own, let alone when 
one tries to combine them in the genetic studies of eating disorders. 
Multidisciplinary collaborations between clinicians, molecular biologists, and 
statisticians are thus essential to make any progress in this field. Collaborations 
will also be needed because sample sizes will have to increase; it has become 
apparent that genetic risk variants underlying complex disorders and traits have 
(very) small effect sizes which can only be detected using very large samples 
(tens of thousands of cases). I have to agree with Kim et al that underpowered 
studies are not worth undertaking anymore (Kim et al., 2011), time and money 
would be better spent on recruiting more cases and collecting more data. Indeed 
promising progress is being made by researchers from consortia such as the 
Japanese Genetic Research Group for Eating Disorders (JGRED), the Price 
5 .4 .  F u tu r e  d i r e c t i o n s  
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Foundation Genetic Studies of Eating Disorders, and the Genetic Consortium for 
Anorexia Nervosa (GCAN).  
 
The overlap of symptoms between eating disorder categories, the instability of 
eating disorder diagnoses over time, and the disproportionate number of 
patients with a diagnosis of eating disorder not otherwise specified (EDNOS) 
pose further challenges for the study of genetics of eating disorders. It is 
encouraging however that several genetic risk variants have now been identified 
for body mass index (BMI). BMI is not a stable phenotype either; it can fluctuate 
significantly over time, and its aetiology is arguably as multifactorial as that of 
eating disorders. Again the key word for success has been large sample sizes; a 
discovery sample of more than 100,000 individuals followed by a replication in 
more than 100,000 individuals has lead to the robust association of more than 50 
genetic risk variants for BMI (Speliotes et al., 2010). Such sample sizes may 
simply not be feasible for eating disorders. Secondary analyses, such as gene and 
pathway association analyses may be able to identify genetic risk variants in 
smaller sample sizes. From a biological perspective it would not be surprising if 
multiple different genetic risk factors could underly the same disorder, hence 
studying them through their aggregation into genes and pathways could improve 
the chances of detecting the underlying mechanism of disease (Cantor et al., 
2010). Currently these secondary analyses are still in their infancy, and proof of 
principle should ideally be obtained by successfully analysing datasets with 
known genetic disease risk variants (Lehne et al., 2011,Huang et al., 2011a). 
Given the comorbidity of eating disorders with other psychiatric disorders (Jacobi 
et al., 2004b,Hudson et al., 2007,Swanson et al., 2011,Dalle, 2011,Treasure et al., 
2010), it may be worth combining samples of different psychiatric disorders. This 
may introduce heterogeneity, but larger sample sizes do have more power to 
detect genetic risk variants with small effect sizes.  
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Endophenotypes of complex disorders are an appealing concept, and they may 
lead to more successful genetic analyses (Gottesman and Gould, 2003), though 
success is not guaranteed (Flint and Munafo, 2007,Walters and Owen, 2007). The 
results of this thesis are encouraging though, among the top genes associated 
with drive for thinness, bulimia, and body dissatisfaction in a general population 
sample were several previously implicated in the aetiology of eating disorders. 
The results did not pass a correction for multiple testing, but compared to other 
studies of complex traits the sample I analysed was relatively small. It would be 
feasible to increase the sample size for quantitative trait measurements such as 
the Eating Disorders Inventory (EDI) (Garner, 2004), or other candidate 
quantitative traits for eating disorders such as for example, the Eating Disorder 
Diagnostic Scale (EDDS) (Stice et al., 2000), or measures of Weight Concerns 
(Killen et al., 1994). When using these measures it is important to take note of 
their observed dimensionality (Garcia-Grau et al., 2010). For example, future 
studies may want to run genetic analyses on the observed rather than the 
suggested factor structures, e.g. by combining the drive for thinness and body 
dissatisfaction items of the EDI, since analyses by Garcia-Grau et al demonstrate 
that they load onto the same factor (Garcia-Grau et al., 2010). One should also 
take note of the correlates of the candidate endophenotypes; e.g. the EDI scores 
are significantly associated with BMI. Whether higher EDI scores truly represent 
more disordered eating behaviour when accompanied by higher BMIs remains to 
be ascertained, it will be important to study disordered eating in the context of 
current BMI and BMI history. If higher EDI scores truly represent more 
disordered eating then it will also be important to include older age groups in 
research, since EDI scores were very equal between women of different age 
groups.   
 
Apart from genetic variants in gene regions there are many more factors which 
could interfere with protein functionality. Very interesting to my opinion are 
epigenetic mechanisms (Campbell et al., 2011) and microRNAs (Huang et al., 
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2011b). Both are important in the fine tuning of gene function, and it is plausible 
that they are involved in the aetiology of eating disorders. However, before they 
could be implicated in the aetiology of eating disorders it is very important that 
the clinical presentation is well captured by precise phenotyping. Hence, for the 
foreseeable future I think all effort should be focussed on obtaining extremely 
well documented very large cohorts, because progress in a scientific field so 
challenging can only result from collaborative multi-national multi-disciplinary 
labour.  
What if eating disorders really have a genetic basis, would that mean there is 
nothing we can do about it? That they are inevitable? Unsolvable? No, most 
certainly not. Day and Loos discuss the 50 genetic risk variants that have now 
robustly been associated with obesity; the effect of body mass index-increasing 
genetic variants is however reduced by physical activity (Day and Loos, 2011). A 
genetic basis does imply though, that for some individuals it is truly more difficult 
to manage their eating behaviour than it is for others. This is not really novel, for 
example everybody knew already that it is more difficult for some people to 
deliver a speech than it is for other people (genetic factors contribute to the 
variability in cortisol changes in response to the Trier Social Stress Test 
(Kirschbaum et al., 1993)). The presumed genetic architecture of eating disorders 
also indicates that genetics would not be a good screening tool to identify people 
at risk for an eating disorder in the general population, as it is not for obesity 
(Day and Loos, 2011); it would be far more easy to buy a weighing scale and a 
measuring tape. The same holds true for anorexia nervosa. I have nevertheless 
been arguing for about 200 pages that genetics of eating behaviour is useful. And 
the answer to the unasked question following the previous statement is 
‘knowledge’. Though perhaps appropriate for a degree in philosophy, I realise 
this may sound a bit daft. What I mean is that, if we understand better why some 
individuals fall ill, we can help them better. If for example the studies on the 
5.5.  Concluding remarks
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gene FTO, which was discovered to be associated with body mass index (Frayling 
et al., 2007), lead to a better understanding of why it is so difficult for some 
individuals to balance their energy intake and expenditure on a day to day basis, 
then maybe we can finally get rid of all the “crash-diet” and “weigh-less-in-3-
minutes” books. Similarly, if it turns out that glucagon signalling is truly 
associated with eating disorders (suggestive evidence from (Pinheiro et al., 2010) 
and from Chapter 4 of this thesis), e.g. through impaired hunger signalling, then 
a simple drug may be able to pull a whole group out of a danger zone. Glucagon 
drugs will most certainly not be the answer to eating disorders; if there is one 
thing this thesis underscores then it is the complexity and multifactor”reality“ of 
eating disorders. Yet one new insight into the aetiology of eating disorders could 
be lifechanging for one individual.  
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Table 52: HWE and HapMap frequencys - all SNPs Chapter 2 
SNPs are sorted on the difference between the HapMap and sample reference 
homozygote genotype frequencies.  Control sample consisted of London and Vienna 
control samples (n= 674). All SNPs genotype frequencies are ± 10% of the HapMap 
frequencies (maximum difference is 0.095). * x indicate published SNPs. ** HapMap 
genotype frequencies were not available, but the average heterozygosity of this SNP 
was 0.496. One SNP violates HWE significantly (p= 0.0007, rs17210001, in bold), two 
SNPs are suggestive of HWE violation (in bold). Rs4633 was excluded from analyses (see 
paragraph 2.5, page 77), it is shown in grey. 
Appendix  1 :  HWE and  HapMap f requency  de ta i l s  for
Chapte r  2  
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Table 53: Results case control analyses - all SNPs Chapter 2 (1)  
* x indicate published SNPs. Some SNPs are suggestively associated with AN (in bold), 
however taking multiple testing into account none of the SNPs are associated with AN.  
Appendix  2 :  Addi t iona l  da ta  for  Chapter  2
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Table 54: Results case control analyses - all SNPs Chapter 2 (2) 
* x indicate published SNPs. Some SNPs are suggestively associated with AN (in bold), 
however taking multiple testing into account none of the SNPs are associated with AN. 
Rs4633 was excluded from analyses, it is shown in grey.  
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Table 55: Results within-case analyses - all SNPs Chapter 2 - lowest BMI  
* x indicate published SNPs. Some SNPs are suggestively associated with AN (in bold), 
however taking multiple testing into account none of the SNPs are associated with AN. 
Lowest p value is 0.01 which does not pass the Bonferroni correction threshold for 26 
SNPs: α = 0.05 / 26 SNPs = 0.002). Note: Percentage Missing refers to missing genotypes, 
lowest BMI was missing for 22% of the cases. Rs4633 was excluded from analyses, it is 
shown in grey.  
 
- 235 - 
 
Table 56: Results within-case analyses - all SNPs Chapter 2 - highest BMI 
* x indicate published SNPs. Some SNPs are suggestively associated with AN (in bold), 
however taking multiple testing into account none of the SNPs are associated with AN. 
Lowest p value is 0.01 which does not pass the Bonferroni correction threshold for 26 
SNPs: α = 0.05 / 26 SNPs = 0.002). Note: Percentage Missing refers to missing genotypes, 
highest BMI was missing for 31% of the cases. Rs4633 was excluded from analyses, it is 
shown in grey.  
 
Table 57: Results within-case association – lowest BMI - haplotype rank 1 Pinheiro et al 
There is no sign of association between any of the haplotype combinations and lowest 
BMI.  
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Table 58: Results within-case association – lowest BMI - haplotype rank 9 Pinheiro et al 
There is no sign of association between any of the haplotype combinations and lowest 
BMI.  
 
Table 59: Results within-case association - highest BMI - haplotype rank 17 Pinheiro et al 
There is no sign of association between any of the haplotype combinations and highest 
BMI.  
- 237 - 
 
 
Table 60: Available data from the TwinsUK Autumn 2008 questionnaire 
The full questionnaire can be viewed online at 
http://www.twinsuk.ac.uk/phenotypes.html. Eating Disorder Inventory (EDI)-3 Eating 
Disorder risk scale questions are indicated by DT (drive for thinness), B (bulimia), and BD 
(body dissatisfaction) (Garner, 2004). R indicates reverse scoring was necessary before 
calculation of scale scores. Questions on breakfast frequency and waist measurement 
were not analysed in this thesis (indicated in italic).  
Appendix  3 :  Ava i l ab le  da ta  f rom TwinsUK Autumn 2008




Figure 63: Mean DT scores decrease with age – TwinsUK (females) 
DT scores decrease significantly with increasing age (unstandardised coefficient -0.081 ± 
0.01; 95% confidence intervals -0.102 to -0.06; n=3,448; p= 2.04E-14). The effect of this 
association is however very small; when age increases with one unit (one year) DT 
scores on average decrease with -0.081 units, indicating that women 30 years older only 
score 2.43 units lower on DT (on a scale of 7 to 42, also see Figure 30, page 125).  
Appendix  4 :  Addi t iona l  da ta  for  Chapter  3
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Figure 64: Mean B scores decrease with age – TwinsUK (females) 
B scores decrease significantly with increasing age (unstandardised coefficient -0.1 ± 
0.0075; 95% confidence intervals -0.114 to -0.085; n=3,486; p < 1.00E-15). The effect of 
this association is however very small; when age increases with one unit (one year) B 
scores on average decrease with -0.1 units, indicating that women 30 years older score 3 
units lower on B (on a scale of 8 to 48, also see Figure 31, page 126).  
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Figure 65: Mean BD scores decrease with age – TwinsUK (females) 
BD scores decrease significantly with increasing age (unstandardised coefficient -0.068 ± 
0.02; 95% confidence intervals -0.102 to -0.034; n=3,387; p= 8.07E-05). The effect of this 
association is however very small; when age increases with one unit (one year) BD 
scores on average decrease with -0.068 units, indicating that women 30 years older 
score 2.04 units lower on BD (on a scale of 10 to 60, also see Figure 32, page 127). Of the 
three EDI scores BD descreases with age, which is in line with the literature (also see 
paragraph 3.6.5 R e l a t i o n s h i p  b e t w e e n  ED I  s c o r e s  a n d  a g e , page 151).  
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Figure 66: Mean current BMI increases with age – TwinsUK (females) 
Current BMI increases significantly with increasing age (unstandardised coefficient 0.029 
± 0.0074; 95% confidence intervals 0.015 to 0.044; n=3,403; p= 8.12E-05). The effect of 
this association is however very small; when age increases with one unit (one year) 
current BMI increases on average with 0.029 units, indicating that women 30 years older 
on average have a BMI 0.087 higher (on a scale of 9.4 to 33, also see Figure 14, page 88).  
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Figure 67: Distribution of height – TwinsUK (females) 
 
 
Figure 68: Distribution of current weight – TwinsUK (females) 
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Figure 69: Distribution of lowest weight – TwinsUK (females) 
 
 
Figure 70: Distribution of highest weight – TwinsUK (females) 
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Appendix  5 :  Gene  names  (a lphabet ica l )  fo r  Chapter  4  
 
Table 61: Gene names Chapter 4 A  – CN 
Gene names were downloaded from genenames.org, The HUGO Gene Nomenclature 
Committee (HGNC) (Seal et al., 2011) 
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Table 62: Gene names Chapter 4 CN – KR 
Gene names were downloaded from genenames.org, The HUGO Gene Nomenclature 
Committee (HGNC) (Seal et al., 2011) 
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Table 63: Gene names Chapter 4 KR – LO 
Gene names were downloaded from genenames.org, The HUGO Gene Nomenclature 
Committee (HGNC) (Seal et al., 2011) 
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Table 64: Gene names Chapter 4 LO – RP 
Gene names were downloaded from genenames.org, The HUGO Gene Nomenclature 
Committee (HGNC) (Seal et al., 2011) 
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Table 65: Gene names Chapter 4 RP – Z 
Gene names were downloaded from genenames.org, The HUGO Gene Nomenclature 
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The top pathway associated with drive for thinnes (DT) scores according to the 
GATES-Simes method (Gui et al., 2011) (also see paragraph 4.4.4 A n o t e  o n  
g e n om e -w i d e  p a t hw a y  a n a l y s e s , 168), was the Reactome Glucagon Type Ligand 
Receptors pathway (see Table 66, page 250). The pathway p value (p = 3.62E-03) 
did not pass a correction for multiple pathway testing (n = 880 pathways). GLP2R 
was the top gene of the pathway, i.e. the gene most significantly associated with 
DT scores (gene p value = 1.17E-04). GLP2R was the third most significant gene 
associated with DT following the GATES method (rank 3, Table 47, page 176), but 
it did not pass a correction for multiple gene testing. GLP2R ranked 921st 
according the VEGAS-Sum method of gene-based association (also see Table 47, 
page 176). The VEGAS-Sum and the GATES methods are designed to identify 
different underlying genetic architectures; GATES is designed to identify genes 
with one or a few disease-susceptibility loci and relatively many neutral SNPs (Li 
et al., 2011), and VEGAS-Sum is designed to detect genes with multiple disease-
susceptibility loci (Liu et al., 2010,Li et al., 2011). GLP2R, which ranked very 
differently for both methods, apparently is a gene with one or a few disease-
susceptibility loci rather than with multiple disease-susceptibility loci. Indeed, the 
top SNP of GLP2R was the second most significant SNP overall associated with DT 
(Table 47, page 176). 
 
The limitation of the GATES methodology is that, as a secondary gene or pathway 
analysis, it has little added value over primary GWA SNP analyses (also see 
paragraph 4.8.3 App ra i s a l  o f  g e n e - b a s e d  m e t h o d s , page 193). Moreover, it 
poses a risk of overanalysing; the pathway associated with DT appeared to be 
driven by a single SNP p value, while there was no evidence for any of the other 
genes in the pathway to be even suggestively associated with the phenotype (see 
Appendix  6 :  Addi t iona l  da ta  for  Chapter  4  
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- 250 - 
Table 66, page 250). Hence, rather than stating that the pathway Glucagon Type 
Ligand Receptors was suggestively associated with DT, or even stating that the 
gene GLP2R was suggestively associated with DT, it would be much more 
accurate and appropriate to say that a SNP: rs7218549, located on chromosome 
17 (near the gene GLP2R) was suggestively associated with DT.  
 
Table 66: Top pathway for DT – GATES-Simes method (Gui et al., 2011) 
The Reactome Glucagon Type Ligand Receptors pathway was the top pathway 
associated with drive for thinness scores (p = 3.62E-03), but it did not pass a correction 
for multiple pathway testing. Looking at the calculation details it becomes clear that 
GLP2R is the only gene with a p value below 0.05 (shown in bold). The pathway p value 
equals the p value of the most significant gene after correction for the number of genes 
in the pathway (n = 33 genes) (also see paragraph 4.4.4, page 168). Genes shaded in 
grey are located relatively closely together, and could potentially violate the assumption 
of gene independence as they may be in (partial) LD. 
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R e s u l t s  GA T ES -H yp e r  p a t h wa y  a s s o c i a t i o n  m e t h o d  -  D T 
The top pathway for drive for thinness (DT) according to hypergeometric 
pathway association analyses (i.e. GATES-Hyper (Gui et al., 2011), is the KEGG 
Allograft rejection pathway (see Table 67, page 252). This pathway method tests 
the by chance enrichment of pathways by significant genes (also see paragraph 
4.4.4 A  n o t e  o n  g e n om e - w i d e  p a t h wa y  a n a l y s e s , page 168). The association of 
this pathway with DT is however a spurious result caused by the fact that many 
of the genes of this pathway are in strong LD (shaded in grey in Table 67), the 
genes were thus not independent; they were in LD, hence this pathway was not 
enriched with significant genes by chance (violating the assumption of 
independence of genes for this method). The fact that extended gene regions are 
used exaggerates the problem of LD, illustrated by Figure 71; even when genes 
are not in LD with each other the extended gene regions cause significant 
overlap and LD between genes (see Figure 71, page 253).  
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Table 67: Top pathway for DT – GATES-Hyper method (Gui et al., 2011) 
The KEGG Allograft Rejection pathway was the top pathway associated with drive for 
thinnes (DT) scores according to the the GATES-Hyper method (Gui et al., 2011) (p = 
1.93E-03; this p value did not pass a correction for multiple pathway testing). This is 
however a spurious result, because the genes of this pathway are in strong LD (shaded 
in grey). Also see Figure 71 on the next page, page 253. Note: the most right column 
shows the calculation details of the GATES-Simes method for pathway association (Gui 
et al., 2011); this pathway ranked 37th according to the GATES-Simes method. According 
to GATES-Simes the gene IL12A had the most significant (corrected) gene p value, 
rendering a pathway p value of 5.00E-02 (i.e. p = 0.05), which did not pass a correction 
for multiple pathway testing.  
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Figure 71: Linkage disequilibrium between HLA-DPA1 and HLA-DPB1 
The image was generated using Haploview (Barrett et al., 2005). It shows a region on 
chromosome six (~33,140k to 33,170k) comprising two genes; HLA-DPA1 and HLA-DPB1. 
There is strong pairwise LD between SNPs within the genes (indicated by black blocks), 
but there is no strong pairwise LD of SNPs between genes (indicated by white and grey 
blocks). However given the fact that an extended gene region of 50kb is used there is 
considerable overlap – and thus no independence between the genes, causing possible 
spurious results when genes are assumed to be independent in pathway association 
analyses (also see Table 67, page 252).  
 




Figure 72: Plot of BDNF SNPs - DT - extended 
The plotted region includes the gene region ± 50 kb which has been extended to include 
the genomic region in LD (≥ 0.4) with the top SNP. This is an extended version of the plot 
in figure 52, page 174. The left Y axis indicates the –log10 p value of the SNPs. The right 
Y axis and the line in the graph indicate the recombination rate. The square indicates the 
SNP is a missense SNP, and the colours indicate the extent of LD of the SNPs with the 
top SNP of the gene. The second most significant SNP of the gene (the missense SNP) is 
not in strong LD with the top SNP (LD between 0.4 and 0.6, the green triangle), the third 
up until the sixth most significant SNP of the gene are in moderate LD with the top SNP 
(LD between 0.6 and 0.8, in orange). The plot was generated using LocusZoom (Pruim et 
al., 2010).   
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Figure 73: Plot of CNIH3 SNPs - DT - extended 
The plotted region includes the gene region ± 50 kb which has been extended to include 
the genomic region in LD (≥ 0.4) with the top SNP. This is an extended version of the plot 
in figure 54, page 177. The right Y axis and the line in the graph indicate the 
recombination rate. The left Y axis indicates the –log10 p value of the SNPs, and the 
colours indicate the extent of LD of the SNPs with the top SNP of the gene. The 
extension shows there are three more SNPs with relatively low p values in the region 
outside the gene boundary; these SNPs are in low to moderate LD with the top SNP (LD 
between 0.4 and 0.6, in green). The plot was generated using LocusZoom (Pruim et al., 
2010).   
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Figure 74: Plot of the SNPs from the top genes GATES - BD - extended 
The top four genes for BD according to the GATES method (NCDN, TFAP2E, KIAA0319L, 
and LOC100419802) had an overlapping top SNP (rs7523017). The plotted region in this 
graph includes the gene region ± 50 kb which has been extended to include the genomic 
region in LD (≥ 0.4) with the top SNP.  This is an extended version of the plot in figure 60, 
page 187. The left Y axis indicates the –log10 p value of the SNPs. The right Y axis and 
the line in the graph indicate the recombination rate. The square indicates the SNP is a 
missense SNP, and the colours indicate the extent of LD of the SNPs with the top SNP of 
the gene. There are several SNPs in low to moderate LD with the top SNP (in green), 
these all have lower p values than the SNPs not in LD with the top SNP (in dark blue). 
The plot was generated using LocusZoom (Pruim et al., 2010).    
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Figure 75: PCA plot Chapter 4 - in colour 
The genotypes of the individuals from the TwinsUK sample were plotted against samples 
from various ethnicities. The black dots represent the individuals from TwinsUK; they 
cluster well with the CEU population (in bright-green); who have Northern and Western 
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